<SEC-DOCUMENT>0001104659-23-052980.txt : 20230428
<SEC-HEADER>0001104659-23-052980.hdr.sgml : 20230428
<ACCEPTANCE-DATETIME>20230428161546
ACCESSION NUMBER:		0001104659-23-052980
CONFORMED SUBMISSION TYPE:	DEF 14A
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20230614
FILED AS OF DATE:		20230428
DATE AS OF CHANGE:		20230428

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cellectar Biosciences, Inc.
		CENTRAL INDEX KEY:			0001279704
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				043321804
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEF 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36598
		FILM NUMBER:		23866423

	BUSINESS ADDRESS:	
		STREET 1:		100 CAMPUS DRIVE
		CITY:			FLORHAM PARK
		STATE:			NJ
		ZIP:			07932
		BUSINESS PHONE:		(608) 441-8120

	MAIL ADDRESS:	
		STREET 1:		100 CAMPUS DRIVE
		CITY:			FLORHAM PARK
		STATE:			NJ
		ZIP:			07932

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NOVELOS THERAPEUTICS, INC.
		DATE OF NAME CHANGE:	20050617

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	COMMON HORIZONS INC
		DATE OF NAME CHANGE:	20040211
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEF 14A
<SEQUENCE>1
<FILENAME>tm232136d1_def14a.htm
<DESCRIPTION>DEF 14A
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">



<P STYLE="margin: 0pt"></P>

<P STYLE="margin: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0pt">&nbsp;</P>



<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt">UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</FONT><BR>
Washington, D.C. 20549</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SCHEDULE 14A&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Proxy Statement Pursuant to Section 14(a) of
the</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 25%; font-size: 10pt">Filed by the Registrant&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT></TD>
    <TD STYLE="width: 75%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-size: 10pt">Filed by a party other than the Registrant&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2">Check the appropriate box:</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD>
    <TD STYLE="width: 97%">Preliminary Proxy Statement</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD>
    <TD>Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT></TD>
    <TD>Definitive Proxy Statement</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD>
    <TD>Definitive Additional Materials</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD>
    <TD>Soliciting Material under &sect;240.14a-12</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CELLECTAR BIOSCIENCES, INC.<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Name of Registrant as Specified in its Charter)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Name of Person(s) Filing Proxy Statement,
if other than the Registrant)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Payment of Filing Fee (Check all boxes that apply):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">No fee required.</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">Fee paid previously with preliminary materials.</TD></TR>
  <TR>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="width: 91%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Cellectar Biosciences, Inc.<BR>
100 Campus Drive<BR>
Florham Park, New Jersey 07932</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Notice of 2023 Annual Meeting of Stockholders<BR>
To Be Held on June 14, 2023</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The 2023 Annual Meeting of
Stockholders (the &#8220;Annual Meeting&#8221;) of Cellectar Biosciences, Inc. (the &#8220;Company&#8221;) will be held on Wednesday,
June 14, 2023 at 10:00 A.M., local time, virtually over the internet. You will be able to attend the Annual Meeting, vote your shares
electronically and submit your questions online by visiting www.virtualshareholdermeeting.com/CLRB2023 and entering the 16-digit control
number included in the notice containing instructions on how to access Annual Meeting materials, your proxy card, or the voting instructions
that accompanied the proxy materials. We will hold the Annual Meeting for the following purposes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1.</TD><TD>To vote upon the election of two Class III directors named in this proxy statement;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">2.</TD><TD>To approve an increase in the number of shares of common stock available for issuance under our 2021 Stock Incentive Plan by 1,100,000
shares;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">3.</TD><TD>To ratify the appointment of Baker Tilly US, LLP as our independent registered public accounting firm for the fiscal year ending December
31, 2023;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">4.</TD><TD>To hold a non-binding advisory vote to approve named executive officer compensation; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">5.</TD><TD>To transact such other business as may properly come before the Annual Meeting.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Stockholders of record at the close of business
on Tuesday, April 25, 2023 are entitled to notice of, and to vote at, the Annual Meeting and any adjournment or postponement thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Your vote is important. Whether or not you plan
to attend the Annual Meeting, please authorize proxies to cast your votes today by following the easy instructions in the Notice of Internet
Availability of Proxy Materials or, if you requested a printed set of proxy materials, on the proxy card enclosed with the proxy materials.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">YOUR VOTE IS IMPORTANT</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You may cast your vote over
the Internet, by telephone or by completing and mailing a proxy card. Returning the proxy does not deprive you of your right to attend
the Annual Meeting and to vote your shares in person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Proxies forwarded by or for
banks, brokers or other nominees should be returned as requested by them. We encourage you to vote promptly to ensure your vote is represented
at the Annual Meeting, regardless of whether you plan to attend in person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You can find detailed information
regarding voting in the section entitled &#8220;General Information&#8221; on pages [2] through [7] of the accompanying proxy statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">IMPORTANT NOTICE REGARDING THE INTERNET AVAILABILITY
OF PROXY MATERIALS<BR>
FOR THE ANNUAL MEETING OF STOCKHOLDERS<BR>
TO BE HELD ON JUNE 14, 2023:</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The Notice of the Annual Meeting, the Proxy Statement and the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December
31, 2022, are available at www.proxyvote.com.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%; font-size: 10pt">By order of the Board of Directors</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><IMG SRC="tm232136d1_def14aimg001.jpg" ALT=""></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">Chad J. Kolean, Secretary</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">Florham Park, New Jersey</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">April 28, 2023</TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 2; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">TABLE OF CONTENTS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%">
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="width: 90%; text-align: left; padding-bottom: 5pt"><A HREF="#a_001">GENERAL INFORMATION</A></TD>
    <TD STYLE="width: 10%; text-align: right; padding-bottom: 5pt"><A HREF="#a_001">4</A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 5pt"><A HREF="#a_002">QUESTIONS AND ANSWERS</A></TD>
    <TD STYLE="text-align: right; padding-bottom: 5pt"><A HREF="#a_002">4</A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 5pt"><A HREF="#a_003">PROPOSAL 1 ELECTION OF DIRECTORS</A></TD>
    <TD STYLE="text-align: right; padding-bottom: 5pt"><A HREF="#a_003">9</A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 5pt"><A HREF="#a_004">Class III Director Nominees</A></TD>
    <TD STYLE="text-align: right; padding-bottom: 5pt"><A HREF="#a_004">9</A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 5pt"><A HREF="#a_005">Class I Directors &#8211; Term Expiring 2024</A></TD>
    <TD STYLE="text-align: right; padding-bottom: 5pt"><A HREF="#a_005">10</A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 5pt"><A HREF="#a_006">Class II Directors &#8211; Term Expiring 2025</A></TD>
    <TD STYLE="text-align: right; padding-bottom: 5pt"><A HREF="#a_006">10</A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 5pt"><A HREF="#a_007">Recommendation</A></TD>
    <TD STYLE="text-align: right; padding-bottom: 5pt"><A HREF="#a_007">11</A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-indent: -0.25in; padding-left: 0.25in; text-align: left; padding-bottom: 5pt"><A HREF="#a_008">PROPOSAL 2 APPROVAL OF AN INCREASE IN THE NUMBER OF SHARES OF COMMON STOCK AVAILABLE FOR ISSUANCE UNDER OUR 2021 PLAN</A></TD>
    <TD STYLE="text-align: right; padding-bottom: 5pt"><A HREF="#a_008">12</A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 5pt"><A HREF="#a_009">Summary of the Amended 2021 Plan</A></TD>
    <TD STYLE="text-align: right; padding-bottom: 5pt"><A HREF="#a_009">12</A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 5pt"><A HREF="#a_010">New Plan Benefits</A></TD>
    <TD STYLE="text-align: right; padding-bottom: 5pt"><A HREF="#a_010">15</A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 5pt"><A HREF="#a_011">Historical Equity Awards Table</A></TD>
    <TD STYLE="text-align: right; padding-bottom: 5pt"><A HREF="#a_011">15</A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 5pt"><A HREF="#a_012">Federal Income Tax Information with Respect to the Amended 2021 Plan</A></TD>
    <TD STYLE="text-align: right; padding-bottom: 5pt"><A HREF="#a_012">16</A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 5pt"><A HREF="#a_013">Recommendation</A></TD>
    <TD STYLE="text-align: right; padding-bottom: 5pt"><A HREF="#a_013">17</A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 5pt"><A HREF="#a_014">PROPOSAL 3 RATIFICATION OF APPOINTMENT OF OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</A></TD>
    <TD STYLE="text-align: right; padding-bottom: 5pt"><A HREF="#a_014">18</A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 5pt"><A HREF="#a_015">Audit and Other Fees</A></TD>
    <TD STYLE="text-align: right; padding-bottom: 5pt"><A HREF="#a_015">18</A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 5pt"><A HREF="#a_016">Policy on Pre-Approval of Audit and Non-Audit Services</A></TD>
    <TD STYLE="text-align: right; padding-bottom: 5pt"><A HREF="#a_016">19</A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 5pt"><A HREF="#a_017">Recommendation</A></TD>
    <TD STYLE="text-align: right; padding-bottom: 5pt"><A HREF="#a_017">19</A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 5pt"><A HREF="#a_049">AUDIT COMMITTEE REPORT</A></TD>
    <TD STYLE="text-align: right; padding-bottom: 5pt"><A HREF="#a_049">20</A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 5pt"><A HREF="#a_018">PROPOSAL 4 ADVISORY VOTE ON EXECUTIVE COMPENSATION</A></TD>
    <TD STYLE="text-align: right; padding-bottom: 5pt"><A HREF="#a_018">21</A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 5pt"><A HREF="#a_019">Recommendation</A></TD>
    <TD STYLE="text-align: right; padding-bottom: 5pt"><A HREF="#a_019">21</A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 5pt"><A HREF="#a_020">EXECUTIVE OFFICERS</A></TD>
    <TD STYLE="text-align: right; padding-bottom: 5pt"><A HREF="#a_020">22</A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 5pt"><A HREF="#a_021">CORPORATE GOVERNANCE</A></TD>
    <TD STYLE="text-align: right; padding-bottom: 5pt"><A HREF="#a_021">24</A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 5pt"><A HREF="#a_022">Classified Board of Directors</A></TD>
    <TD STYLE="text-align: right; padding-bottom: 5pt"><A HREF="#a_022">24</A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 5pt"><A HREF="#a_023">Director Independence</A></TD>
    <TD STYLE="text-align: right; padding-bottom: 5pt"><A HREF="#a_023">24</A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 5pt"><A HREF="#a_024">Board Leadership Structure</A></TD>
    <TD STYLE="text-align: right; padding-bottom: 5pt"><A HREF="#a_024">24</A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 5pt"><A HREF="#a_025">Board Diversity Matrix</A></TD>
    <TD STYLE="text-align: right; padding-bottom: 5pt"><A HREF="#a_025">25</A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 5pt"><A HREF="#a_026">Board Committees</A></TD>
    <TD STYLE="text-align: right; padding-bottom: 5pt"><A HREF="#a_026">25</A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 5pt"><A HREF="#a_027">Director Qualification Standards</A></TD>
    <TD STYLE="text-align: right; padding-bottom: 5pt"><A HREF="#a_027">26</A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 5pt"><A HREF="#a_028">Code of Business Conduct and Ethics</A></TD>
    <TD STYLE="text-align: right; padding-bottom: 5pt"><A HREF="#a_028">26</A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 5pt"><A HREF="#a_029">Compensation Committee Interlocks and Insider Participation</A></TD>
    <TD STYLE="text-align: right; padding-bottom: 5pt"><A HREF="#a_029">26</A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 5pt"><A HREF="#a_030">Role of the Board in Risk Oversight</A></TD>
    <TD STYLE="text-align: right; padding-bottom: 5pt"><A HREF="#a_030">26</A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 5pt"><A HREF="#a_031">Evaluations of the Board of Directors</A></TD>
    <TD STYLE="text-align: right; padding-bottom: 5pt"><A HREF="#a_031">27</A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 5pt"><A HREF="#a_032">Meetings of the Board of Directors</A></TD>
    <TD STYLE="text-align: right; padding-bottom: 5pt"><A HREF="#a_032">27</A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 5pt"><A HREF="#a_033">Director Attendance at the Annual Meeting of Stockholders</A></TD>
    <TD STYLE="text-align: right; padding-bottom: 5pt"><A HREF="#a_033">27</A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 5pt"><A HREF="#a_034">Prohibition on Hedging and Pledging of Company Securities</A></TD>
    <TD STYLE="text-align: right; padding-bottom: 5pt"><A HREF="#a_034">27</A></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%">
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 5pt"><A HREF="#a_035">Communications with the Board</A></TD>
    <TD STYLE="text-align: right; padding-bottom: 5pt"><A HREF="#a_035">27</A></TD></TR>

<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="width: 90%; text-align: left; padding-bottom: 5pt"><A HREF="#a_036">CERTAIN RELATIONSHIPS AND RELATED-PERSON TRANSACTIONS</A></TD>
    <TD STYLE="width: 10%; text-align: right; padding-bottom: 5pt"><A HREF="#a_036">28</A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 5pt"><A HREF="#a_037">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</A></TD>
    <TD STYLE="text-align: right; padding-bottom: 5pt"><A HREF="#a_037">29</A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 5pt"><A HREF="#a_038">COMPENSATION OF EXECUTIVE OFFICERS AND DIRECTORS</A></TD>
    <TD STYLE="text-align: right; padding-bottom: 5pt"><A HREF="#a_038">30</A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 5pt"><A HREF="#a_039">Executive Compensation</A></TD>
    <TD STYLE="text-align: right; padding-bottom: 5pt"><A HREF="#a_039">30</A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 5pt"><A HREF="#a_040">Employment Agreements</A></TD>
    <TD STYLE="text-align: right; padding-bottom: 5pt"><A HREF="#a_040">30</A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 5pt"><A HREF="#a_051">2022 Outstanding Equity Awards at Fiscal Year-End</A></TD>
    <TD STYLE="text-align: right; padding-bottom: 5pt"><A HREF="#a_051">32</A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 5pt"><A HREF="#a_043">Risks Related to Compensation Policies and Practices</A></TD>
    <TD STYLE="text-align: right; padding-bottom: 5pt"><A HREF="#a_043">32</A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 5pt"><A HREF="#a_044">Pay Versus Performance</A></TD>
    <TD STYLE="text-align: right; padding-bottom: 5pt"><A HREF="#a_044">33</A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 5pt"><A HREF="#a_045">2022 Director Compensation</A></TD>
    <TD STYLE="text-align: right; padding-bottom: 5pt"><A HREF="#a_045">35</A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 5pt"><A HREF="#a_050">EQUITY COMPENSATION PLAN INFORMATION</A></TD>
    <TD STYLE="text-align: right; padding-bottom: 5pt"><A HREF="#a_050">36</A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 5pt"><A HREF="#a_046">WHERE YOU CAN FIND MORE INFORMATION</A></TD>
    <TD STYLE="text-align: right; padding-bottom: 5pt"><A HREF="#a_046">37</A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 5pt"><A HREF="#a_047">FORM 10-K</A></TD>
    <TD STYLE="text-align: right; padding-bottom: 5pt"><A HREF="#a_047">37</A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 5pt"><A HREF="#a_048">APPENDIX A&nbsp; CELLECTAR BIOSCIENCES, INC. 2021 STOCK INCENTIVE PLAN, AS AMENDED</A></TD>
    <TD STYLE="text-align: right; padding-bottom: 5pt"><A HREF="#a_048">A-1</A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Cellectar Biosciences, Inc.<BR>
PROXY STATEMENT<BR>
FOR THE ANNUAL MEETING OF STOCKHOLDERS<BR>
To be held on June 14, 2023</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><A NAME="a_001"></A>GENERAL
INFORMATION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This proxy statement is furnished to the stockholders
of Cellectar Biosciences, Inc. (the &#8220;Company&#8221;, &#8220;Cellectar&#8221;, &#8220;we&#8221;, &#8220;us&#8221;, &#8220;our&#8221;)
in connection with the solicitation of proxies by and on behalf of the Board of Directors of the Company (the &#8220;Board of Directors&#8221;
or the &#8220;Board&#8221;) for use at the 2023 Annual Meeting of Stockholders (the &#8220;Annual Meeting&#8221;) on June 14, 2023 at
10:00 A.M., local time, and at any adjournment or adjournments thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We will hold the Annual Meeting as a virtual meeting
held entirely over the Internet. You will be able to attend the Annual Meeting, vote your shares electronically and submit your questions
online by visiting www.virtualshareholdermeeting.com/CLRB2023 and entering the 16-digit control number included in your Notice of Internet
Availability of Proxy Materials (the &#8220;Notice&#8221;), your proxy card, or the voting instructions that accompanied these proxy materials.
We believe that conducting the Annual Meeting as a virtual meeting will encourage higher levels of stockholder participation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As permitted by the rules of the SEC, we are making
this proxy statement and our Annual Report on Form 10-K for the fiscal year ended December 31, 2022, available to our stockholders electronically
via the Internet at www.proxyvote.com. On or about April 28, 2023, we mailed to our stockholders a Notice containing instructions on how
to access this proxy statement and vote online. If you received a Notice by mail, you will not receive a printed copy of the proxy materials
in the mail unless you specifically request them pursuant to the instructions provided in the Notice. This process allows us to provide
our stockholders with the information they need on a more timely basis, while reducing the environmental impact and lowering the costs
of printing and distributing our proxy materials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Please note that information contained on our website
does not constitute a part of, and is not incorporated by reference into, this proxy statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><A NAME="a_002"></A>QUESTIONS
AND ANSWERS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Why am I receiving these materials?</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are distributing our proxy materials because
our Board of Directors is soliciting your proxy to vote at the Annual Meeting. This proxy statement summarizes the information you need
to vote at the Annual Meeting. You do not need to attend the Annual Meeting to vote your shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>What proposals will be voted on at our Annual Meeting?</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Stockholders will vote on four proposals at our
Annual Meeting:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">1.</TD><TD>the election of two Class III director nominees;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">2.</TD><TD>the approval of an increase in the number of shares of common stock available for issuance under our 2021 Stock Incentive Plan (the
 &#8220;2021 Plan&#8221;) by 1,100,000 shares (the &#8220;2021 Plan Proposal&#8221;);</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">3.</TD><TD>the ratification of the appointment of Baker Tilly US, LLP as our independent registered public accounting firm for the fiscal year
ending December 31, 2023; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">4.</TD><TD>to hold a non-binding advisory vote to approve named executive officer compensation.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We will also consider other business, if any,
that properly comes before our Annual Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>What happens if other business not discussed in this proxy statement
comes before the meeting?</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company does not know of any business to be
presented at the Annual Meeting other than the proposals discussed in this proxy statement. If other business comes before the meeting
and is proper under our Certificate of Incorporation, our by-laws, and Delaware General Corporation Law (&#8220;DGCL&#8221;), the named
proxies will use their discretion in casting all of the votes that they are entitled to cast.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>How does our Board recommend that stockholders vote on the proposals?</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our Board recommends that stockholders vote &#8220;<B>FOR</B>&#8221;
the election of each director nominee, &#8220;<B>FOR</B>&#8221; the approval of the 2021 Plan Proposal, &#8220;<B>FOR</B>&#8221; the
ratification of the appointment of Baker Tilly US, LLP as our independent registered public accounting firm for the fiscal year ending
December 31, 2023 and &#8220;<B>FOR</B>&#8221; the approval, on a non-binding advisory basis, of named executive officer compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Who is entitled to vote?</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Record Date for our Annual Meeting is the close
of business on April 25, 2023. As of the Record Date, there were issued, outstanding and entitled to vote 9,740,507 shares of our common
stock, $0.00001 par value per share. Only stockholders of record of our common stock as of the Record Date will be entitled to receive
notice of, and to vote at, the Annual Meeting or any adjournment or postponement thereof. Each stockholder is entitled to one vote for
each share of our common stock held by such stockholder on the Record Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>What do I need for admission to our Annual Meeting?</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You will be able to attend
the Annual Meeting by visiting www.virtualshareholdermeeting.com/CLRB2023 and using your 16-digit control number included on your Notice,
on your Proxy Card, or on the instructions that accompanied your Proxy Materials to enter the meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The virtual meeting platform
is fully supported across major web browsers and multiple device types. Participants should ensure that they have a strong internet connection
wherever they intend to participate in the Annual Meeting. Please allow ample time for online check-in, which will begin at 9:45 a.m.
Eastern Time. We will have technicians ready to assist you with any technical difficulties you may have accessing the virtual Annual Meeting.
If you encounter any difficulties accessing the virtual Annual Meeting during check-in or during the meeting, please call the technical
support number that will be posted on the virtual meeting login page. We will endeavor to answer as many questions submitted by stockholders
as time permits at the Annual Meeting. Further information regarding procedures for asking questions and rules of conduct for the meeting
will be posted on the virtual meeting login page. A replay of our Annual Meeting webcast will be available at www.virtualshareholdermeeting.com/CLRB2023
and will remain there for one year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>How can I vote my shares without attending our Annual Meeting?</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If you are a holder of record of shares of common
stock of the Company, you may direct your vote without attending the Annual Meeting by following the instructions on your Notice or proxy
card.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If you are a beneficial owner who holds your shares
in street name, you have the right to direct your broker, bank, trustee, or other nominee on how to vote the shares held in your account.
You should follow the instructions in the proxy materials provided to you by that organization to vote your shares or direct the organization
on how to vote your shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Can I change my vote or revoke my proxy? </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">You may change your vote or revoke your proxy at
any time before it is voted at the Annual Meeting. If you are a stockholder of record, you may change your vote or revoke your proxy by:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>delivering a written notice of revocation of your proxy to the attention of the Secretary at the following address: 100 Campus Drive,
Florham Park, New Jersey 07932;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>delivering to us an authorized proxy bearing a later date (including a proxy over the Internet or by telephone); or</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>attending the virtual Annual Meeting and voting during the meeting. Attendance at the Annual Meeting will not, by itself, revoke a
proxy.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If your shares are held in the name of a bank,
broker or other nominee, you may change your vote by submitting new voting instructions to your bank, broker or other nominee, or as otherwise
instructed by such bank, broker or nominee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>What is a broker non-vote? </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Brokers, banks or other
nominees holding shares on behalf of a beneficial owner may vote those shares in their discretion on certain &#8220;routine&#8221;
matters even if they do not receive timely voting instructions from the beneficial owner. With respect to &#8220;non-routine&#8221;
matters, the broker, bank or other nominee is not permitted to vote shares for a beneficial owner without timely received voting
instructions. The only routine matter to be presented at the Annual Meeting is the proposal to ratify the appointment of Baker Tilly
US, LLP as our independent registered public accounting firm for the fiscal year ending December&nbsp;31, 2023 (Proposal Three). The
election of the Class&nbsp;III directors (Proposal One), the 2021 Plan Proposal (Proposal Two) and the approval, on a non-binding
advisory basis, of named executive officer compensation (Proposal Four) are non-routine matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">A broker non-vote occurs when
a broker, bank or other nominee does not vote on a non-routine matter because the beneficial owner of such shares has not provided voting
instructions with regard to such matter. If a broker, bank or other nominee exercises their discretionary voting authority on Proposal
Four, such shares will be considered present at the Annual Meeting for quorum purposes and broker non-votes will occur as to the other
proposals or any other non-routine matters that are properly presented at the Annual Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>What constitutes a quorum?</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In accordance with our by-laws, the presence at
the Annual Meeting, either in person or by proxy, of holders of a majority of the aggregate number of shares of our issued and outstanding
common stock entitled to vote thereat as of the Record Date shall constitute a quorum for the transaction of business at the Annual Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>What vote is required to approve each matter to be considered at
our Annual Meeting?</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Election of Class III Directors (Proposal One).</I>
Our by-laws provide for a plurality voting standard for the election of directors in uncontested elections. An abstention or a broker
non-vote on Proposal One will not have any effect on the election of the director.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>2021 Plan Proposal (Proposal Two).</I> Proposal
Two asks our stockholders to approve an increase in the number of shares of common stock available for issuance under our 2021 Plan by
1,100,000 shares. The affirmative vote of a majority of the votes cast is required for approval of Proposal Two. An abstention or a broker
non-vote will not affect the outcome of Proposal Two.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Ratification of the Appointment of Baker Tilly
US, LLP as Our Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2023 (Proposal Three). </I>The affirmative
vote of a majority of the votes cast is required for the approval of Proposal Three. An abstention on Proposal Four will not have any
effect on Proposal Three. Brokers will have discretionary authority to vote on this proposal. Accordingly, there will not be any broker
non-votes on Proposal Three.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Advisory Vote on Executive Compensation (Proposal
Four)</I>. The affirmative vote of a majority of the votes cast is required for approval of Proposal Four. An abstention or a broker non-vote
will not affect the outcome of Proposal Four.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>What is the deadline for submitting a proxy? </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">To ensure that proxies are received in time to
be counted prior to the Annual Meeting, proxies submitted by Internet or by telephone should be received by 11:59 p.m. Eastern Time on
the day before the Annual Meeting, and proxies submitted by mail should be received by the close of business on the day prior to the date
of the Annual Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>What does it mean if I receive more than one Notice or proxy card?
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If you hold your shares in more than one account,
you will receive a Notice or proxy card for each account. To ensure that all of your shares are voted, please complete, sign, date and
return a proxy card for each account or follow the voting instructions on the Notice or proxy card for each account to vote your shares.
To ensure that all your shares are represented at the Annual Meeting, we recommend that you vote with regard to every Notice or proxy
card that you receive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>How will my shares be voted if I return a blank proxy card or a
blank voting instruction card? </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If you are a holder of record
of our common stock and you sign and return a proxy card or otherwise submit a proxy without giving specific voting instructions, your
shares will be voted:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>&#8220;<B>FOR</B>&#8221; the election of two Class III director nominees;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>&#8220;<B>FOR</B>&#8221; the 2021 Plan Proposal;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">&#8220;<B>FOR</B>&#8221; the ratification of the appointment of Baker Tilly US, LLP as our independent
registered public accounting firm for the fiscal year ended December 31, 2023; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">&#8220;<B>FOR</B>&#8221; the approval, on a non-binding advisory basis, of named executive officer compensation.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">If you hold your shares in
street name via a broker, bank or other nominee and do not provide the broker, bank or other nominee with voting instructions, your shares:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">will be counted as present for purposes of establishing a quorum;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">will be voted in accordance with the broker&#8217;s, bank&#8217;s or other nominee&#8217;s discretion
the proposal to ratify the appointment of Baker Tilly US, LLP as our independent registered public accounting firm for the fiscal year
ending December 31, 2023 (Proposal Three); and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">will not be voted in connection with the election of two Class&nbsp;III director nominees named in this
proxy statement (Proposal One), the 2021 Plan Proposal (Proposal Two) or the approval, on a non-binding advisory basis, of named executive
officer compensation (Proposal Four), or any other non-routine matters that are properly presented at the Annual Meeting. For each of
these proposals, your shares will be treated as &#8220;broker non-votes.&#8221; A broker non-vote will have no impact on voting results
of the proposals to be presented at the Annual Meeting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Our Board of Directors knows
of no matter to be presented at the Annual Meeting other than as described above. If any other matters properly come before the Annual
Meeting upon which a vote properly may be taken, shares represented by all proxies received by us will be voted with respect thereto as
permitted and in accordance with the judgment of the proxy holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Who is making this solicitation and who will pay the costs?</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This proxy solicitation is being made on behalf
of the Board. We will pay all of the costs of this proxy solicitation. We will also reimburse brokers, banks, nominees and other fiduciaries
for their expenses in sending these materials to you and getting your voting instructions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Will a stockholder list be available for inspection?</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In accordance with DGCL, a list of stockholders
of record entitled to vote at the Annual Meeting will be open to examination by any stockholder, for any purpose germane to the Annual
Meeting, during normal business hours for a period of ten days before the Annual Meeting at our corporate offices at 100 Campus Drive,
Florham Park, New Jersey 07932.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>What is &#8220;householding&#8221; and how does it affect me?</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have adopted a procedure approved by the SEC,
called &#8220;householding.&#8221; Under this procedure, we send only one proxy statement and one annual report to eligible stockholders
who share a single address, unless we have received instructions to the contrary from any stockholder at that address. This practice is
designed to eliminate duplicate mailings, conserve natural resources and reduce our printing and mailing costs. Stockholders who participate
in householding will continue to receive separate proxy cards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If you share an address with another stockholder
and receive only one set of proxy materials but would like to request a separate copy of these materials, please contact our mailing agent,
Broadridge Financial Solutions toll free at 1-866-540-7095 or via mail at the Householding Department, 51 Mercedes Way, Edgewood, New
York 11717. Similarly, if you receive multiple copies of the proxy materials and would prefer to receive a single copy in the future,
you may also contact Broadridge Financial Solutions, Inc. at the above telephone number or address. Stockholders can also contact Investor
Relations, Cellectar Biosciences, Inc., 100 Campus Drive, Florham Park, New Jersey 07932, by telephone at (608) 441-8120 or by e-mail
to investors@cellectar.com in this manner to indicate that they wish to receive separate sets of proxy materials, or to request that we
send only a single set of materials, as applicable. If you own shares through a bank, broker, or other nominee, you should contact the
nominee concerning householding procedures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>How can I find out the results of the voting at the Annual Meeting?
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We will announce preliminary voting results at
the Annual Meeting. We will also disclose voting results on a Current Report on Form 8-K that we will file with the Securities and Exchange
Commission (the &#8220;SEC&#8221;) within four business days after the Annual Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>When are stockholder proposals or director nominations due for next
year&#8217;s Annual Meeting?</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our stockholders are entitled to present proposals
for action at a forthcoming meeting if they comply with the requirements of our Certificate of Incorporation, our by-laws, and the rules
established by the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under Rule 14a-8 under the Securities Exchange
Act of 1934 (the &#8220;Exchange Act&#8221;), if you want us to include a proposal in the proxy materials for our 2023 annual meeting
of stockholders, we must receive the proposal at our executive offices at 100 Campus Drive, Florham Park, New Jersey 07932, no later than
December 30, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to our by-laws, a stockholder proposal
of business submitted outside of the process established in Rule 14a-8 and nominations of directors must be received no earlier than February
15, 2024 and not later than March 16, 2024 and must otherwise comply with the requirements set forth in our by-laws. Any proposal or nomination
should be addressed to the attention of the Secretary, and we suggest that it be sent by certified mail, return receipt requested or through
another mailing service that provides tracking information and proof of receipt.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition to satisfying the requirements of our
by-laws, to comply with the universal proxy rules, stockholders who intend to solicit proxies in support of director nominees other than
the Company&#8217;s nominees must provide notice that sets forth the information required by Rule 14a-19 under the Exchange Act no later
than April 15, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Who can I contact for further information? </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If you would like additional copies, without charge,
of this proxy statement or if you have questions about the Annual Meeting, the proposals, or the procedures for voting your shares, you
should contact the Company&#8217;s Secretary at 100 Campus Drive, Florham Park, New Jersey 07932 or by telephone at (608) 441-8120. &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">MATTERS TO BE CONSIDERED AT THE ANNUAL MEETING</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><A NAME="a_003"></A>PROPOSAL
1<BR>
ELECTION OF DIRECTORS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our Board of Directors currently consists of six
directors divided into three classes: Class I, Class II and Class III. Each director serves a term of three years and until his or her
successor is duly elected and qualified. This year, the term of the Class III directors, Stefan D. Loren, Ph.D. and Douglas J. Swirsky,
is expiring.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our Board of Directors has nominated Dr. Loren
and Mr. Swirsky to serve as Class III directors for a three-year term, until the 2026 Annual Meeting of Stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If a nominee at the time of the election is unable
or unwilling to serve or is otherwise unavailable for election and our Board of Directors designates another nominee, the persons named
as proxies will vote the proxy for such substitute, if any. Our nominees have consented to being named in this proxy statement and have
agreed to serve if reelected, and our Board of Directors has no reason to believe that the nominees will be unable to serve.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our directors as of the date hereof are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">Name</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Class</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Age</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold">Director Since</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">Board Committee</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 27%; font-size: 10pt; text-align: left">James V. Caruso<SUP>(1)</SUP></TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 6%; font-size: 10pt; text-align: center">II</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 6%; font-size: 10pt; text-align: center">64</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 10%; font-size: 10pt; text-align: center">2015</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#8210;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Douglas J. Swirsky<SUP>(2)</SUP></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">III</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">53</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">2017</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">Compensation, Nominating and Corporate Governance</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Asher Chanan-Khan, M.B.B.S., M.D.</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">I</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">54</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">2021</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">Audit</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Frederick W. Driscoll </TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">II</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">72</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">2017</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">Compensation, Audit (Chair)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Stefan D. Loren, Ph.D. <SUP></SUP></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">III</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">59</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">2015</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">Nominating and Corporate Governance (Chair), Audit</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">John Neis </TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">I</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">67</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">2008</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">Compensation (Chair), Nominating and Corporate Governance</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><SUP>(1)</SUP></TD><TD>President and Chief Executive Officer</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><SUP>(2)</SUP></TD><TD>Chairman of the Board</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following biographical descriptions set forth
certain information with respect to the nominees for election as Class III directors as well as the continuing directors who are not up
for election at the Annual Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><A NAME="a_004"></A>Class III Director Nominees</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Stefan D. Loren, Ph.D. </B>Dr. Loren is currently
a managing director with Oppenheimer and Company&#8217;s healthcare investment banking group, a position he has held since November 2017.
Prior to this position, he was the founder and managing member of Loren Capital Strategy (LCS), a strategic consulting and investment
firm focused on life science companies since February 2014. Prior to LCS, he headed the life science practice of Westwicke Partners, a
healthcare-focused consulting firm from July 2008 to February 2014. Prior to joining Westwicke, he worked as an Analyst/Portfolio Manager
with Perceptive Advisors, a health care hedge fund, and MTB Investment Advisors, a long-term oriented family of equity funds. His focus
areas included biotechnology, specialty pharmaceuticals, life science tools, and health care service companies. Prior to moving to the
buy side, Dr. Loren was Managing Director, Health Care Specialist/Desk Analyst for Legg Mason where he discovered, evaluated, and communicated
investment opportunities in the health care area to select clients. In addition, he assisted both advising management teams on strategic
options. He started his Wall Street career as a sell side analyst at Legg Mason covering biotechnology, specialty pharmaceuticals, life
science tools, pharmaceuticals, and chemistry outsourcing companies. In his research career, Dr. Loren was an early member of Abbott Laboratories
Advanced Technologies Division, analyzing and integrating new technological advances in Abbott&#8217;s pharmaceutical research. Prior
to that, he was a researcher at The Scripps Research Institute, a nonprofit American medical research facility, working with Nobel Laureate
K. Barry Sharpless on novel synthetic routes to chiral drugs. Dr. Loren received a doctorate in Organic Chemistry from the University
of California at Berkeley and an undergraduate degree in Chemistry from UCSD. His scientific work has been featured in Scientific American,
Time, Newsweek, and Discover, as well as other periodicals and journals. Dr. Loren&#8217;s extensive experience in the biotechnology and
financial industries make him a highly qualified member of our Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Douglas J. Swirsky.</B> Since
March&nbsp;2023, Mr.&nbsp;Swirsky has served as Chief Financial Officer of MaxCyte, Inc., a publicly traded biotechnology company.
Prior to joining MaxCyte, Mr. Swirsky served as Chief Financial Officer and Treasurer of AavantiBio, Inc., a privately held
biotechnology company from February 2021 to December 2022, and previously served as AavantiBio&#8217;s Interim President and a
director from May 2020 to October 2020. Prior to AavantiBio, Mr.&nbsp;Swirsky served as President, Chief Executive Officer and a
director of Rexahn Pharmaceuticals, a clinical-stage biopharmaceutical company from November&nbsp;2018 to November&nbsp;2020, having
previously served as Rexahn&#8217;s President and Chief Financial Officer from January&nbsp;2018 until his appointment as CEO. Prior
to Rexahn, Mr.&nbsp;Swirsky served as President and Chief Executive Officer of GenVec,&nbsp;Inc., a clinical-stage biopharmaceutical
company, from 2013 to June&nbsp;2017. From 2006 until his appointment as CEO in 2013, Mr.&nbsp;Swirsky served as Senior Vice
President, Chief Financial Officer, Treasurer and Corporate Secretary of GenVec. Mr.&nbsp;Swirsky previously held investment banking
positions at Stifel, UBS, PaineWebber, Morgan Stanley, and Legg Mason. His experience also includes positions in public accounting
and consulting. Mr.&nbsp;Swirsky received his undergraduate degree in business administration from Boston University and his M.B.A.
from the Kellogg School of Management at Northwestern University. Mr.&nbsp;Swirsky is a Certified Public Accountant and a
CFA<SUP>&reg;</SUP>&nbsp;charterholder. Within the past five years, Mr.&nbsp;Swirsky has also served on the board of Fibrocell
Science,&nbsp;Inc., Pernix Therapeutics Holdings,&nbsp;Inc. and NeuroBo Pharmaceuticals, Inc. Mr.&nbsp;Swirsky&#8217;s distinguished
career in financial services and corporate management, including his investment banking experience and his experience serving as a
principal executive officer and principal financial officer, make him a highly qualified member of our Board of Directors.
Mr.&nbsp;Swirsky has completed the NACD Directorship Certification<SUP>&reg;</SUP>&nbsp;program, which is designed to enhance a
director&#8217;s ability to effectively contribute in the boardroom.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><A NAME="a_005"></A>Class I Directors &#8211; Term Expiring 2024</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Asher Chanan-Khan, M.B.B.S., M.D.</B> Dr. Chanan-Khan
currently serves as Professor of Medicine &amp; Oncology at the Mayo Clinic School of Medicine, a position he has held since November
2011. He served as Chair, Department of Hematology &amp; Oncology at the Mayo Clinic, Florida from October 2011 to January 2018. Prior
to joining Mayo Clinic, Dr. Chanan-Khan spent over a decade as an attending physician at the Roswell Park Comprehensive Cancer Center.
He was a tenured member of the Faculty of Medicine at the State University of New York (SUNY) Buffalo. Dr. Chanan-Khan received his Bachelor
of Medicine and Bachelor of Surgery from the Allama Iqbal Medical College of Punjab University in Lahore Pakistan. He then completed an
internship and residency in Internal Medicine from the College of Physicians &amp; Surgeons at Columbia University in New York followed
by fellowships in Hematology and Medical Oncology from New York University. In addition, he also completed a fellowship in translational
research from Dr. Takeshita&#8217;s laboratory at NYU. Dr. Chanan-Khan&#8217;s extensive experience in oncology and hematology make him
a highly qualified member of our Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>John Neis. </B> Mr. Neis is a Managing Director
of Venture Investors LLC, a healthcare-focused venture capital firm, a position he has held since 2021. He led the firm and headed the
firm&#8217;s Health Care practice from 2000 to 2021. He was recently named to join the Board of Directors of the National Venture Capital
Association. He also serves on the Board of Directors of privately held Delphinus Medical Technologies, Inc. and Health Scholars, Inc.
He serves on the Board of Directors of the Wisconsin Technology Council, the science and technology advisor to Wisconsin&#8217;s Governor
and Legislature. He serves on the Board of Trustees at the Morgridge Institute for Research. He also serves on the Weinert Applied Ventures
Program Advisory Board in the School of Business and chairs the Tandem Press Advisory Board in the School of Education at the University
of Wisconsin &#8211; Madison. He holds a B.S. in finance from the University of Utah, and received a M.S. in Marketing and Finance from
the University of Wisconsin &#8211; Madison. He is a Chartered Financial Analyst. Mr. Neis&#8217; extensive experience leading emerging
companies and his financial experience makes him a highly qualified member of our Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><A NAME="a_006"></A>Class II Directors &#8211; Term Expiring 2025</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>James V. Caruso. </B>Mr. Caruso came to Cellectar
from Hip Innovation Technology, a medical device company where he was a founder and served as Executive Vice President and Chief Operating
Officer from August 2010 to June 2015, and he currently serves on their board. Prior to his time at Hip Innovation Technology, he was
Executive Vice President and Chief Commercial Officer of Allos Therapeutics, Inc., an oncology company acquired by Spectrum Pharmaceuticals,
from June 2006 to August 2010. He was also Senior Vice President, Sales and Marketing, from June 2002 to May 2005, at Bone Care International,
Inc., a specialty pharmaceutical company that was acquired by Genzyme Corporation. In addition, Mr. Caruso has held key positions at several
well-known pharmaceutical companies, including Novartis, where he was Vice President of Neuroscience Specialty Sales, BASF Pharmaceuticals-Knoll,
where he was Vice President, Sales, and Bristol-Myers Squibb Company in several senior roles. Mr. Caruso earned a Bachelor of Science
degree in Finance from the University of Nevada. Mr. Caruso&#8217;s extensive experience in the biotechnology industry and his recent
experience as our Chief Executive Officer make him a highly qualified member of our Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Frederick W. Driscoll. </B>Mr. Driscoll
currently serves as Interim CFO for Invivyd, Inc., a biopharmaceutical company developing antibody therapies for infectious
diseases, a position he has held since October 2022. Mr. Driscoll served as CFO of Renovacor from March to June in 2022, while the
company was in the process of being sold to Rocket Pharmaceuticals. Mr. Driscoll served as Chief Financial Officer at Flexion
Therapeutics, a biopharmaceutical company, from 2013 to 2017, spearheading an initial public offering in 2014. Prior to joining
Flexion, he was Chief Financial Officer at Novavax, Inc., a publicly traded biopharmaceutical company, from 2009 to 2013. From 2008
to 2009, Mr. Driscoll served as Chief Executive Officer of Genelabs Technologies, Inc., a publicly traded biopharmaceutical and
diagnostics company later acquired by GlaxoSmithKline. He previously served as Genelabs&#8217; Chief Financial Officer from 2007 to
2008. From 2000 to 2006, Mr. Driscoll served as Chief Executive Officer at OXiGENE, Inc., a biopharmaceutical company. Mr. Driscoll
has also served as Chairman of the Board and Audit Committee Chair at OXiGENE and as a member of the Audit Committee for Cynapsus, a
specialty central nervous system pharmaceutical company which was sold to Sunovion Pharmaceuticals in 2016. Mr. Driscoll earned a
Bachelor&#8217;s degree in accounting and finance from Bentley University. Mr. Driscoll is a member of the board of directors of Cue
Biopharma and MEI Pharma. Mr. Driscoll&#8217;s significant corporate management and board experience at multiple biotechnology
companies as well as his strong financial background make him a highly qualified member of our Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><A NAME="a_007"></A>Recommendation</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Our Board of Directors recommends that you vote
<U>FOR</U> the election of Dr. Loren and Mr. Swirsky.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">MATTERS TO BE CONSIDERED AT ANNUAL MEETING</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><A NAME="a_008"></A>PROPOSAL
2<BR>
APPROVAL OF AN INCREASE IN THE NUMBER OF SHARES OF COMMON STOCK AVAILABLE FOR ISSUANCE UNDER OUR 2021 PLAN</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our Board has adopted and is seeking stockholder
approval of an amendment to our 2021 Plan to increase the number of shares of common stock that are available to be issued under the 2021
Plan by 1,100,000 shares (subject to adjustment for stock splits, stock dividends and similar events). No additional changes to the 2021
Plan are proposed. There were 10,754 shares of common stock available for future grants or awards as of April 25, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our Board recommends approval of the increase in
shares of common stock available under the 2021 Plan in order to enable us to continue to provide equity compensation to attract, retain
and motivate current and prospective directors, officers, employees and consultants. Our Board believes that stock options and other forms
of equity compensation promote growth and provide a meaningful incentive to directors and employees of successful companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As a clinical phase biopharmaceutical business,
the Company relies heavily upon stock incentive compensation to attract and retain key employees and other key service providers and has
limited financial resources to utilize cash compensation as an alternative means to attract and retain such individuals. As of the Record
Date, there were 9,740,507 shares of our common stock outstanding. Our current dilution (which is the number of shares available for grant
under our equity compensation plans plus the number of shares subject to unexercised or unvested outstanding equity awards as of April&nbsp;25,
2023, divided by the total number of shares of our common stock outstanding) is approximately 13%. If the proposed amendment to the 2021
Plan is approved, the potential dilution from authorized issuances for stock-based awards will increase to approximately 24%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following is a summary of the material terms
of our 2021 Plan (as proposed to be amended, the &#8220;Amended 2021 Plan&#8221;). The summary is qualified in its entirety by reference
to the complete text of the Amended 2021 Plan. Stockholders are urged to read the actual text of the 2021 Plan and the proposed plan amendment,
which are set forth as Appendix A to this proxy statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><A NAME="a_009"></A>Summary of the Amended 2021 Plan</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Amended 2021 Plan terminates on the tenth anniversary
of its effective date of March&nbsp;4, 2021, unless it is earlier terminated by our Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Amended 2021 Plan authorizes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>the grant of stock options to purchase shares of common stock intended to qualify as incentive stock options (&#8220;incentive options&#8221;)&#894;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>the grant of stock options not intended to qualify as incentive options or which otherwise do not satisfy the requirements to be incentive options (&#8220;non-statutory options&#8221;)&#894;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>the grant of restricted and unrestricted shares of common stock&#894;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>the grant of rights to receive shares of common stock, cash payments or a combination of shares and cash based on, or measured by, appreciation in the market price of common stock (&#8220;stock appreciation rights&#8221;)&#894;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>the grant of units representing the right to receive, upon vesting, shares of common stock (&#8220;restricted stock units&#8221;); and</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>the grant of awards entitling the recipient to acquire shares of common stock or cash upon attainment of specified performance goals (&#8220;performance shares&#8221;).</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Amended 2021 Plan is administered by the Compensation
Committee of our Board (the &#8220;Compensation Committee&#8221;) consisting of not less than two (2) persons each of whom qualifies as
a &#8220;non-employee director&#8221; for purposes of Rule&nbsp;16b-3 under the Exchange Act. The Compensation Committee selects the individuals
to whom awards are granted and determines the terms of each award, subject to the provisions of the Amended 2021 Plan. The Compensation
Committee has the power and authority to grant and modify awards consistent with the terms of the Amended 2021 Plan, including the power
and authority to accelerate the exercisability or vesting of all or any portion of an award. Participants do not have a right to receive
dividend payments or dividend equivalent payments with respect to unvested shares of common stock subject to any outstanding awards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Awards other than incentive options may be
granted under the Amended 2021 Plan to officers, directors, employees, consultants and advisers who render services to us and our
subsidiaries. Incentive options may be granted under the Amended 2021 Plan to employees (including officers and directors who are
employees) of us or one of our subsidiaries. As of the Record Date, 5 non-employee directors, 5 executive officers and 10
non-officer employees were eligible to participate in the Amended 2021 Plan, if selected by the Compensation Committee for
participation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Shares Issuable Under the Amended 2021 Plan</I>.
The maximum number of shares of common stock which may be issued in respect of awards granted under the plan, subject to adjustment upon
changes in capitalization as described below, is 3,100,000 shares of common stock, plus an additional number of shares of common stock
that were available for awards under the Company&#8217;s Amended and Restated 2015 Stock Incentive Plan and Amended and Restated 2006
Stock Incentive Plan (the &#8220;Prior Plans&#8221;) at the time of the 2021 Plan first became effective. For purposes of this limitation,
the shares of common stock underlying any awards, or awards under the Prior Plans, as applicable, which are forfeited, cancelled, reacquired
by the Company or otherwise terminated (other than (i) shares of common stock tendered as payment for a stock option exercise; (ii) shares
of common stock withheld to cover taxes; (iii) shares of common stock added back that have been repurchased by the Company using stock
option proceeds; and (iv) stock-settled awards where only the actual shares delivered count against the plan) shall be added back to
the shares of common stock with respect to which awards may be granted under the Amended 2021 Plan. Shares of common stock issued under
the Amended 2021 Plan may be authorized but unissued shares or shares reacquired by the Company. As of the Record Date, the closing stock
price of a share of common stock as reported on Nasdaq was $1.48.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Incentive Options and Non-Statutory Options.</I>&nbsp;Stock
options represent the right to purchase shares of our common stock. The exercise price of all stock options granted under the Amended
2021 Plan must be at least equal to the fair market value of the common stock on the date of grant (110% in the case of an incentive option
granted to an optionee who owns stock possessing more than 10% of the voting power of all classes of our stock or the stock of any subsidiary
or parent corporation). The Compensation Committee determines when options become vested and exercisable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Stock options may not be exercisable more than
ten years from the date of grant (five years in the case of an incentive option held by an optionee who owns stock possessing more than
10% of the voting power of all classes of our stock or the stock of any subsidiary or parent corporation). The aggregate fair market value
(determined at the time of grant) of shares issuable pursuant to incentive options, which first become exercisable by an employee or officer
in any calendar year, may not exceed $100,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Options are non-transferable except by will or
by the laws of descent or distribution and are exercisable, during the optionee&#8217;s lifetime, only by the optionee. The Compensation
Committee in its discretion may determine the conditions with respect to any transfer or termination of any stock options granted under
the Amended 2021 Plan. In the absence of a specific period of time set forth in the applicable award agreement, following a termination
of employment, stock options generally will remain exercisable (to the extent vested as of the termination date) until:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>90 days following retirement or termination by us without cause&#894;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>30 days following voluntary termination by the optionee&#894;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>90 days following the permanent disability of the optionee&#894; and</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>180 days following the death of the optionee.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Provided however that in no event will any stock
option be exercisable after the expiration of the term of such stock option, and provided further that in the event that the optionee&#8217;s
employment with us or one of our subsidiaries is terminated for cause, any stock option held by such optionee will immediately terminate
and be of no further force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Payment of the exercise price may be made by one
or more of the following methods:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>with cash, certified or bank check or other instrument acceptable to the Compensation Committee&#894;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>if provided for in the option agreement, with shares of common stock that are not subject to restrictions having a fair market value equal to the option price for such shares&#894;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>if provided for in the option agreement, an exercise notice with irrevocable instructions to a broker to promptly deliver cash or a check payable to us to pay the purchase price&#894; or</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>if provided for in the option agreement, reduction of the number of shares of common stock otherwise issuable to the optionee upon the exercise of the stock option by a number of shares of common stock having a fair market value equal to the aggregate exercise price.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Restricted and Unrestricted Stock Awards</I>.
Restricted stock awards entitle the recipient the right to acquire, for such purchase price, if any, as may be determined by the Compensation
Committee, shares of common stock that are subject to restrictions on transferability and such other restrictions and conditions as the
Compensation Committee may determine at the time of grant. The Compensation Committee determines the restrictions and conditions, including
continued employment and/or achievement of pre-established performance goals and objectives. In the event of a termination of employment
by us or our subsidiaries for any reason, any shares of restricted stock which are not then vested will be automatically forfeited to
us. Upon satisfaction of the applicable restrictions and conditions, the shares of common stock subject to a restricted stock award become
transferable and our right of forfeiture will lapse., Unrestricted stock awards entitle the recipient to shares of common stock free
of any restrictions under the Amended 2021 Plan, as a purchase price (if any) determined by the Compensation Committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Stock Appreciation Rights</I>. Stock appreciation
rights entitle the holder the right to receive the appreciation of the fair market value of a specified number of shares of common stock
over the exercise price of the stock appreciation rights, subject to the satisfaction of such restrictions and conditions as the Compensation
Committee may determine. The exercise price of all stock appreciation rights granted under the Amended 2021 Plan must be at least equal
to the fair market value of the common stock on the date of grant. In the applicable award agreement, the Compensation Committee may determine
whether the amount of such appreciation will be settled in stock, cash or a combination of both.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Restricted Stock Units</I>. Restricted stock
unit awards entitle the holder the right to receive shares of common stock (or equivalent cash, at the Compensation Committee&#8217;s
discretion), subject to the satisfaction of such restrictions and conditions as the Compensation Committee may determine at the time of
grant. The Compensation Committee determines the restrictions and conditions applicable to any restricted stock units. Except to the extent
that the Compensation Committee provides otherwise, a recipient&#8217;s right in restricted stock units that have not vested will automatically
terminate immediately following the recipient&#8217;s termination of employment (or cessation of service relationship) with us and our
subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Performance Share Awards and Other Performance-Based
Awards</I>. Performance share awards entitle the holder the right to receive shares of common stock (or equivalent cash, at the Compensation
Committee&#8217;s discretion) upon the attainment of specified performance goals, subject to the satisfaction of such other restrictions
and conditions as the Compensation Committee may determine at the time of grant. The Compensation Committee determines the performance
goals, the periods during which the performance is measured and all other restrictions and conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Amendment or Termination of the Amended 2021
Plan</I>. Our Board may amend or terminate the Amended 2021 Plan at any time and from time to time, and the Compensation Committee may
amend or cancel outstanding awards for changes in the law or other lawful purpose, provided that (i) such changes may not adversely affect
the rights under outstanding awards without the consent of the holder and (ii) neither the Board nor the Compensation Committee will have
the power or authority to decrease the exercise price of any outstanding stock option or stock appreciation right, other than in connection
with certain corporate events impacting the Company&#8217;s capital stock. No award granted under the Amended 2021 Plan while the plan
is in effect will be adversely altered or impaired by the termination of the plan without the consent of the holder</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><I>Adjustments.</I> If, as a
result of any reorganization, recapitalization, reclassification, stock dividend, stock split, reverse stock split or other similar change
in the Company&#8217;s capital stock, the outstanding shares of common stock are increased or decreased or are exchanged for a different
number or kind of shares or other securities of the Company, or additional shares or new or different shares or other securities of the
Company or other non-cash assets are distributed with respect to such shares of common stock or other securities, or, if, as a result
of any merger or consolidation, sale of all or substantially all of the assets of the Company, the outstanding shares of common stock
are converted into or exchanged for a different number or kind of securities of the Company or any successor entity (or a parent or subsidiary
thereof), the Compensation Committee will make an appropriate or proportionate adjustment in (i) the maximum number of shares reserved
for issuance under the Amended 2021 Plan, (ii) the number of shares of common stock that may be granted to any individual recipient, (iii)
the maximum number of shares that may be granted under a performance-based award, (iv) the number and kind of shares or other securities
subject to any then outstanding awards under the Amended 2021 Plan, (v) the repurchase price per share subject to each outstanding restricted
stock award, and (vi) the exercise price for each share of common stock subject to any then outstanding stock options and stock appreciation
rights under the Amended 2021 Plan. The adjustment by the Compensation Committee will be final, binding and conclusive. <B>&#9;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Change of Control</I>. Upon the occurrence of
a &#8220;Change of Control&#8221; under the Amended 2021 Plan, the Compensation Committee may, in its discretion, take one or more of
the following actions: (i) provide for the acceleration of exercisability or payment of an award; (ii) provide for termination of awards
not exercised prior to the Change of Control; (iii) provide cancellation an award in exchange for payment to the award holder of cash
or other property with a fair market value equal to the amount that would have been received upon the exercise or payment of the award
had the award been exercised or paid upon the change in control; (iv) adjust the terms of the award in a manner determined by the Compensation
Committee to reflect the Change of Control; (v) cause the award to be assumed or substituted by another entity; or (vi) make such other
provision as the Compensation Committee deems equitable to the holders of the awards and in the best interests of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Under the 2021 Amended Plan,
 &#8220;Change of Control&#8221; is defined to mean, generally, (i) with respect to an award that is subject to Section 409A of the Internal
Revenue Code of 1986, as amended (the &#8220;Code&#8221;), the occurrence of any event which constitutes a change of control under Section
409A of the Code and the regulations thereunder, and (ii) with respect to any other award, (A) certain acquisitions of more than 50% of
the combined voting power of the Company&#8217;s then outstanding voting securities, (B) certain changes in the majority composition of
the Board, (C) the consummation of certain mergers, consolidations, or similar corporate transactions involving the Company, (iv) a complete
liquidation or dissolution of the Company, or (v) a sale or other disposition of all or substantially all of the Company&#8217;s assets
(other than a transfer to a subsidiary).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><A NAME="a_010"></A>New Plan Benefits</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In general, benefits that will be awarded or paid
under the Amended 2021 Plan, if stockholder approval of this Proposal Two is obtained, cannot currently be determined as such future awards
are within the Compensation Committee&#8217;s discretion. Although future benefits cannot be determined, in 2023, the Compensation Committee
awarded stock options to certain employees of the Company that were contingent on obtaining stockholder approval of an increase in the
available shares under the Amended 2021 Plan. In the event stockholders do not approve the Amended 2021 Plan, such stock options will
terminate for no consideration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table shows information regarding
the awards made on January 16, 2023 under the Amended 2021 Plan, which were contingent on stockholder approval of the Amended 2021 Plan.
The effectiveness of these awards was expressly made subject to stockholder approval of the Amended 2021 Plan at the Annual Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid"><B>Name and Position</B></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><B>Number of Stock Options</B></TD>
    <TD>&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 79%">James V. Caruso, President and Chief Executive Officer</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 18%; text-align: right">261,000</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Chad J. Kolean, Chief Financial Officer</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">104,000</TD>
    <TD>&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Jarrod Longcor, Chief Operating Officer</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">144,000</TD>
    <TD>&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>All current executive officers, as a group (5 persons)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">609,000</TD>
    <TD>&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>All current directors who are not executive officers, as a group (5 persons)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">_</TD>
    <TD>&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>All employees, including all current officers who are not executive officers, as a group (11 persons)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">609,000</TD>
    <TD>&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Each nominee for election as a director (2 persons)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&#8212;</TD>
    <TD>&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Each associate of any executive officers, current directors or director nominees</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&#8212;</TD>
    <TD>&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Each other person who received or is to receive 5% of awards</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&#8212;</TD>
    <TD>&nbsp;</TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><A NAME="a_011"></A>Historical Equity Awards Table</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table shows the number of awards
made under the 2021 Plan to named executive officers, current executive officers as a group, current directors who are not executive officers
as a group, and all employees, including all current officers who are not executive officers, as a group, in each case since the inception
of the 2021 Plan:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold">Name and Position</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><B>Number of Stock Options </B><FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>(1)</SUP></FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; width: 79%">James V. Caruso, President and Chief Executive Officer</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 18%; font-size: 10pt; text-align: right">858,400</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Chad J. Kolean, Chief Financial Officer</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">208,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Jarrod Longcor, Chief Operating Officer</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">394,050</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">All current executive officers, as a group (5 persons)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,560,450</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">All current directors who are not executive officers, as a group (5 persons)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">118,447</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">All employees, including all current officers who are not executive officers, as a group (11 persons)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">180,447</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Each nominee for election as a director (2 persons):</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font-size: 10pt; text-align: left">Stefan D. Loren, Ph.D.</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">7,800</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font-size: 10pt; text-align: left">Douglas J. Swirsky</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">11,700</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Each associate of any executive officers, current directors or director nominees</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Each other person who received or is to receive 5% of awards</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(1)</TD><TD>The amounts in this column are inclusive of the options disclosed in the New Plan Benefits table that were granted subject to stockholder
approval.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>




<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><A NAME="a_012"></A>Federal Income Tax Information with Respect
to the Amended 2021 Plan</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following summarizes certain U.S. federal income
tax considerations generally applicable to awards granted under the Amended 2021 Plan. This summary does not purport to be complete and
is based on current provisions of the U.S. federal tax laws and regulations, all of which are subject to change (possibly with retroactive
effect) and does not address any tax consequences arising under the laws of any state, local or foreign jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Non-Statutory Options</I>. The grantee of a
non-statutory option recognizes no income for federal income tax purposes on the grant thereof. On the exercise of a non-statutory option,
the excess of the fair market value of the underlying shares of common stock on the exercise date over the option exercise price is treated
as compensation to the holder of the option taxable as ordinary income in the year of exercise, and such fair market value becomes the
basis for the underlying shares which will be used in computing any capital gain or loss upon disposition of such shares (which will be
long-term capital gain if the shares are held for more than one year). Subject to certain limitations, we may deduct for the year of exercise
an amount equal to the amount recognized by the option holder as ordinary income upon exercise of a non-statutory option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Incentive Options</I>. The grantee of an incentive
option recognizes no income for federal income tax purposes on the grant thereof. There is no tax upon exercise of an incentive option,
but the excess of the fair market value of the underlying shares over the option exercise price at the time of exercise will constitute
an item of tax preference for purposes of the alternative minimum tax. If no disposition of shares acquired upon exercise of the option
is made by the option holder within the later of (i)&nbsp;two years from the date of the grant of the option and (ii)&nbsp;one year after
exercise of the incentive option, any gain realized by the option holder on the subsequent sale of such shares is treated as a long-term
capital gain for federal income tax purposes. If the shares are sold prior to the expiration of such periods, the difference between the
lesser of the value of the shares at the date of exercise or at the date of sale and the exercise price of the incentive option is treated
as compensation to the employee and is taxable as ordinary income and the excess gain, if any, is treated as capital gain (which will
be long-term capital gain if the shares are held for more than one year).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In connection with the sale of the shares covered
by incentive options, we are allowed a deduction for federal tax purposes only to the extent, and at the time, the option holder receives
ordinary income (for example, by reason of the sale of shares by the holder of an incentive option within the later of two years of the
date of the option grant or one year after the exercise of the option), subject to certain limitations on the deductibility of compensation
paid to executives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Restricted Stock Awards</I>. The grantee of
a restricted stock award recognizes no income for federal income tax purposes upon the receipt of common stock pursuant to that award,
unless, as described below, the grantee otherwise elects. Instead, the grantee will recognize ordinary income in an amount equal to the
fair market value of the common stock on the date that it is no longer subject to a substantial risk of forfeiture less the amount, if
any, the grantee paid for such stock. Such fair market value becomes the basis for the underlying shares and will be used in computing
any capital gain or loss upon the disposition of such shares (which will be long-term capital gain if the grantee held the shares for
more than one year after the date on which the shares are no longer subject to a substantial risk of forfeiture).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Alternatively, the grantee of a restricted stock
award may elect, pursuant to Section&nbsp;83(b)&nbsp;of the Code, within 30 days of the acquisition of common stock pursuant to the restricted
stock award, to include in gross income as ordinary income for the year in which the common stock is received, the fair market value of
the common stock on the date of grant less the amount, if any, the grantee paid for such stock. Such fair market value will become the
basis for the shares and will be used in determining any capital gain or loss upon the disposition of such shares (which will be long-term
capital gain if the disposition is more than one year after the date of grant). Grantees of restricted stock awards are advised to consult
their own tax advisors with regard to elections pursuant to Section&nbsp;83(b)&nbsp;of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Unrestricted Stock Awards</I>. Upon receipt
of common stock pursuant to an unrestricted stock award, the grantee will recognize as ordinary income the difference between the fair
market value of the common stock less the amount, if any, the grantee paid for such stock. The grantee&#8217;s basis in such shares will
be equal to the fair market value of the shares on the date of receipt, and this basis will be used in determining any capital gain or
loss upon a subsequent disposition of the shares (which will be long-term capital gain if the disposition is more than one year after
the date the shares are received).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Subject to certain limitations, we may deduct an
amount equal to the amount recognized by the grantee of a restricted or unrestricted stock award as ordinary income for the year in which
such income is recognized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Stock Appreciation Rights</I>. The grantee
of a stock appreciation right recognizes no income for federal income tax purposes on the grant thereof. On the exercise of a stock
appreciation right, the grantee will recognize as ordinary income the excess of the fair market value of the common stock delivered
to the grantee (and the amount of cash, if any, paid to the grantee) in connection with such exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Subject to certain limitations, we may deduct an
amount equal to the amount recognized by the grantee of a stock appreciation right as ordinary income for the year in which the stock
appreciation right is exercised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Restricted Stock Units</I>. The grantee of a
restricted stock unit recognizes no income for federal income tax purposes on the grant thereof. When the cash or shares (as applicable)
are transferred (upon vesting of the award), the grantee will recognize as ordinary income the value of cash or shares transferred. If
shares are received, the grantee&#8217;s basis in such shares will be equal to the fair market value of the shares upon receipt, and this
basis will be used in determining any gain or loss upon a subsequent disposition of the shares (which will be long-term capital gain if
the disposition is more than one year after the date the shares are received).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Subject to certain limitations, we may deduct an
amount equal to the amount recognized by the grantee of a restricted stock unit as ordinary income for the year in which such income is
recognized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Performance Share Awards</I>. The federal income
tax laws applicable to performance share awards are the same as those applicable to restricted stock units, described above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Withholding</I>. Subject to certain limitations,
we are required to withhold taxes from amounts taxable to our employees as compensation.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><A NAME="a_013"></A>Recommendation</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Shares available under the 2021 Plan will not be
increased unless the amendment is approved by stockholders. If the amendment to the 2021 Plan is not approved by stockholders, the 2021
Plan will remain in effect in its current form, with the remaining pool of shares, and we may not have sufficient shares available to
meet our needs for the next year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Our Board of Directors recommends that you vote
<U>FOR</U> the approval of the increase in the number of shares of common stock available for issuance under our 2021 Plan.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">MATTERS TO BE CONSIDERED AT ANNUAL MEETING</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><A NAME="a_014"></A>PROPOSAL
3<BR>
RATIFICATION OF APPOINTMENT OF OUR<BR>
INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Proposal 3 concerns the ratification of the appointment
by our Audit Committee of Baker Tilly US, LLP to be our independent registered public accounting firm for the fiscal year ending December
31, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under the rules of the SEC and the Nasdaq Stock
Market, the appointment of our independent registered public accounting firm is the direct responsibility of our Audit Committee. Although
ratification by our stockholders of this appointment is not required by law, our Board of Directors believes that seeking stockholder
ratification is a good practice, which provides stockholders an avenue to express their views on this important matter. If the selection
of the independent registered public accounting firm is not ratified, the Audit Committee will reconsider its selection. Even if the selection
is ratified, the Audit Committee in its discretion may direct the appointment of a different independent registered public accounting
firm at any time if the Audit Committee believes that such a change would be in the best interest of the Company and our stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our Audit Committee has appointed Baker Tilly US,
LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023. Our Board of Directors recommends
that stockholders vote to ratify the appointment. If our stockholders do not ratify the appointment of Baker Tilly US, LLP, the Audit
Committee may reconsider its decision. In any case, the Audit Committee may, in its discretion, appoint a new independent registered public
accounting firm at any time during the year if it believes that such change would be in our best interest and the best interest of our
stockholders. We expect that representatives of Baker Tilly US, LLP will not attend the Annual Meeting, but will be available by telephone.
They will have an opportunity to make a statement if they wish and will be available to respond to appropriate questions from stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><A NAME="a_015"></A>Audit and Other Fees</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table shows fees for professional
audit services, audit-related fees, tax fees and other services rendered by Baker Tilly US, LLP, including its affiliates, for the audit
of our annual financial statements for the fiscal years ended December 31, 2021 and 2022:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 88%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">Fee Category</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: right; border-bottom: Black 1pt solid">Fiscal 2021</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: right; border-bottom: Black 1pt solid">Fiscal 2022</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 72%; font-size: 10pt; text-align: left">Audit fees</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 11%; font-size: 10pt; text-align: right">247,117</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 11%; font-size: 10pt; text-align: right">294,939</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Audit-related fees</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&ndash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&ndash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Tax fees</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&ndash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&ndash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">All other fees</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Total fees</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">247,117</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">294,939</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Audit Fees</I>. Audit fees were for professional
services rendered for the audit of our annual financial statements, the review of quarterly financial statements and the preparation of
statutory and regulatory filings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Audit-Related Fees</I>. Audit-related fees include
fees for assurance and related services by the principal accountant that are reasonably related to the performance of audit and reviews
but that are not included under &#8220;Audit Fees&#8221; above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Tax Fees</I>. Tax fees consist of fees billed
for professional services for tax compliance, tax planning and tax advice. These services include assistance regarding federal, state
and international tax compliance and planning and mergers and acquisitions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>All Other Fees</I>. All other fees include assistance
with miscellaneous reporting requirements and interpretation of technical issues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our Audit Committee has determined that the services
Baker Tilly US, LLP performed for us during fiscal 2022 were at all times compatible with its independence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>




<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><A NAME="a_016"></A>Policy on Pre-Approval of Audit and Non-Audit
Services</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">At present, our Audit Committee approves each engagement
for audit and non-audit services before we engage Baker Tilly US, LLP to provide those services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our Audit Committee has not established any pre-approval
policies or procedures that would allow our management to engage Baker Tilly US, LLP to provide any specified services with only an obligation
to notify the Audit Committee of the engagement for those services. None of the services provided by Baker Tilly US, LLP for the fiscal
year ended December&nbsp;31, 2022 were obtained in reliance on the waiver of the pre-approval requirement afforded in SEC regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><A NAME="a_017"></A>Recommendation</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Our Board of Directors and the Audit Committee
recommend that you vote <U>FOR</U> ratification of the appointment of Baker Tilly US, LLP as our independent registered public accounting
firm for the year ending December 31, 2023.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>




<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><A NAME="a_049"></A>AUDIT
COMMITTEE REPORT</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Board appointed the Audit Committee to review
the Company&#8217;s financial statements and financial reporting procedures, the adequacy and effectiveness of its accounting and financial
controls and the independence and performance of its independent registered public accounting firm. The Audit Committee also selects our
independent registered public accounting firm.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company&#8217;s management is responsible for
the financial reporting process, including the system of internal controls, and for the preparation of financial statements in accordance
with generally accepted accounting principles. The Company&#8217;s independent auditors are responsible for auditing those financial statements
and affirming their independence on an annual basis. Our responsibility is to monitor and review these processes. However, we are not
professionally engaged in the practice of accounting or auditing and are not experts in the fields of accounting or auditing, including
with respect to auditor independence. We have relied, without independent verification, on the information provided to us and on the representations
made by the Company&#8217;s management and independent registered public accounting firm.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In fulfilling our oversight responsibilities, we
have:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top"><TD STYLE="width: 3%"></TD><TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="width: 94%">reviewed
and discussed our financial statements as of and for the fiscal year ended December 31, 2022 with management and Baker Tilly US, LLP;</TD></TR>
<TR STYLE="vertical-align: top"><TD STYLE="width: 3%"></TD><TD STYLE="width: 3%">&nbsp;</TD><TD STYLE="width: 94%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top"><TD STYLE="width: 3%"></TD><TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="width: 94%">discussed
with Baker Tilly US, LLP the matters required to be discussed by the applicable requirements of the Public Company Accounting Oversight
Board and the SEC;</TD></TR>
<TR STYLE="vertical-align: top"><TD STYLE="width: 3%"></TD><TD STYLE="width: 3%">&nbsp;</TD><TD STYLE="width: 94%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top"><TD STYLE="width: 3%"></TD><TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="width: 94%">received
the written disclosures and the letter from Baker Tilly US, LLP required by the applicable requirements of the Public Company Accounting
Oversight Board; and</TD></TR>
<TR STYLE="vertical-align: top"><TD STYLE="width: 3%"></TD><TD STYLE="width: 3%">&nbsp;</TD><TD STYLE="width: 94%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top"><TD STYLE="width: 3%"></TD><TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="width: 94%">discussed
the independence of Baker Tilly US, LLP with that firm.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Based on the Audit Committee&#8217;s review and
discussions noted above, the Audit Committee recommended to our Board of Directors, and our Board of Directors approved, that the audited
financial statements be included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 for filing with the SEC.
The Audit Committee also appointed Baker Tilly US, LLP as our independent registered public accounting firm for fiscal year ending December
31, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Submitted by the Audit Committee of our Board of Directors,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Frederick W. Driscoll, Chairman<BR>
Asher Chanan-Khan, M.B.B.S., M.D.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Stefan D. Loren, Ph.D.</P>




<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">MATTERS TO BE CONSIDERED AT ANNUAL MEETING</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><A NAME="a_018"></A>PROPOSAL
4<BR>
ADVISORY VOTE ON EXECUTIVE COMPENSATION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to Section 14A of the Exchange Act, we
are submitting a proposal to our stockholders for a non-binding advisory vote to approve the compensation of our NEOs as disclosed in
the Proxy Statement. We refer to this non-binding advisory vote as the &#8220;say on pay&#8221; vote. Although this vote is not binding
on us, we value the opinion of our stockholders and will carefully consider the outcome of the vote as we make future decisions on executive
compensation. In accordance with the preference expressed by our stockholders at the 2021 annual meeting, we intend to hold an advisory
vote on executive compensation every year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Accordingly, we ask our stockholders to vote in
favor of the following resolution at the Annual Meeting:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8220;RESOLVED, that the stockholders of Cellectar
Biosciences, Inc. approve, on a non-binding advisory basis, the compensation paid to its named executive officers, as disclosed in the
Proxy Statement for the 2023 Annual Meeting of Stockholders.&#8221;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><A NAME="a_019"></A>Recommendation</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Our Board of Directors recommends that you vote&nbsp;<U>FOR</U>&nbsp;the
approval, on a non-binding advisory basis, of the compensation of our NEOs.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B></B></P>

<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><A NAME="a_020"></A>EXECUTIVE
OFFICERS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our executive officers as of the date hereof are
as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">Name</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Age</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">Position</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 46%; font-size: 10pt; text-align: left">James V. Caruso</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 8%; font-size: 10pt; text-align: center">64</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">President, Chief Executive Officer and Director</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Chad J. Kolean</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">58</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">Vice President, Secretary and Chief Financial Officer</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Jarrod Longcor</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">50</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">Chief Operating Officer</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Shane Lea</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">50</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">Chief Commercial Officer</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Andrei Shustov</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">52</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">Senior Vice President, Medical</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Biographical information for Mr. Caruso is provided
under the header &#8220;Proposal One: Election of Directors.&#8221; Biographical information for our executive officers who are not directors
is set forth below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Jarrod Longcor.</B> Mr. Longcor was appointed
Chief Operating Officer in February 2022. He previously served as Chief Business Officer from September 2017 to January 2022 and Senior
Vice President of Corporate Development and Operations from July 2016 to August 2017. Mr. Longcor brings years of pharmaceutical and biotech
experience to Cellectar and was previously the Chief Business Officer for Avillion LLP, a drug development company. In this role, he was
responsible for executing the company&#8217;s unique co-development partnership strategy. Prior to Avillion, Mr. Longcor was the Vice
President of Corporate Development for Rib-X Pharmaceuticals, Inc. (now Melinta Therapeutics), a publicly-traded biopharmaceutical company
where he was responsible for identifying and concluding several critical collaborations for the company, including a major discovery collaboration
with Sanofi Aventis valued over $700M. Prior to Rib-X, Mr. Longcor held key positions in several small to midsized biotech companies where
he was responsible for business development, strategic planning and operations. Mr. Longcor holds a B.S. from Dickinson College, a M.S.
from Boston University School of Medicine and an M.B.A. from Saint Joseph&#8217;s University&#8217;s Haub School of Business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Chad J. Kolean.</B> Mr. Kolean was appointed
our Vice President and Chief Financial Officer in February 2022 and our Secretary in April 2022. Mr. Kolean has more than 30 years of
experience at both public and private companies. Most recently, he served as Chief Financial Officer of Vivex Biologics, Inc., a developer,
manufacturer and distributor of regenerative medical products from October 2019 to January 2022. Prior to his service at Vivex Biologics,
Inc., Mr. Kolean served as Chief Financial Officer of Titan Spine, Inc., a designer, manufacturer and distributor of titanium spinal implants
from September 2017 to September 2019 (Titan was acquired by Medtronic plc in June 2019). Prior to his time at Vivex, Mr. Kolean served
as Chief Financial Officer of Cellectar from May 2014 to September 2017. Before that, Mr. Kolean served as Chief Financial Officer of
Pioneer Surgical Technology, Inc., a global manufacturer and distributor of spinal, biological and orthopedic implants from April 2012
until its acquisition by RTI Biologics in July 2013, and Chief Accounting Officer from September 2011 to March 2012. Prior to Pioneer,
Mr. Kolean was the Corporate Controller of TomoTherapy, Inc., a publicly traded developer and manufacturer of radiation oncology equipment
from July 2010 to August 2011 (TomoTherapy merged with Accuray Incorporated in June 2011). Mr. Kolean also served as Director of Financial
Reporting for Pioneer Surgical Technology, Inc. from March 2009 to July 2010. From 2001 to 2008, Mr. Kolean held a number of leadership
positions at Metavante Corporation, a provider of banking and payments technologies and services to financial institutions, including:
Director of Planning, Analysis and Reporting, Vice President and FSG Controller and Vice President of Shared Services. Prior to his tenure
at Metavante, Mr. Kolean held leadership roles at Snap-On Inc., Herman Miller, Inc. and Kaydon Corporation. Mr. Kolean began his career
at Arthur Andersen LLP where he practiced as a certified public accountant. Mr. Kolean holds a B.A. in Business Administration from Hope
College.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Shane Lea</B>. Mr. Lea was appointed our Chief
Commercial Officer in November 2022. Mr. Lea brings to Cellectar Biosciences comprehensive commercial leadership experience in hematology
and oncology. In his most recent prior role as senior vice president hematology at TG Therapeutics, a biotech company, he oversaw the
sales, marketing and analytics teams for the hematology franchise. Mr. Lea held this position from October 2021 to July 2022. Prior to
TG Therapeutics, Mr. Lea served as vice president, hematology myeloid franchise at Bristol Myers Squibb, a global pharmaceutical company,
from November 2019 to September 2021. Prior to this position, he had served in various roles at Celgene Corporation, a pharmaceutical
company (prior to its acquisition by Bristol-Myers Squibb Company (&#8220;BMS&#8221;)), since 2012. Mr. Lea was responsible for building
and leading commercial teams supporting the successful launches for Revlimid in lymphoma, Idhifa, Inrebic, Reblozyl and Onureg during
his tenure at Celgene and BMS. Earlier in his career he served in a variety of commercial leadership roles across biotech and multinational
pharmaceutical companies, including: Allos Therapeutics, ImClone Systems, Abraxis Bioscience, Sanofi-Aventis, Aventis Oncology, Parke-Davis
and Novartis. Mr. Lea holds a Bachelor of Business Administration, Marketing from the University of Louisiana Monroe.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Andrei Shustov.</B> Dr. Shustov was
appointed our Senior Vice President, Medical in February 2023. Dr. Shustov brings over three decades of research, clinical,
development, and academic experience in hematologic malignancies. He most recently served as Senior Medical Director, Late-Stage
Clinical Development at Seagen, Inc., a biotechnology company focused on antibody-drug-conjugate-based therapies for the treatment
of cancer, where he provided clinical expertise and oversight of regulatory submissions and development activities within the Global
Development Team from October 2021 through January 2023. Prior to Seagen, Dr. Shustov spent 15 years serving on faculty in the
Division of Hematology, Department of Medicine at the University of Washington and Fred Hutchinson Cancer Research Center in
Seattle, finishing his academic career as full Professor of Medicine. His clinical and translational research focus was lymphoid
malignancies and novel treatment platforms. Dr. Shustov is author or co-author on over 100 research papers; author of 10
hematology/oncology chapters in medical textbooks; and has been principal or lead investigator in over 40 clinical studies
investigating new therapies in hematology for companies such as Bristol-Myers Squibb, Celgene, Merck, Gilead, Seattle Genetics,
Millennium, AstraZeneca, and Pfizer among others, several of which resulted in regulatory approvals. Dr. Shustov completed his
residency in internal Medicine in 2003 at WellSpan Health in York, PA, and his fellowship in hematology/medical oncology in 2006 at
the University of Washington School of Medicine in Seattle, Washington. He received his Doctor of Medicine in 1987 from the Crimea
Medical Institute, Simferopol, Ukraine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B>&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><A NAME="a_021"></A>CORPORATE
GOVERNANCE</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><A NAME="a_022"></A>Classified Board of Directors</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our Board consists of six members and is divided
into three classes of directors that serve staggered three-year terms. At each annual meeting of stockholders, a class of directors will
be elected for a three-year term to succeed the same class whose term is then expiring. As a result, only one class of directors will
be elected at each annual meeting of our stockholders, with the other classes continuing for the remainder of their respective three-year
terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><A NAME="a_023"></A>Director Independence</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our Board of Directors has determined that, with
the exception of Mr. Caruso, who is our employee, all of the members of our Board of Directors are &#8220;independent directors&#8221;
under the applicable rules and regulations of the SEC and the listing requirements of the Nasdaq Stock Market. Our Board of Directors
has also determined that each member of our Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee
is an &#8220;independent director&#8221; under the rules of the Nasdaq Stock Market applicable to such committees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><A NAME="a_024"></A>Board Leadership Structure</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Board does not have a formal policy on whether
the roles of Chairman of the Board and Chief Executive Officer should be separate and believes that it should retain the flexibility to
make this determination in the manner it believes will provide the most appropriate leadership for our Company from time to time. Currently,
we split these positions with Douglas Swirsky serving as Chairman of the Board and James V. Caruso serving as Chief Executive Officer.
We believe that our current separation of the positions of Chairman of the Board and Chief Executive Officer reinforces the independence
of our board of directors from management, creates an environment that encourages objective oversight of management&#8217;s performance
and enhances the effectiveness of our board of directors as a whole.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 69.2pt 0pt 0; text-indent: 19.95pt"><FONT STYLE="color: #231F20">The duties
of </FONT>our independent Chairman <FONT STYLE="color: #231F20">include the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 69.2pt 0pt 0; text-indent: 19.95pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231F20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 22.3pt"></TD><TD STYLE="width: 10.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>Oversee that governance policies and practices are in place.</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
                                                                                                                                                                                                               </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 22.5pt"></TD><TD STYLE="width: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #231F20"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD><FONT STYLE="color: #231F20">Approve </FONT>board of directors <FONT STYLE="color: #231F20">meeting agenda.</FONT></TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
                                                                                                                                                                                                                                                                                   </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231F20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 22.5pt"></TD><TD STYLE="width: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>Work with committee chairs to set committee agendas, considering strategic issues facing the Company, and with input from other directors
and the CEO.</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
                      </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 22.5pt"></TD><TD STYLE="width: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #231F20"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD><FONT STYLE="color: #231F20">Preside over </FONT>board of directors <FONT STYLE="color: #231F20">and annual shareholder meetings.</FONT></TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
                                                                                                                                                                                                                                                                                                         </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231F20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 22.5pt"></TD><TD STYLE="width: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>Attend committee meetings as appropriate.</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
                                                                                                                                                                                          </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231F20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 22.5pt"></TD><TD STYLE="width: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>Coordinate effective communication between respective committee chairs and management.</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
                                                                                                                                                                                                                                       </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231F20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 22.5pt"></TD><TD STYLE="width: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>Oversee orientation for new directors and ongoing education for directors.</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
                                                                                                                                                                                                                           </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 22.5pt"></TD><TD STYLE="width: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #231F20"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD><FONT STYLE="color: #231F20">Oversee that the </FONT>board of directors <FONT STYLE="color: #231F20">receives accurate, timely, and
clear information on:</FONT></TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
                                      </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231F20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 53pt"></TD><TD STYLE="width: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>The Company&#8217;s performance;</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
                                                                                                                                                                               </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231F20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 53pt"></TD><TD STYLE="width: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>The issues, challenges, and opportunities facing the Company; and</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
                                                                                                                                                                                                                </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231F20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 53pt"></TD><TD STYLE="width: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>Matters reserved to it for decision.</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
                                                                                                                                                                                   </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 22.5pt"></TD><TD STYLE="width: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #231F20"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD><FONT STYLE="color: #231F20">Facilitate effective communication and constructive relationships between the </FONT>board of directors
<FONT STYLE="color: #231F20">and management.</FONT></TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
                                                             </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 22.5pt"></TD><TD STYLE="width: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #231F20"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD><FONT STYLE="color: #231F20">Serve as spokesperson for the </FONT>board of directors<FONT STYLE="color: #231F20">. </FONT></TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
                                                                                                                                                                                                                                                                                           </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231F20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 22.5pt"></TD><TD STYLE="width: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>Meet with shareholders when engagement requested.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 32.5pt; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 32.5pt; color: #231F20"></P>

<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 32.5pt; color: #231F20">&nbsp;</P>




<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><A NAME="a_025"></A>Board Diversity Matrix</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The table below provides information regarding
certain diversity attributes of our Board members and nominees as of April 25, 2023, with categories as set forth by Nasdaq Listing Rule
5605(f).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 55%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: #CCECFF">
    <TD COLSPAN="3" STYLE="border: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><B>Board Diversity Matrix </B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><B>Total Number of Directors</B>:&nbsp;&nbsp;6</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCECFF">
    <TD STYLE="width: 34%; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="width: 33%; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Female</TD>
    <TD STYLE="width: 33%; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Male</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><B><I>Gender Identity</I></B></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">Directors</TD>
    <TD STYLE="vertical-align: bottom; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&mdash;</TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">6</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><B><I>Demographic Background</I></B></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">Asian</TD>
    <TD STYLE="vertical-align: bottom; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&mdash;</TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">1</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">White</TD>
    <TD STYLE="vertical-align: bottom; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&mdash;</TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">5</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><A NAME="a_026"></A>Board Committees</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our Board has established an Audit Committee, a
Compensation Committee and a Nominating and Corporate Governance Committee. Each committee operates pursuant to a written charter. The
composition and responsibilities of each of the committees of our Board of Directors are described below and copies of the charters are
available on our website at www.cellectar.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Audit Committee. </I>Our Audit Committee is
currently composed of Mr. Driscoll (Chairman), Dr. Chanan-Khan and Dr. Loren. The Board has determined that each member of our Audit Committee
is independent within the meaning of Rule 10A-3 under the Exchange Act. The Board has also determined that Mr. Driscoll is an &#8220;audit
committee financial expert&#8221; within the meaning of the applicable SEC rules and regulations. The Audit Committee provides the opportunity
for direct contact between our independent registered public accounting firm and members of the Board, and the independent registered
public accounting firm reports directly to the Audit Committee. The Audit Committee assists the Board in overseeing the integrity of our
financial statements, our compliance with legal and regulatory requirements, and our independent registered public accounting firm&#8217;s
qualifications, independence and performance. The Audit Committee is directly responsible for appointing, compensating, evaluating and,
when necessary, terminating our independent registered public accounting firm. The Audit Committee has established procedures for the
treatment of complaints regarding accounting, internal accounting controls or auditing matters, including procedures for the confidential
and anonymous submission by our employees of concerns regarding questionable accounting, internal accounting controls or auditing matters.
Our Audit Committee met four times during the fiscal year ended December 31, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Compensation Committee. </I>Our Compensation
Committee is currently composed of Mr. Neis (Chairman), Mr. Driscoll and Mr. Swirsky. The Board has determined that each member of our
Compensation Committee is independent under the Nasdaq listing standards and a &#8220;non-employee director&#8221; as defined in Rule
16b-3 promulgated under the Exchange Act. The Compensation Committee&#8217;s responsibilities include providing recommendations to the
Board regarding the compensation levels of directors; approving, or recommending for approval by the Board, the compensation levels of
executive officers; providing recommendations to our Board regarding compensation programs; administering our incentive compensation plans
and equity-based plans; authorizing grants under our 2021 Plan; and authorizing other equity compensation arrangements. Our Compensation
Committee met twice during the fiscal year ended December 31, 2022. The Compensation Committee shall have the authority to retain, at
Company expense, independent advisers (including legal counsel, accountants and independent compensation or other consultants) as it determines
necessary to carry out its duties, and shall be directly responsible for the appointment, compensation and oversight of the work of any
compensation consultant, legal counsel and other adviser retained by the Committee. In 2021, the Compensation Committee retained Aon/Radford
as an independent consultant to advise it on compensation matters. Aon/Radford was engaged directly by and reported directly to our Compensation
Committee and did no other work for the Company. The Compensation Committee considered the applicable Nasdaq listing rules and determined
that Aon/Radford qualified as an independent compensation consultant in accordance with applicable SEC and Nasdaq listing rules and regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Nominating and Corporate Governance Committee.
</I>Our Nominating and Corporate Governance Committee is currently composed of Dr. Loren (Chairman), Mr. Neis and Mr. Swirsky. The Board
has determined that each member of our Nominating and Corporate Governance Committee is independent under the applicable Nasdaq listing
standards. The Nominating and Corporate Governance Committee&#8217;s responsibilities include, to the extent deemed necessary or appropriate
by the committee: developing and recommending to the Board criteria for the selection of individuals to be considered as candidates for
election to the Board; identifying individuals qualified to become members of the Board; making recommendations to the Board regarding
its size and composition; approving director nominations to be presented for stockholder approval at the Company&#8217;s annual meeting;
approving nominations to fill any vacancies on the Board; and developing and recommending corporate governance principles to the Board.
Our Nominating and Corporate Governance Committee met once during the fiscal year ended December 31, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><A NAME="a_027"></A>Director Qualification Standards</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The process followed by the Nominating and Corporate
Governance Committee to identify and evaluate director candidates includes requests to the Board members and others for recommendations,
meetings from time to time to evaluate biographical information and background materials relating to potential candidates, and interviews
of selected candidates by members of the committee and other members of the Board. The committee may also solicit the opinions of third
parties with whom the potential candidate has had a business relationship. Once the committee is satisfied that it has collected sufficient
information on which to base a judgment, the committee votes on the candidate or candidates under consideration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In evaluating the qualifications of any candidate
for director, the Nominating and Corporate Governance Committee considers, among other factors, the candidate&#8217;s depth of business
experience, reputation for personal integrity, understanding of financial matters, familiarity with the periodic financial reporting process,
reputation, degree of independence from management, possible conflicts of interest and willingness and ability to serve. The Nominating
and Corporate Governance Committee also considers the degree to which the candidate&#8217;s skills, experience and background complement
or duplicate those of our existing directors and the long-term interests of our stockholders. The Nominating and Corporate Governance
Committee considers factors such as gender, ethnicity/race and other characteristics when evaluating how a candidate for director could
contribute to the diversity of the Board. In the case of incumbent directors whose terms are set to expire, the Nominating and Corporate
Governance Committee also gives consideration to each director&#8217;s prior contributions to the Board. In selecting candidates to recommend
for nomination as a director, the Nominating and Corporate Governance Committee abides by our company-wide non-discrimination policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Nominating and Corporate Governance Committee
will consider director candidates recommended by stockholders and uses the same process to evaluate candidates regardless of whether the
candidates were recommended by stockholders, directors, management or others. We suggest that stockholders make recommendations by writing
to the chairman of the Nominating and Corporate Governance Committee, in care of our offices, with sufficient information about the candidate,
his or her work experience, his or her qualifications for director, and his or her references to enable the Nominating and Corporate Governance
Committee to evaluate the candidacy properly. We also suggest that stockholders make their recommendations well in advance of the anticipated
mailing date of our next proxy statement so as to provide the Nominating and Corporate Governance Committee an adequate opportunity to
complete a thorough evaluation of the candidacy, including personal interviews. Stockholder may also directly nominate director candidates
through the procedures set forth in our by-laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><A NAME="a_028"></A>Code of Business Conduct and Ethics</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have adopted a Code of Ethics (the &#8220;Code&#8221;)
applicable to our employees, officers and directors. A copy of our Code is available on our principal corporate website at <I>www.cellectar.com</I>.
Amendments to the Code or waivers of this Code may be made only by the Audit Committee and the Board of Directors and must be promptly
disclosed to stockholders as required by Nasdaq listing rules, SEC regulation or any other law or regulation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><A NAME="a_029"></A>Compensation Committee Interlocks and Insider
Participation</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">None of the members of our Compensation Committee
is or has been an officer or employee of us or any of our subsidiaries. In addition, none of our executive officers serves or has served
as a member of the Board of Directors, Compensation Committee or other board committee performing equivalent functions of any entity that
has one or more executive officers serving as one of our directors or on our Compensation Committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><A NAME="a_030"></A>Role of the Board in Risk Oversight</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Management is responsible for the day-to-day
management of the risks that we face, while our Board, as a whole and through its committees, has responsibility for the oversight
of risk management. In its risk oversight role, the Board is responsible for satisfying itself that our risk management processes
are adequate and functioning as designed. Our Board&#8217;s involvement in risk oversight includes receiving regular reports from
members of management and evaluating areas of material risk, including operational, cybersecurity and technology, financial, legal
and compliance, regulatory, strategic and competitive, and brand and reputational risks. As a smaller reporting company with a small
Board of Directors, we believe it is appropriate to have the involvement and input of all of our directors in risk oversight
matters. In addition, the Board has delegated risk oversight to each of its committees within their areas of responsibility. Our
Compensation Committee assists the Board in its risk oversight function by overseeing strategies related to our incentive
compensation programs and key employee retention. Our Audit Committee assists the Board in its risk oversight function by reviewing
our system of disclosure controls and procedures and our internal control over financial reporting. Our Nominating and Corporate
Governance Committee assists the Board in its risk oversight function by managing risks associated with director candidate
selection, governance and succession matters. Our Nominating and Corporate Governance Committee also oversees the Company&#8217;s
environmental, sustainability and governance (ESG) efforts and related risks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="a_031"></A>&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Evaluations of the Board of Directors</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Board of Directors evaluates
its performance and the performance of its committees and individual directors on an annual basis through an evaluation process administered
by our Nominating and Corporate Governance Committee. The Board of Directors discusses each evaluation to determine what, if any, actions
should be taken to improve the effectiveness of the Board of Directors or any committee thereof or of the directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><A NAME="a_032"></A>Meetings of the Board of Directors</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Board Meetings. </I>Our Board of Directors held
four meetings during the fiscal year ended December 31, 2022. Each of our directors attended all of the meetings held by the Board and
the committees of the Board on which he served during the fiscal year ended December 31, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Meetings of Independent Directors. </I>Our independent
directors are expected, but not required, to meet without management present at least twice per year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><A NAME="a_033"></A>Director Attendance at the Annual Meeting of
Stockholders</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We encourage our director to attend our annual
meetings of stockholders. All of our directors except Mr. Driscoll attended the 2022 annual meeting of stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><A NAME="a_034"></A>Prohibition on Hedging and Pledging of Company
Securities</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We maintain an insider trading policy that applies
to our officers, directors and employees that prohibits them from engaging in speculative transactions in our securities, such as short
sales, puts, calls, straddles, hedging or monetization transactions, including but not limited to prepaid variable forwards, equity swaps,
collars and exchange funds, or similar transactions. Since the adoption of our insider trading policy, the Audit Committee has not granted
any such exemptions to the policy&#8217;s general prohibition on hedging and pledging.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><A NAME="a_035"></A>Communications with the Board</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Stockholders and interested parties wishing to
communicate with the Board or any director or group of directors should direct their communications to: Secretary, Cellectar Biosciences,
Inc., 100 Campus Drive, Florham Park, New Jersey 07932. The Secretary will forward the stockholder or interested-party communication to
the Board or to any individual director or directors to whom the communication is directed; provided, however, that if the communication
is unduly hostile, profane, threatening, illegal or otherwise inappropriate, the Secretary has the authority to discard the communication
and take any appropriate legal action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><A NAME="a_036"></A>CERTAIN
RELATIONSHIPS AND RELATED-PERSON TRANSACTIONS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We do not have a written policy for the review,
approval or ratification of transactions with related parties or conflicted transactions. When such transactions arise, they are referred
to the Audit Committee for consideration or referred to the Board of Directors for consideration. Since January 1, 2021, we have not entered
into or participated in any transactions in which the amount involved in the transaction exceeds or will exceed $120,000 and in which
any of our directors, executive officers or holders of more than 5% of our capital stock, or any immediate family member of, or person
sharing the household with, any of these individuals, had or will have a direct or indirect material interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><A NAME="a_037"></A>SECURITY
OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As of April 25, 2023, there were 9,740,507 shares
of our common stock outstanding. The following table provides information regarding beneficial ownership of our common stock as of such
date by:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>each person known by us to be the beneficial owner of more than 5% of our common stock;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>each of our directors;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>each executive officer named in the summary compensation table; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>all of our current directors and executive officers as a group.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The persons named in this table have sole voting
and investment power with respect to the shares listed, except as otherwise indicated. In these cases, the information with respect to
voting and investment power has been provided to us by the security holder. The identification of natural persons having voting or investment
power over securities held by a beneficial owner listed in the table below does not constitute an admission of beneficial ownership of
any such natural person. Shares included in the &#8220;Right to Acquire&#8221; column consist of shares that may be purchased through
the exercise of options or warrants that are exercisable within 60 days of April 25, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">Name and Address of Beneficial Owner</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Outstanding</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Right to<BR> Acquire</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Percentage</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%; font-size: 10pt; text-align: left">Rosalind Advisors, Inc.<SUP>(1)</SUP></TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">986,293</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">2,158,272</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">3,144,565</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">9.9</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">James V. Caruso <SUP>(2)</SUP></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">8,622</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">205,702</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">214,324</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2.2</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Chad J. Kolean</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">24</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">5,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">5,024</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">*</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Jarrod Longcor <SUP>(3)</SUP></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">10,214</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">68,673</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">78,887</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">*</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Frederick W. Driscoll</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,941</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">22,650</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">24,591</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">*</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Asher Chanan-Khan, M.B.B.S., M.D.</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">10,400</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">10,400</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">*</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Stefan D. Loren, Ph.D.</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">22,885</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">22,885</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">*</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="text-transform: capitalize">John Neis</FONT>
    <FONT STYLE="text-transform: uppercase"><SUP>(4)</SUP></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">6,260</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">22,887</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">29,147</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">*</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Douglas Swirsky</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,500</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">34,425</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">428,748</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">*</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">All directors and officers as a group (10 persons)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">35,909</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">785,678</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">857,496</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">8.1</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">*</TD><TD>Less than 1%</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(1)</TD><TD>As reported in Schedule 13G/A filed with the SEC on February 14, 2023. Based on such 13G/A filing, each of Rosalind Advisors, Inc.,
Rosalind Master Fund L.P., Steven Salamon and Gilad Aharon has sole voting power over no shares, shared voting power over 3,144,565 shares,
sole dispositive power over no shares and shared dispositive power over 3,144,565 shares. The address of each of Rosalind Advisors, Inc.,
Steven Salamon and Gilad Aharon is 15 Wellesley Street West, Suite 326, Toronto, Ontario, M4Y 0G7 Canada. The address of Rosalind Master
Fund L.P. is P.O. Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(2)</TD><TD>Shares in the &#8220;Right to Acquire&#8221; column consist of (i) 10,870 shares of common stock issuable upon the exercise of warrants
held by Mr. Caruso and (ii) common stock issuable currently or within 60 days upon exercise of options to purchase 882,083 shares of common
stock issued to Mr. Caruso.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(3)</TD><TD>Shares in the &#8220;Right to Acquire&#8221; column consist of (i) 32,609 shares of common stock issuable upon the exercise of warrants
held by Mr. Longcor and (ii) common stock issuable currently or within 60 days upon exercise of options to purchase 279,666 shares of
common stock issued to Mr. Longcor.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(4)</TD><TD>Consists of shares of common stock held by Advantage Capital Wisconsin Partners I, Limited Partnership. Venture Investors LLC is the
submanager and special limited partner of Advantage Capital Wisconsin Partners I, Limited Partnership. The investment decisions of Venture
Investors LLC are made collectively by five managers, including Mr. Neis. Each such manager and Mr. Neis disclaim such beneficial ownership
except to the extent of his pecuniary interest therein. The address of Mr. Neis is c/o Venture Investors LLC, 505 South Rosa Road, #201,
Madison, Wisconsin 53719. Shares in the &#8220;Right to Acquire&#8221; column consist of common stock issuable currently or within 60
days upon exercise of options to purchase 54,844 shares of common stock issued to Mr. Neis in his capacity as director.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 30 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>




<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><A NAME="a_038"></A>COMPENSATION
OF EXECUTIVE OFFICERS AND DIRECTORS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><A NAME="a_039"></A>Executive Compensation</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This section provides information, in tabular and
narrative formats specified in applicable SEC rules, regarding the amounts of compensation paid to each of our named executive officers,
or NEOs and related information. As a smaller reporting company, the Company has presented such information in accordance with the scaled
disclosure requirements permitted under applicable SEC regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table sets forth certain information
concerning all cash and non-cash compensation awarded to, earned by or paid to our each of NEOs for the years ended 2022 and 2021:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2022 Summary Compensation Table</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid">Name&nbsp;and&nbsp;Principal&nbsp;Position</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Year</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Salary&nbsp;($)</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Non-Equity Incentive Plan Compensation<BR> ($) <SUP>(1)</SUP></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Option<BR> Awards&nbsp;<BR> ($)&nbsp;<SUP>(2)</SUP></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Other<BR> Compensation<BR> ($)&nbsp;<SUP>(3)</SUP></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Total&nbsp;($)</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 22%; font-size: 10pt; text-align: left">James V. Caruso</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">2022</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">569,250</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">277,225</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">616,697</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">-</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">1,463,172</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font-size: 10pt; text-align: left">President and Chief Executive Officer</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2021</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">522,500</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">156,750</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,472,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,151,250</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Jarrod Longcor</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2022</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">450,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">175,320</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">206,435</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">831,755</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font-size: 10pt; text-align: left">Chief Operating Officer <SUP>(4)</SUP></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2021</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">385,037</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">92,409</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">414,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">891,446</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Chad J. Kolean</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2022</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">290,417</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">113,146</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">58,080</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">461,643</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font-size: 10pt; text-align: left">Chief Financial Officer <SUP>(5)</SUP></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2021</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">N/A</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">N/A</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">N/A</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">N/A</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">N/A</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(1)</TD><TD>Amounts in this column represent bonuses approved by the Compensation Committee based on its annual review of the performance of the
executive officers against predetermined financial and strategic objectives established for the year. NEOs are paid the same percentage
upon the achievement of financial objectives and may be paid varied percentages upon the achievement of strategic objectives depending
on the subject matter.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(2)</TD><TD>The reported amounts represent the aggregate grant date fair value computed in accordance with ASC 718. All assumptions made regarding
the valuation of equity awards can be referenced in Note 7 to the financial statements included in our Annual Report on Form 10-K filed
with the SEC on March 9, 2023.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(3)</TD><TD>The methodology used to compute the aggregate incremental cost of perquisites and other personal benefits for each individual NEO
is based on the total cost to the Company, and such costs are required to be reported under SEC rules when the total costs are equal to
or greater than $10,000 in the aggregate for a NEO.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(4)</TD><TD>Mr. Longcor was promoted to the Company&#8217;s Chief Operating Officer on February 22, 2022. He had previously served as the Company&#8217;s
Chief Business Officer and Senior Vice President of Operations since 2017.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(5)</TD><TD>Mr. Kolean was appointed as the Company&#8217;s Chief Financial Officer on February 22, 2022.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><A NAME="a_040"></A>Employment Agreements</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>James V. Caruso.&nbsp;</I>We entered into an
employment agreement with Mr.&nbsp;Caruso as of June&nbsp;15, 2015, as amended and restated on April&nbsp;15, 2019, pursuant to which
Mr.&nbsp;Caruso serves as President and Chief Executive Officer of the Company. Under the agreement, the Company pays Mr.&nbsp;Caruso
a base salary that is adjusted from time to time. Mr.&nbsp;Caruso is also eligible for an annual bonus, based on performance, with an
initial target of up to 50% of his base salary at the discretion of the Compensation Committee. If Mr.&nbsp;Caruso is terminated other
than for cause or by Mr.&nbsp;Caruso for good reason within 12 months after a change in control (i.e. double trigger), he is entitled
to severance in an amount equal to (i)&nbsp;18 months of base salary, (ii)&nbsp;his then applicable target bonus payable over 18 months
(a total of 1.5x the annual target bonus payable at the time of termination) and (iii)&nbsp;18 months of payment or reimbursement of health
insurance (equal to the premium paid by the Company prior to the date of termination), each payable in installments over 18 months. Following
a termination of employment by the Company without cause or by Mr.&nbsp;Caruso for good reason that is not within 12 months after a change
in control, Mr. Caruso is entitled to severance in an amount equal to 12 months base salary plus payment or reimbursement of health insurance
for 12 months (equal to the premium paid by the Company prior to the date of termination). Each of the foregoing severance benefits is
conditioned on Mr. Caruso&#8217;s execution of a release agreement in favor of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 31 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Jarrod Longcor.&nbsp;</I>We entered into an
employment agreement with Mr.&nbsp;Longcor as of July&nbsp;15, 2016, as amended and restated on April&nbsp;15, 2019 and amended on November&nbsp;10,
2019. Under the agreement, Mr.&nbsp;Longcor receives a base salary that may be adjusted from time to time. Mr.&nbsp;Longcor is eligible
for an annual bonus, based on performance, with an initial target of up to 30% of his base salary. If Mr.&nbsp;Longcor&#8217;s employment
is terminated other than for cause or by Mr.&nbsp;Longcor for good reason, contingent upon the execution of a release agreement in favor
of the Company, Mr.&nbsp;Longcor is entitled to (i) severance in an amount equal to nine months of 75% of Mr.&nbsp;Longcor&#8217;s annual
base salary, provided that if such termination occurs within 12 months after a change in control (i.e. double trigger), such severance
is increased to 12 months of Mr. Longcor&#8217;s full base salary, each payable in monthly installments, (ii)&nbsp;payment or reimbursement
of health insurance (for nine 9 or 12 months, as applicable), each payable in monthly installments, (iii) a payment amount equal to the
annual bonus Mr.&nbsp;Longcor would have received for the calendar year in which the termination occurred prorated for the number of days
elapsed in such year, and (iv) outplacement services not to exceed $7,500.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Chad J. Kolean. </I>We entered into an employment
agreement with Mr. Kolean as of February 22, 2022. Pursuant to his employment agreement, Mr. Kolean receives an annual base salary of
$340,000 and is eligible to receive an annual performance bonus with a target amount equal to 40% of his base salary. In the event of
a dismissal without cause or resignation by Mr. Kolean for good reason, Mr. Kolean will be entitled to nine months of severance. In the
event of dismissal without cause or resignation by Mr. Kolean for good reason, within the twelve months following a change in control,
Mr. Kolean will be entitled to eighteen months of severance. Additionally, Mr. Kolean was granted an option to purchase 150,000 shares
of the Company&#8217;s common stock at an exercise price equal to the closing price of the Company&#8217;s common stock on February 22,
2022. The shares subject to the option award vest annually over three years such that 1/3 of the number of shares granted become exercisable
on each anniversary of the grant date, with the option to purchase shares fully vested on the third anniversary of the grant date. Mr.
Kolean is eligible for annual equity awards under the Company&#8217;s Amended and Restated 2021 Stock Incentive Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 32 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><A NAME="a_051"></A>2022 Outstanding Equity Awards at Fiscal Year-End</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><A NAME="a_042"></A>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table sets forth certain information
with respect to outstanding equity awards as of December&nbsp;31, 2022 with respect to our NEOs:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: center">&nbsp;</TD>
    <TD COLSPAN="9" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Option Awards</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: center">&nbsp;</TD>
    <TD COLSPAN="5" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock Awards</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date of<BR>
Award</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number&nbsp;of<BR>
securities<BR>
underlying<BR>
unexercised<BR>
options<BR>
(#&nbsp;exercisable)</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number&nbsp;of<BR>
securities<BR>
underlying<BR>
unexercised<BR>
options<BR>
(# unexercisable)</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Option<BR>
Exercise<BR>
Price<BR>
($/share)</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Option<BR>
Expiration<BR>
date</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of<BR>
Shares or<BR>
Units of<BR>
Stock that<BR>
Have Not<BR>
Vested (#)</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market<BR>
Value of<BR>
Shares or<BR>
Units of<BR>
Stock that<BR>
Have Not<BR>
Vested ($)</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">James V. Caruso</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/25/2022<SUP>(1)</SUP></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">141,900</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.50</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/25/2032</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/4/2021<SUP>(2)</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">53,333</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">106,667</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.40</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/4/2031</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2/3/2020<SUP>(2)</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,666</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,334</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">27.10</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2/3/2030</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/17/2019</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,500</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.90</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/17/2029</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10/12/2018</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">26.10</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10/12/2028</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5/12/2016</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">148.00</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5/12/2026</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6/15/2015</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">375</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,640.00</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6/15/2025</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="background-color: White"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jarrod Longcor</FONT></TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/25/2022<SUP>(1)</SUP></FONT></TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">47,500</FONT></TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="background-color: White; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.50</FONT></TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/25/2032</FONT></TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="background-color: White">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/4/2021<SUP>(2)</SUP></FONT></TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15,000</FONT></TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">30,000</FONT></TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="background-color: White; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.40</FONT></TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/4/2031&#9;</FONT></TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="background-color: White">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2/3/2020<SUP>(2)</SUP></FONT></TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,666</FONT></TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,334</FONT></TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="background-color: White; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">27.10</FONT></TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2/3/2030</FONT></TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="background-color: White">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/17/2019</FONT></TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,000</FONT></TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="background-color: White; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.90</FONT></TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/17/2029</FONT></TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="background-color: White">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10/12/2018</FONT></TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,300</FONT></TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="background-color: White; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">26.10</FONT></TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10/12/2028</FONT></TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="background-color: White">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/18/2017</FONT></TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">250</FONT></TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="background-color: White; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">183.00</FONT></TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/18/2027</FONT></TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="background-color: White">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/15/2016</FONT></TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">750</FONT></TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="background-color: White; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">293.00</FONT></TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/15/2026</FONT></TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chad J. Kolean</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2/22/2022<SUP>(2)</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.90</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2/21/2032</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(1)</TD><TD>These shares vest in increments of one-third at first anniversary from grant date and then vesting in 24 equal monthly installments
over a 24-month period beginning on the first anniversary of the grant date.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(2)</TD><TD>These shares vest annually in increments of one-third over three years from the date of grant. The exercise price equals the closing
price on the date of grant.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(3)</TD><TD>These shares vest in three equal annual installments beginning on the first anniversary of the grant date.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(4)</TD><TD>These shares vest in three equal annual installments beginning on the first anniversary of the grant date, subject to continuous employment
by the Issuer on each vesting date.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the terms of the option award agreements, options granted
pursuant to the Amended and Restated 2015 Stock Incentive Plan and the 2021 Plan become fully vested upon a termination event within one
year following a change in control, as defined therein. A termination event is defined as either termination of employment other than
for cause or constructive termination resulting from a significant reduction in either the nature or scope of duties and responsibilities,
a reduction in compensation or a required relocation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><A NAME="a_043"></A>Risks Related to Compensation Policies and Practices</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">When determining our compensation policies and
practices, the Compensation Committee considers various matters relevant to the development of a reasonable and prudent compensation program,
including whether the policies and practices are reasonably likely to have a material adverse effect on us. We believe that the mix and
design of our executive compensation plans and policies do not encourage management to assume excessive risks and are not reasonably likely
to have a material adverse effect on us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 33 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><A NAME="a_044"></A>Pay Versus Performance</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD COLSPAN="20" STYLE="border-bottom: Black 1pt solid; background-color: White; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 9pt"><B>Pay
    Versus Performance</B></FONT></TD><TD STYLE="background-color: White; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap; background-color: White; font-size: 10pt; font-weight: bold; text-align: center"><FONT STYLE="font-size: 9pt"><B>&nbsp;</B></FONT></TD><TD STYLE="white-space: nowrap; background-color: White; padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: center"><FONT STYLE="font-size: 9pt"><B>&nbsp;</B></FONT></TD><TD STYLE="white-space: nowrap; text-align: center; background-color: White; font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-size: 9pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: center"><FONT STYLE="font-size: 9pt"><B>&nbsp;</B></FONT></TD><TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; background-color: White; padding-bottom: 2.5pt; text-align: center"><FONT STYLE="font-size: 9pt"><B>&nbsp;</B></FONT></TD><TD STYLE="white-space: nowrap; text-align: center; background-color: White; font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-size: 9pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: center"><FONT STYLE="font-size: 9pt"><B>&nbsp;</B></FONT></TD><TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; background-color: White; padding-bottom: 2.5pt; text-align: center"><FONT STYLE="font-size: 9pt"><B>&nbsp;</B></FONT></TD><TD STYLE="white-space: nowrap; text-align: center; background-color: White; font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-size: 9pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: center"><FONT STYLE="font-size: 9pt"><B>&nbsp;</B></FONT></TD><TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; background-color: White; padding-bottom: 2.5pt; text-align: center"><FONT STYLE="font-size: 9pt"><B>&nbsp;</B></FONT></TD><TD STYLE="white-space: nowrap; text-align: center; background-color: White; font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-size: 9pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: center"><FONT STYLE="font-size: 9pt"><B>&nbsp;</B></FONT></TD><TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; background-color: White; padding-bottom: 2.5pt; text-align: center"><FONT STYLE="font-size: 9pt"><B>&nbsp;</B></FONT></TD><TD STYLE="white-space: nowrap; text-align: center; background-color: White; font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-size: 9pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: center"><FONT STYLE="font-size: 9pt"><B>&nbsp;</B></FONT></TD><TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: center"><FONT STYLE="font-size: 9pt"><B>Value
                                            of Initial Fixed <BR>
                                            $100 Investment<BR>
                                            Based On:</B></FONT></TD><TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; background-color: White; padding-bottom: 2.5pt; text-align: center"><FONT STYLE="font-size: 9pt"><B>&nbsp;</B></FONT></TD><TD STYLE="white-space: nowrap; text-align: center; background-color: White; font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-size: 9pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: center"><FONT STYLE="font-size: 9pt"><B>&nbsp;</B></FONT></TD><TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; background-color: White; padding-bottom: 2.5pt; text-align: center"><FONT STYLE="font-size: 9pt"><B>&nbsp;</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; background-color: White; font-size: 10pt; font-weight: bold; text-align: center"><FONT STYLE="font-size: 9pt"><B><BR>Year(1)</B></FONT></TD><TD STYLE="white-space: nowrap; background-color: White; padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center; background-color: White; padding-bottom: 1pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: center"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 9pt"><B>Summary<BR>
                                            Compensation Table <BR>
                                            Total for PEO</B></FONT></P> <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 9pt"><B>($)(2)</B></FONT></P></TD><TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; background-color: White; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center; background-color: White; padding-bottom: 1pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: center"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 9pt"><B>Compensation<BR>
                                            Actually Paid to<BR>
                                            PEO</B></FONT></P> <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 9pt"><B>($)(3)</B></FONT></P></TD><TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; background-color: White; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center; background-color: White; padding-bottom: 1pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: center"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 9pt"><B>Average
                                            Summary Compensation<BR>
                                            Table Total for Non-PEO Named<BR>
                                            Executive Officers</B></FONT></P> <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 9pt"><B>($)(2)</B></FONT></P></TD><TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; background-color: White; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center; background-color: White; padding-bottom: 1pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: center"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 9pt"><B>Average
                                            Compensation<BR>
                                            Actually Paid to Non-PEO <BR>
                                            Named Executive Officers</B></FONT></P> <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 9pt"><B>($)(4)</B></FONT></P></TD><TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; background-color: White; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center; background-color: White; padding-bottom: 1pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: center"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: center"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 9pt"><B>Total
                                            Shareholder<BR>
                                            Return</B></FONT></P> <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 9pt"><B>($)(5)</B></FONT></P></TD><TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; background-color: White; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center; background-color: White; padding-bottom: 1pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: center"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 9pt"><B>Net
                                            Income<BR>
                                            (Loss)</B></FONT></P> <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 9pt"><B>($)</B></FONT></P></TD><TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; background-color: White; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 18%; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">2022</FONT></TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 12%; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">1,463,172</FONT></TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 12%; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">146,850</FONT></TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 11%; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">514,617</FONT></TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 11%; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">294,040</FONT></TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="width: 11%; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">6.87</FONT></TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 11%; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">(28,601,254</FONT></TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">2021</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">2,151,250</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">1,228,994</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">812,048</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">491,289</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">26.51</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">(24,122,362</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">)</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(1)</TD><TD>James V. Caruso served as the Company&#8217;s principal executive officer (&#8220;PEO&#8221;) for the entirety of 2021 and 2022 and
the Company&#8217;s other NEOs for the applicable years were as follows:</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD>2022: Chad J. Kolean and Jarrod Longcor.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD>2021: Jarrod Longcor; John E. Friend II, M.D.; and Dov Elefant.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(2)</TD><TD>Amounts reported in this column represent (i) the total compensation reported in the Summary Compensation Table for the applicable
year in the case of Mr. Caruso and (ii) the average of the total compensation reported in the Summary Compensation Table for the applicable
year for the Company&#8217;s NEOs reported for the applicable year other than the principal executive officer for such years.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(3)</TD><TD>Amounts reported in this column represent the compensation actually paid to Mr. Caruso as the Company&#8217;s President and Chief
Executive Officer in the indicated fiscal years, based on his total compensation reported in the Summary Compensation Table for the indicated
fiscal years and adjusted as shown in the table below:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">PEO</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2022</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2021</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; font-size: 10pt; text-align: left">Summary Compensation Table - Total Compensation(a)</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">1,463,172</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">2,151,250</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">- Grant Date Fair Value of Option Awards Granted in Fiscal Year(b)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(616,697</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(1,472,000</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">+ Fair Value at Fiscal Year-End of Outstanding and Unvested Option Awards Granted in Fiscal Year(c)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">127,710</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">715,200</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">+ Change in Fair Value of Outstanding and Unvested Option Awards Granted in Prior Fiscal Years(d)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(430,237</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(109,629</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">+ Fair Value at Vesting of Option Awards Granted in Fiscal Year That Vested During Fiscal Year(e)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">178,023</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">93,111</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">+ Change in Fair Value as of Vesting Date of Option Awards Granted in Prior Fiscal Years For Which Applicable Vesting Conditions Were Satisfied During Fiscal Year(f)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(84,783</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(1,417</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">- Fair Value as of Prior Fiscal Year-End of Option Awards Granted in Prior Fiscal Years That Failed to Meet Applicable Vesting Conditions During Fiscal Year(g)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(490,338</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(147,572</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">= Compensation Actually Paid</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">146,850</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">1,228,944</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD>Represents Total Compensation as reported in the Summary Compensation Table for the indicated fiscal year.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD>Represents the aggregate grant date fair value of the option awards granted to Mr. Caruso during the indicated fiscal year, calculated
using the same methodology as used in the Company&#8217;s financial statements under generally accepted accounting principles.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD>Represents the aggregate fair value as of the indicated fiscal year-end of Mr. Caruso&#8217;s outstanding and unvested option awards
granted during such fiscal year, calculated using the same methodology as used in the Company&#8217;s financial statements under generally
accepted accounting principles.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>




<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(d)</TD><TD>Represents the aggregate change in fair value during the indicated fiscal year of the outstanding and unvested option awards held
by Mr. Caruso as of the last day of the indicated fiscal year, calculated using the same methodology as used in the Company&#8217;s financial
statements under generally accepted accounting principles.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(e)</TD><TD>Represents the aggregate fair value at vesting of the option awards that were granted to Mr. Caruso and vested during the indicated
fiscal year, calculated using the same methodology as used in the Company&#8217;s financial statements under generally accepted accounting
principles.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(f)</TD><TD>Represents the aggregate change in fair value, measured from the prior fiscal year-end to the vesting date, of each option award held
by Mr. Caruso that was granted in a prior fiscal year and which vested during the indicated fiscal year, calculated using the same methodology
as used in the Company&#8217;s financial statements under generally accepted accounting principles.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(g)</TD><TD>Represents the aggregate fair value as of the last day of the prior fiscal year of Mr. Caruso&#8217;s option awards that were granted
in a prior fiscal year and which failed to meet the applicable vesting conditions in the indicated fiscal year, calculated using the same
methodology as used in the Company&#8217;s financial statements under generally accepted accounting principles.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(4)</TD><TD>Amounts reported in this column represent the compensation actually paid to the Company&#8217;s NEOs other than Mr. Caruso in the
indicated fiscal year, based on the average total compensation for such NEOs reported in the Summary Compensation Table for the indicated
fiscal year and adjusted as shown in the table below:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 88%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Other NEOs Average(a)</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2022</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2021</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; font-size: 10pt; text-align: left">Summary Compensation Table - Total Compensation(b)</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">514,617</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">812,048</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">- Grant Date Fair Value of Option Awards Granted in Fiscal Year(c)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(132,258</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(371,067</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">+ Fair Value at Fiscal Year-End of Outstanding and Unvested Option Awards Granted in Fiscal Year(d)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">28,350</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">136,982</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">+ Change in Fair Value of Outstanding and Unvested Option Awards Granted in Prior Fiscal Years(e)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(61,221</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(49,257</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">+ Fair Value at Vesting of Option Awards Granted in Fiscal Year That Vested During Fiscal Year(f)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">26,358</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">38,782</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">+ Change in Fair Value as of Vesting Date of Option Awards Granted in Prior Fiscal Years For Which Applicable Vesting Conditions Were Satisfied During Fiscal Year(g)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(12,048</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(9,863</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">- Fair Value as of Prior Fiscal Year-End of Option Awards Granted in Prior Fiscal Years That Failed to Meet Applicable Vesting Conditions During Fiscal Year(h)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(69,758</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(66,337</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">= Compensation Actually Paid</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">294,040</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">491,289</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD>Please see footnote 1 for the NEOs included in the average for each indicated fiscal year.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD>Represents the average Total Compensation as reported in the Summary Compensation Table for the reported NEOs in the indicated fiscal
year.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD>Represents the average aggregate grant date fair value of the option awards granted to the reported NEOs during the indicated fiscal
year, calculated using the same methodology as used in the Company&#8217;s financial statements under generally accepted accounting principles.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(d)</TD><TD>Represents the average aggregate fair value as of the indicated fiscal year-end of the reported NEOs&#8217; outstanding and unvested
option awards granted during such fiscal year, calculated using the same methodology as used in the Company&#8217;s financial statements
under generally accepted accounting principles.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(e)</TD><TD>Represents the average aggregate change in fair value during the indicated fiscal year of the outstanding and unvested option awards
held by the reported NEOs as of the last day of the indicated fiscal year, calculated using the same methodology as used in the Company&#8217;s
financial statements under generally accepted accounting principles.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>




<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(f)</TD><TD>Represents the average aggregate fair value at vesting of the option awards that were granted to the reported NEOs and vested during
the indicated fiscal year, calculated using the same methodology as used in the Company&#8217;s financial statements under generally accepted
accounting principles.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(g)</TD><TD>Represents the average aggregate change in fair value, measured from the prior fiscal year-end to the vesting date, of each option
award held by the reported NEOs that was granted in a prior fiscal year and which vested during the indicated fiscal year, calculated
using the same methodology as used in the Company&#8217;s financial statements under generally accepted accounting principles.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(h)</TD><TD>Represents the average aggregate fair value as of the last day of the prior fiscal year of the reported NEOs&#8217; option awards
that were granted in a prior fiscal year and which failed to meet the applicable vesting conditions in the indicated fiscal year, calculated
using the same methodology as used in the Company&#8217;s financial statements under generally accepted accounting principles.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(5)</TD><TD>Pursuant to rules of the SEC, the comparison assumes $100 was invested on December 31, 2020 in our common stock. Historic stock price
performance is not necessarily indicative of future stock price performance.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Relationship Between Pay and Performance </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We believe the &#8220;Compensation Actually Paid&#8221; in each of
the years reported above and over the two-year cumulative period are reflective of the Compensation Committee&#8217;s emphasis on &#8220;pay-for-performance&#8221;
as the &#8220;Compensation Actually Paid&#8221; fluctuated year-over-year, primarily due to the result of our stock performance and our
varying levels of achievement against pre-established performance goals used to determine our named executive officers&#8217; annual bonus
payouts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As is the case with many companies in the biotechnology industry, the
Company&#8217;s incentive objectives are generally tied to the Company&#8217;s strategic and operational goals rather than financial goals.
Accordingly, the Company&#8217;s compensation program is less influenced by metrics, such as net income. For 2021, the Company incurred
a net loss of $24,122,362 while the &#8220;Compensation Actually Paid&#8221; for the CEO and for the other NEOs, on average, was $1,228,994
and $491,289, respectively. For 2022, the Company&#8217;s net loss increased to $28,601,254 while the &#8220;Compensation Actually Paid&#8221;
for the CEO and for the other NEOs, on average, declined to $146,850 and $294,040, respectively. Because of the weighting of the Company&#8217;s
executive compensation program towards long-term incentives in the form of stock options, our TSR, assuming a $100 investment in our common
stock as of December 31, 2020, was $26.51 and $6.87 as of December 31, 2021 and 2022, respectively, while our &#8220;Compensation Actually
Paid&#8221; for our CEO and the average of our other NEOs declined by $1,082,144 and $197,249, respectively, over the same period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><A NAME="a_045"></A>2022 Director Compensation</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table sets forth certain information about the compensation
of our non-employee directors who served during the year ended December&nbsp;31, 2022:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">Name</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><B>Director<BR> Fees<BR> ($)<SUP>(1)</SUP></B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><B>Option<BR> Awards<BR> ($)<SUP>(2)</SUP></B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total&nbsp;($)</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%; font-size: 10pt; text-align: left">Asher Chanan-Khan, M.B.B.S., M.D.</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: center">2022</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">60,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">23,010</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">83,010</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Frederick W. Driscoll</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">2022</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">60,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">23,010</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">83,010</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Stefan D. Loren, Ph.D.</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">2022</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">60,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">23,010</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">83,010</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">John Neis</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">2022</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">60,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">23,010</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">83,010</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Douglas J. Swirsky</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">2022</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">60,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">34,515</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">94,515</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(1)</TD><TD>Director fees consist of annual cash fees for service.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(2)</TD><TD>Granted on June 24, 2022 at an exercise price of $4.10 per share, which fully vest on the first anniversary of the grant date, subject
to continued service through applicable vesting date. All assumptions made regarding the valuation of equity awards can be referenced
in Note 7 to the financial statements included in our Annual Report on Form 10-K filed with the SEC on March 9, 2023.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">During 2022, we paid each of our non-employee directors
a quarterly cash fee of $15,000. We reimbursed directors for reasonable out-of-pocket expenses incurred in attending Board and committee
meetings and undertaking certain matters on our behalf. Mr.&nbsp;Swirsky receives additional option awards for his service as Chairman
of the Board of the Company. Directors who are our employees do not receive additional fees for their service as directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 36 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The aggregate number of option awards outstanding
as of December&nbsp;31, 2022 for each non-employee director was as follows:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">Name</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Stock Options<BR> Outstanding</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 87%; font-size: 10pt; text-align: left">Asher Chanan-Khan, M.D.</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">15,600</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Frederick W. Driscoll</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">22,650</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Stefan D. Loren, Ph.D.</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">22,885</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">John Neis</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">22,889</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Douglas J. Swirsky</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">34,425</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><A NAME="a_050"></A>EQUITY
COMPENSATION PLAN INFORMATION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The following table provides information as of
December 31, 2022 regarding the number of shares of our common stock that may be issued under our equity compensation plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1pt solid"><B>Plan
Category</B></P></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">Number of<BR> Securities<BR> to be Issued<BR> upon<BR> Exercise of<BR> Outstanding<BR> Options,<BR> Warrants<BR> and Rights<BR> (a)</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">Weighted<BR> Average<BR> Exercise<BR> Price<BR> of<BR> Outstanding<BR> Options<BR> and<BR> Rights<BR> (b)</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">Number of<BR> Securities<BR> Remaining<BR> Available for<BR> Future<BR> Issuance<BR> Under Equity<BR> Compensation<BR> Plans<BR> (Excluding<BR> Securities<BR> Reflected in<BR> Column (a))<BR> (c)</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%; font-size: 10pt; text-align: left">Equity compensation plans approved by security holders<SUP>(1)</SUP></TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">630,132</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">13.74</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">635,753</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Equity compensation plans not approved by security holders</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">116,125</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">12.69</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">n/a</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">Total</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">746,257</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">13.57</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">635,753</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 1pt 6.6in 1pt 0in"><DIV STYLE="font-size: 1pt; border-top: Black 0.75pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 36pt">(1)</TD><TD STYLE="text-align: left">Includes our Amended and Restated 2015 Stock Incentive Plan and the Amended and Restated 2021 Plan. If
Proposal Two is approved by our stockholders at the annual meeting, the number of shares of our common stock remaining available for issuance
under our equity compensation plans will increase by 1,100,000 shares to 1,735,753 shares.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -36.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 37 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><A NAME="a_046"></A>WHERE
YOU CAN FIND MORE INFORMATION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We are subject to the informational
requirements of the Securities Exchange Act of 1934, as amended, and, in accordance therewith, file electronically with the SEC our annual,
quarterly and current reports, proxy statements and other information. We make available on the investor relations page of our website
at https://investor.cellectar.com/ free of charge, copies of these reports, as soon as reasonably practicable after we electronically
file such material with, or furnish it to, the SEC. The SEC maintains a website that contains reports, proxy and information statements,
and other information regarding issuers that file electronically with the SEC. The address of that website is www.sec.gov. The information
in or accessible through the websites referred to above are not incorporated into, and are not considered part of, this proxy statement.
Further, our references to the URLs for these websites are intended to be inactive textual references only.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">You should rely on the information
contained in this proxy statement to vote your shares at the Annual Meeting. We have not authorized anyone to provide you with information
that is different from what is contained in this proxy statement. This proxy statement is dated April 28, 2023. You should not assume
that the information contained in this proxy statement is accurate as of any date other than that date, and the mailing of this proxy
statement to stockholders at any time after that date does not create an implication to the contrary. This proxy statement does not constitute
a solicitation of a proxy in any jurisdiction where, or to or from any person to whom, it is unlawful to make such proxy solicitations
in such jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><A NAME="a_047"></A>FORM
10-K</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We will make available, on or about April 28,
2023, the proxy materials, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 at <U>www.proxyvote.com</U>.
We will also make available, solely for your reference and by courtesy, our Annual Report on Form 10-K for the fiscal year ended December
31, 2022 on the investor relations page of our website at https://investor.cellectar.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We will also provide, without charge, to any stockholder
of record or beneficial owner of our common stock as of the Record Date, upon the written or oral request of any such persons, a copy
or our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 as filed with the SEC. Request for such copies should be
addressed to the Secretary at: Investor Relations, Cellectar Biosciences, Inc., 100 Campus Drive, Florham Park, New Jersey 07932, by
telephone at (608) 441-8120 or by e-mail to <U>investors@cellectar.com</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Please include your contact information with the
request. The exhibits set forth on the exhibit index of the Form 10-K may be made available at a reasonable charge.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 38 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><U><A NAME="a_048"></A>APPENDIX
A</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><U></U>CELLECTAR BIOSCIENCES, INC.<BR>
2021 STOCK INCENTIVE PLAN, AS AMENDED</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>SECTION 1. General Purpose of the Plan; Definitions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The purpose of this 2021 Stock Incentive Plan (the
 &#8220;Plan&#8221;) is to encourage and enable officers and employees of, and other persons providing services to, Cellectar Biosciences,
Inc. (the &#8220;Company&#8221;) and its Subsidiaries (as defined below) to acquire a proprietary interest in the Company. It is anticipated
that providing such persons with a direct stake in the Company&#8217;s welfare will assure a closer identification of their interests
with those of the Company and its stockholders, thereby stimulating their efforts on the Company&#8217;s behalf and strengthening their
desire to remain with the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following terms shall be defined as set forth
below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8220;Award&#8221; or &#8220;Awards&#8221;, except
where referring to a particular category of grant under the Plan, shall include Incentive Stock Options, Non-Statutory Stock Options,
Restricted Stock Awards, Unrestricted Stock Awards, Performance Share Awards, Stock Appreciation Rights and Restricted Stock Units. Awards
shall be evidenced by a written agreement (which may be in electronic form and may be electronically acknowledged and accepted by the
recipient) containing such terms and conditions not inconsistent with the provisions of this Plan as the Committee shall determine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8220;Board&#8221; means the Board of Directors
of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8220;Cause&#8221; shall mean, with respect to
any Award holder, a determination by the Company (including the Board) or any Subsidiary that the Holder&#8217;s employment or other relationship
with the Company or any such Subsidiary should be terminated as a result of (i) a material breach by the Award holder of any agreement
to which the Award holder and the Company (or any such Subsidiary) are parties, (ii) any act (other than retirement) or omission to act
by the Award holder that may have a material and adverse effect on the business of the Company, such Subsidiary or any other Subsidiary
or on the Award holder&#8217;s ability to perform services for the Company or any such Subsidiary, including, without limitation, the
proven or admitted commission of any crime (other than an ordinary traffic violation), or (iii) any material misconduct or material neglect
of duties by the Award holder in connection with the business or affairs of the Company or any such Subsidiary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8220;Change of Control&#8221; shall have the
meaning set forth in Section 16.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8220;Code&#8221; means the Internal Revenue Code
of 1986, as amended, and any successor Code, and related rules, regulations and interpretations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8220;Committee&#8221; shall have the meaning
set forth in Section 2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8220;Disability&#8221; means disability as set
forth in Section 22(e)(3) of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8220;Effective Date&#8221; shall mean March 4,
2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8220;Eligible Person&#8221; shall have the meaning
set forth in Section 4.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8220;Exchange Act&#8221; shall mean the Securities
Exchange Act of 1934, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8220;Fair Market Value&#8221; on any given date
means the closing price per share of the Stock on such date as reported by such registered national securities exchange on which the Stock
is listed, or, if the Stock is not listed on such an exchange, as quoted in the Over-the-Counter Market provided, that, if there is no
trading on such date, Fair Market Value shall be deemed to be the closing price per share on the last preceding date on which the Stock
was traded. If the Stock is not listed on any registered national securities exchange or quoted in the Over-the-Counter Market, the Fair
Market Value of the Stock shall be determined in good faith by the Committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8220;Incentive Stock Option&#8221; means any
Stock Option designated and qualified as an &#8220;incentive stock option&#8221; as defined in Section 422 of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 39; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">A-<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8220;Non-Employee Director&#8221; means any director
who: (i) is not currently an officer of the Company or a Subsidiary, or otherwise currently employed by the Company or a Subsidiary, (ii)
does not receive compensation, either directly or indirectly, from the Company or a Subsidiary, for services rendered as a consultant
or in any capacity other than as a director, except for an amount that does not exceed the dollar amount for which disclosure would be
required pursuant to Rule 404(a) of Regulation S-K promulgated by the SEC, (iii) does not possess an interest in any other transaction
for which disclosure would be required pursuant to Rule 404(a) of Regulation S-K, (iv) is not engaged in a business relationship for which
disclosure would be required pursuant to Rule 404(b) of Regulation S-K and (v) otherwise meets the requirements under applicable law and
the stock exchange on which the Common Stock are then traded.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8220;Non-Statutory Stock Option&#8221; means
any Stock Option that is not an Incentive Stock Option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8220;Option&#8221; or &#8220;Stock Option&#8221;
means any option to purchase shares of Stock granted pursuant to Section 5.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8220;Performance Goals&#8221; means, for a Performance
Period, the one or more goals established by the Committee for the Performance Period based upon business criteria or other performance
measures determined by the Committee in its discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8220;Performance Period&#8221; means one or more
periods of time, which may be of varying and overlapping durations, as the Committee may select, over which the attainment of one or more
Performance Goals will be measured for the purpose of determining a recipient&#8217;s right to and the payment of a Performance-Based
Award granted pursuant to Section 11.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8220;Performance Share Award&#8221; means an
Award pursuant to Section 8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8220;Restricted Stock Award&#8221; means an Award
granted pursuant to Section 6.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8220;Restricted Stock Unit&#8221; means an Award
granted pursuant to Section 10.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8220;SEC&#8221; means the Securities and Exchange
Commission or any successor authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8220;Section 409A&#8221; means Section 409A of
the Code and the regulations and other guidance promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8220;Stock&#8221; means the common stock, $0.00001
par value per share, of the Company, subject to adjustments pursuant to Section 3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8220;Stock Appreciation Right&#8221; means an
Award granted pursuant to Section 9.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8220;Subsidiary&#8221; means any subsidiary corporation
of the Company, as defined in Section 424 of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8220;Termination Date&#8221; means the date,
as determined by the Committee, that an individual&#8217;s employment or service relationship, as applicable, with the Company or a Subsidiary
terminates for any reason.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8220;Unrestricted Stock Award&#8221; means Awards
granted pursuant to Section 7.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>SECTION 2. Administration of Plan; Committee Authority to Select
Participants and Determine Awards.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a) <U>Committee</U>. It is intended that the Plan
shall be administered by the Compensation Committee of the Board (the &#8220;Committee&#8221;), consisting of not less than two (2) persons
each of whom qualifies as a Non-Employee Director, but, except as required by law, the authority and validity of any act taken or not
taken by the Committee shall not be affected if any person administering the Plan is not a Non-Employee Director. Except as specifically
reserved to the Board under the terms of the Plan, and subject to any limitations set forth in the charter of the Committee, the Committee
shall have full and final authority to operate, manage and administer the Plan on behalf of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 40 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">A-<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b) <U>Powers of Committee.</U> The Committee shall
have the power and authority to grant and modify Awards consistent with the terms of the Plan, including the power and authority:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(i) to select the persons to whom Awards may from
time to time be granted;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(ii) to determine the time or times of grant, and
the extent, if any, of Incentive Stock Options, Non-Statutory Stock Options, Restricted Stock, Unrestricted Stock, Performance Shares
and Stock Appreciation Rights, or any combination of the foregoing, granted to any one or more participants;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(iii) to determine the number of shares to be covered
by any Award;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(iv) to determine and modify the terms and conditions,
including restrictions, not inconsistent with the terms of the Plan, of any Award, which terms and conditions may differ among individual
Awards and participants, and to approve the form of written instruments evidencing the Awards, except that repricing of Stock Options
and Stock Appreciation Right and a cash buyout of underwater Stock Options for cash shall not be permitted without stockholder approval;
provided, however, that that if any such amendment impairs a Participant's rights or increases a Participant's obligations under his or
her Award or creates or increases a Participant's federal income tax liability with respect to an Award, such amendment shall also be
subject to the Participant's consent;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(v) to accelerate the exercisability or vesting of
all or any portion of any Award;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(vi) to extend the period in which any outstanding
Stock Option or Stock Appreciation Right may be exercised; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(vii) to adopt, alter and repeal such rules, guidelines
and practices for administration of the Plan and for its own acts and proceedings as it shall deem advisable; to interpret the terms and
provisions of the Plan and any Award (including related written instruments); to make all determinations it deems advisable for the administration
of the Plan; to decide all disputes arising in connection with the Plan; and to otherwise supervise the administration of the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">All decisions and interpretations of the Committee
shall be binding on all persons, including the Company and Plan participants. No member or former member of the Committee or the Board
shall be liable for any action or determination made in good faith with respect to this Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>SECTION 3. Shares Issuable under the Plan; Mergers; Substitution.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a) <U>Shares Issuable.</U> The maximum number
of shares of Stock which may be issued in respect of Awards (including Stock Appreciation Rights) granted under the Plan, subject to
adjustment upon changes in capitalization of the Company as provided in this Section 3, shall be <STRIKE>1,100,000</STRIKE> 2,200,000<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>1
</SUP></FONT>shares, plus an additional number of shares, that are currently available under the Company&#8217;s Amended and Restated
2015 Stock Incentive Plan (the &#8220;2015 Plan&#8221;) Amended and Restated 2006 Stock Incentive Plan (the &#8220;2006 Plan&#8221;)
or may be added back to the Plan pursuant to the next sentence, in each case subject to adjustment upon changes in capitalization of
the Company as provided in this Section 3. All of the shares described in the previous sentence may be granted as Incentive Stock Options.
For purposes of this limitation, the shares of Stock underlying any Awards, or awards under the 2015 Plan or 2006 Plan, as applicable,
which are forfeited, cancelled, reacquired by the Company or otherwise terminated (other than (i) Shares tendered as payment for an option
exercise; (ii) Shares withheld to cover taxes; (iii) Shares added back that have been repurchased by the Company using stock option proceeds;
and (iv) stock-settled awards where only the actual shares delivered count against the Plan) shall be added back to the shares of Stock
with respect to which Awards may be granted under the Plan. Shares issued under the Plan may be authorized but unissued shares or shares
reacquired by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b) <U>Change in Stock</U>. Subject to
Section 16 hereof, if, as a result of any reorganization, recapitalization, reclassification, stock dividend, stock split, reverse
stock split or other similar change in the Company&#8217;s capital stock, the outstanding shares of Stock are increased or decreased
or are exchanged for a different number or kind of shares or other securities of the Company, or additional shares or new or
different shares or other securities of the Company or other non-cash assets are distributed with respect to such shares of Stock or
other securities, or, if, as a result of any merger or consolidation, sale of all or substantially all of the assets of the Company,
the outstanding shares of Stock are converted into or exchanged for a different number or kind of securities of the Company or any
successor entity (or a parent or subsidiary thereof), the Committee shall make an appropriate or proportionate adjustment in (i) the
maximum number of shares reserved for issuance under the Plan, (ii) the number of shares of Stock that can be granted to any one
individual recipient, (iii) the maximum number of shares that may be granted under a Performance-Based Award, (iv) the number and
kind of shares or other securities subject to any then outstanding Awards under the Plan, (v) the repurchase price per share subject
to each outstanding Restricted Stock Award, and (vi) the price for each share subject to any then outstanding Stock Options and
Stock Appreciation Rights under the Plan, without changing the aggregate exercise price (i.e., the exercise price multiplied by the
number of Stock Options or Stock Appreciation Rights) as to which such Stock Options and Stock Appreciation Rights remain
exercisable. The adjustment by the Committee shall be final, binding and conclusive. No fractional shares of Stock shall be issued
under the Plan resulting from any such adjustment, but the Committee in its discretion may make a cash payment in lieu of fractional
shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>1</SUP> Marked changes reflect the impact of the 2022 Plan Amendment
(increasing share pool by 500,000) and, if approved by stockholders at the Annual Meeting, the impact of the 2023 Plan Amendment (increasing
share pool by 1,100,000).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 41 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">A-<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(c) <U>Substitute Awards.</U> The Committee may
grant Awards under the Plan in substitution for stock and stock based awards held by employees of another corporation who concurrently
become employees of the Company or a Subsidiary as the result of a merger or consolidation of the employing corporation with the Company
or a Subsidiary or the acquisition by the Company or a Subsidiary of property or stock of the employing corporation. The Committee may
direct that the substitute awards be granted on such terms and conditions as the Committee considers appropriate in the circumstances.
Any substitute Awards granted under the Plan shall not count against the share limitation applicable to individuals set forth in the penultimate
sentence of Section 3(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>SECTION 4. Eligibility.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Incentive Stock Options may be granted to employees
(including officer and directors who are also employees) of the Company or a Subsidiary, and all other Awards may be granted to officers,
directors and employees of, and consultants and advisers to, the Company and its Subsidiaries (all such persons, &#8220;Eligible Persons&#8221;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>SECTION 5. Stock Options.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Any Stock Option granted under the Plan shall be
in such form as the Committee may from time to time approve.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Stock Options granted under the Plan may be either
Incentive Stock Options (subject to compliance with applicable law) or Non-Statutory Stock Options. Unless otherwise so designated, an
Option shall be a Non-Statutory Stock Option. To the extent that any option does not qualify as an Incentive Stock Option, it shall constitute
a Non-Statutory Stock Option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">No Incentive Stock Option shall be granted under
the Plan after the tenth anniversary of the date of adoption of the Plan by the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Stock Options granted pursuant to this Section
5 shall contain such additional terms and conditions, not inconsistent with the terms of the Plan, as the Committee shall deem desirable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a) <U>Exercise Price</U>. The exercise price per
share for the Stock covered by a Stock Option granted pursuant to this Section 5 shall be determined by the Committee at the time of grant
but shall be not less than one hundred percent (100%) of Fair Market Value on the date of grant. If an employee owns or is deemed to own
(by reason of the attribution rules applicable under Section 424(d) of the Code) more than ten percent (10%) of the combined voting power
of all classes of stock of the Company or any subsidiary or parent corporation and an Incentive Stock Option is granted to such employee,
the option price shall be not less than one hundred ten percent (110%) of Fair Market Value on the date of grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b) <U>Option Term.</U> The term of each Stock
Option shall be fixed by the Committee, but no Stock Option shall be exercisable more than ten (10) years after the date the option is
granted. If an employee owns or is deemed to own (by reason of the attribution rules of Section 424(d) of the Code) more than ten percent
(10%) of the combined voting power of all classes of stock of the Company or any subsidiary or parent corporation and an Incentive Stock
Option is granted to such employee, the term of such option shall be no more than five (5) years from the date of grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(c) <U>Exercisability; Rights of a Stockholder</U>.
Stock Options shall become vested and exercisable at such time or times, whether or not in installments, as shall be determined by the
Committee. The Committee may at any time accelerate the exercisability of all or any portion of any Stock Option. An optionee shall have
the rights of a stockholder only as to shares acquired upon the exercise of a Stock Option and not as to unexercised Stock Options.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 42 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">A-<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(d) <U>Method of Exercise</U>. Stock Options may
be exercised in whole or in part, by delivering written notice of exercise to the Company, specifying the number of shares to be purchased.
Payment of the purchase price may be made by delivery of cash or bank check or other instrument acceptable to the Committee in an amount
equal to the exercise price of such Options, or, to the extent provided in the applicable Option Agreement, by one or more of the following
methods:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(i) by delivery to the Company of (or attestation
to the ownership of) shares of Stock, not subject to restrictions under any Company plan, having a Fair Market Value equal in amount to
the aggregate exercise price of the Options being exercised; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(ii) if the class of Stock is registered under the
Exchange Act at such time, by delivery to the Company of a properly executed exercise notice along with irrevocable instructions to a
broker to deliver promptly to the Company cash or a check payable and acceptable to the Company for the purchase price; provided that
in the event that the optionee chooses to pay the purchase price as so provided, the optionee and the broker shall comply with such procedures
and enter into such agreements of indemnity and other agreements as the Committee shall prescribe as a condition of such payment procedure
(including, in the case of an optionee who is an executive officer of the Company, such procedures and agreements as the Committee deems
appropriate in order to avoid any extension of credit in the form of a personal loan to such officer). The Company need not act upon such
exercise notice until the Company receives full payment of the exercise price; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(iii) by reducing the number of Option shares otherwise
issuable to the optionee upon exercise of the Option by a number of shares of Common Stock having a Fair Market Value equal to such aggregate
exercise price of the Options being exercised; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(iv) by any combination of such methods of payment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The delivery of certificates representing shares
of Stock to be purchased pursuant to the exercise of a Stock Option will be contingent upon receipt from the optionee (or a purchaser
acting in his stead in accordance with the provisions of the Stock Option) by the Company of the full purchase price for such shares and
the fulfillment of any other requirements contained in the Stock Option or imposed by applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(e) <U>Non-transferability of Options.</U> Except
as the Committee may provide with respect to a Non-Statutory Stock Option, no Stock Option shall be transferable other than by will or
by the laws of descent and distribution and all Stock Options shall be exercisable, during the optionee&#8217;s lifetime, only by the
optionee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(f) <U>Annual Limit on Incentive Stock Options.</U>
To the extent required for &#8220;incentive stock option&#8221; treatment under Section 422 of the Code, the aggregate Fair Market Value
(determined as of the time of grant) of the Stock with respect to which Incentive Stock Options granted under this Plan and any other
plan of the Company or its Subsidiaries become exercisable for the first time by an optionee during any calendar year shall not exceed
$100,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(g) <U>Exercise Period following Termination</U>.
When an optionee&#8217;s employment (or other service relationship) with the Company and its Subsidiaries terminates, the optionee&#8217;s
Stock Options may be exercised within the period of time specified in the agreement evidencing the Option, to the extent that the Option
is vested on the optionee&#8217;s Termination Date. In the absence of a specific period of time set forth in such agreement, Stock Options
shall remain exercisable (to the extent vested on the optionee&#8217;s Termination Date): (i) for 90 days following the Termination Date
upon retirement or any termination by us without cause; or (ii) for 30 days following voluntary termination by the optionee; or (iii)
for 90 days following the Disability of the optionee; or (iv) for 180 days following the Termination Date upon termination for death;
provided however that in no event shall any Option be exercisable after the expiration of the term of such Option; and provided further
that in the event that an optionee&#8217;s employment with the Company or a Subsidiary has been terminated by the Company for Cause, as
determined by the Committee in its sole discretion, any Stock Option held by such optionee shall immediately terminate and be of no further
force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(h) <U>No Dividend Rights</U>. Prior to exercise,
Stock Options shall not have a right to receive dividend payments or dividend equivalent payments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>SECTION 6. Restricted Stock Awards.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a) <U>Nature of Restricted Stock Award.</U> The
Committee in its discretion may grant Restricted Stock Awards to any Eligible Person, entitling the recipient to acquire, for such purchase
price, if any, as may be determined by the Committee, shares of Stock subject to such restrictions and conditions as the Committee may
determine at the time of grant (&#8220;Restricted Stock&#8221;), including continued employment and/or achievement of pre-established
performance goals and objectives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 43 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">A-<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b) <U>Acceptance of Award</U>. A participant
who is granted a Restricted Stock Award shall have no rights with respect to such Award unless the participant shall have accepted
the Award within sixty (60) days (or such shorter date as the Committee may specify) following the award date by making payment to
the Company of the specified purchase price, if any, of the shares covered by the Award and by executing and delivering to the
Company a written instrument that sets forth the terms and conditions applicable to the Restricted Stock in such form as the
Committee shall determine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(c) <U>Rights as a Stockholder.</U> Upon complying
with Section 6(b) above, a participant shall have all the rights of a stockholder with respect to the Restricted Stock, including voting
rights, subject to non-transferability restrictions and Company repurchase or forfeiture rights described in this Section 6 and subject
to such other conditions contained in the written instrument evidencing the Restricted Award. Unless the Committee shall otherwise determine,
certificates evidencing shares of Restricted Stock Award shall remain in the possession of the Company until such shares are vested as
provided in Section 6(e) below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(d) <U>Restrictions.</U> Shares of Restricted Stock
may not be sold, assigned, transferred, pledged or otherwise encumbered or disposed of except as specifically provided herein. In the
event of termination of employment by the Company and its Subsidiaries for any reason (including death, Disability, Normal Retirement
and for Cause), any shares of Restricted Stock which have not then vested shall automatically be forfeited to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(e) <U>Vesting of Restricted Stock.</U> The Committee
at the time of grant shall specify the date or dates and/or the attainment of pre-established performance goals, objectives and other
conditions on which the non-transferability of the Restricted Stock and the Company&#8217;s right of forfeiture shall lapse. Subsequent
to such date or dates and/or the attainment of such pre-established performance goals, objectives and other conditions, the shares on
which all restrictions have lapsed shall no longer be Restricted Stock and shall be deemed &#8220;vested.&#8221; The Committee at any
time may accelerate such date or dates and otherwise waive or, subject to Section 14, amend any conditions of the Award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(f) <U>No Dividend Rights</U>. Unvested shares
of Restricted Stock shall not have a right to receive dividend payments or dividend equivalent payments with respect to unvested shares
of Restricted Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>SECTION 7. Unrestricted Stock Awards.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a) <U>Grant or Sale of Unrestricted Stock</U>.
The Committee in its discretion may grant or sell to any Eligible Person shares of Stock free of any restrictions under the Plan (&#8220;Unrestricted
Stock&#8221;) at a purchase price determined by the Committee. Shares of Unrestricted Stock may be granted or sold as described in the
preceding sentence in respect of past services or other valid consideration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b) <U>Restrictions on Transfers.</U> The right
to receive unrestricted Stock may not be sold, assigned, transferred, pledged or otherwise encumbered, other than by will or the laws
of descent and distribution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>SECTION 8. Performance Share Awards.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A Performance Share Award is an award entitling
the recipient to acquire shares of Stock upon the attainment of specified Performance Goals; provided however that the Committee, in its
discretion, may provide either at the time of grant or at the time of settlement that a Performance Share Award will be settled in cash.
The Committee may make Performance Share Awards independent of or in connection with the granting of any other Award under the Plan. Performance
Share Awards may be granted under the Plan to any Eligible Person. The Committee in its discretion shall determine whether and to whom
Performance Share Awards shall be made, the performance goals applicable under each such Award (which may include, without limitation,
continued employment by the recipient or a specified achievement by the recipient, the Company or any business unit of the Company), the
periods during which performance is to be measured, and all other limitations and conditions applicable to the Award or the Stock issuable
thereunder. Upon the attainment of the specified performance goal shares of Stock (or cash, as applicable) shall be issued pursuant to
the Performance Share Award as soon as practicable thereafter, but in no event later than two and one-half months after the calendar year
in which such performance goal is attained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 44 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">A-<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>SECTION 9. Stock Appreciation Rights.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Committee in its discretion may grant
Stock Appreciation Rights to any Eligible Person. A Stock Appreciation Right shall entitle the participant upon exercise thereof to
receive from the Company, upon written request to the Company at its principal offices (the &#8220;Request&#8221;), a number of
shares of Stock, a cash payment, or a combination of shares and cash (as provided in the Stock Appreciation Right) having an
aggregate Fair Market Value equal to the product of (a) the excess of Fair Market Value, on the date of such Request, over the
exercise price per share of Stock specified in such Stock Appreciation Right (which exercise price shall be not less than one
hundred percent (100%) of Fair Market Value on the date of grant), multiplied by (b) the number of shares of Stock for which such
Stock Appreciation Right shall be exercised. Any Stock Appreciation Right granted under the Plan shall contain such terms and
conditions with respect to its termination as the Committee, in its discretion, may from time to time determine; provided however
that the term of a Stock Appreciation Right shall not exceed ten years. Stock Appreciation Fights shall not have a right to receive
dividend payments or dividend equivalent payments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>SECTION 10. Restricted Stock Units.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A Restricted Stock Unit is a bookkeeping entry
representing the right to receive, upon its vesting, one share of Stock (or a percentage or multiple of one share of Stock if so specified
in the agreement evidencing the Award) for each Restricted Stock Unit awarded to a recipient and represents an unfunded and unsecured
obligation of the Company. The Committee shall determine the restrictions and conditions applicable to each Restricted Stock Unit at the
time of grant. Conditions may be based on continuing employment (or other service relationship) and/or achievement of pre-established
performance goals and objectives. At the end of the vesting period, the Restricted Stock Units, to the extent vested, shall be settled
in the form of shares of Stock. Notwithstanding the foregoing, the Committee, in its discretion, may determine either at the time of grant
or at the time of settlement, that a Restricted Stock Unit shall be settled in cash. Except to the extent that the Committee provides
otherwise, a recipient&#8217;s right in all Restricted Stock Units that have not vested shall automatically terminate immediately following
the recipient&#8217;s termination of employment (or cessation of service relationship) with the Company and its Subsidiaries. Restricted
Stock Units shall not have a right to receive dividend payments or dividend equivalent payments with respect to unvested shares of Restricted
Stock Units.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>SECTION 11. Performance-Based Awards.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a) <U>Performance-Based Awards</U>. A Performance-Based
Award shall be payable upon the attainment of Performance Goals that are established by the Committee, in each case on a specified date
or dates or over any period or periods determined by the Committee. The Committee shall define in an objective fashion the manner of calculating
the Performance Goals it selects to use for any Performance Period. The Committee, in its discretion, may adjust or modify the calculation
of Performance Goals for such Performance Period in order to prevent the dilution or enlargement of the rights of an individual (i) in
the event of, or in anticipation of, any unusual or extraordinary corporate item, transaction, event or development, (ii) in recognition
of, or in anticipation of, any other unusual or nonrecurring events affecting the Company, or the financial statements of the Company,
or (iii) in response to, or in anticipation of, changes in applicable laws, regulations, accounting principles, or business conditions;
provided, however, that the Committee may not exercise such discretion in a manner that would increase the amount of the Performance-Based
Award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b) <U>Grant of Performance-Based Awards.</U> With
respect to each Performance-Based Award, the Committee shall select the Performance Goals for such grant (including a threshold level
of performance below which no amount will become payable with respect to such Award). Each Performance-Based Award will specify the amount
payable, or the formula for determining the amount payable, upon achievement of the various applicable Performance Goals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(c) <U>Payment of Performance-Based Awards. </U>Following
the completion of a Performance Period, the Committee shall review and certify in writing whether, and to what extent, the Performance
Goals for the Performance Period have been achieved and, if so, shall calculate and certify in writing the amount of the Performance-Based
Awards earned for the Performance Period. The Committee shall then determine the actual size of each recipient&#8217;s Performance-Based
Award, and, in doing so, may reduce (but not increase) or eliminate the amount of the Performance-Based Award if, in its sole judgment,
such reduction or elimination is appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(d) <U>No Dividend Rights</U>. Performance-Based
Awards shall not have a right to receive dividend payments or dividend equivalent payments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>SECTION 12. Tax Withholding.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a) <U>Payment by Participant.</U> Each participant
shall, no later than the date as of which the value of an Award or of any Stock or other amounts received thereunder first becomes includable
in the gross income of the participant for Federal income tax purposes, pay to the Company, or make arrangements satisfactory to the Committee
regarding payment of any Federal, state, local and/or payroll taxes of any kind required by law to be withheld with respect to such income.
The Company and its Subsidiaries shall, to the extent permitted by law, have the right to deduct any such taxes from any payment of any
kind otherwise due to the participant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 45 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">A-<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b) <U>Payment in Shares</U>. <FONT STYLE="background-color: white">The
Committee may provide, in an award agreement, that the Participant may direct the Company to satisfy such Participant&#8217;s tax
withholding obligations through the withholding of Shares otherwise to be acquired upon the exercise or payment of such Award; <U>provided</U>,
that, in such case, the number of Shares that shall be so withheld shall be limited to the number of Shares having an aggregate Fair
Market Value on the date of withholding equal to the aggregate amount of such tax withholding obligations determined based on an
amount that is up to the applicable maximum statutory tax withholding requirements; <U>provided</U>, that the exercise of such
discretion by the Committee would not cause an Award otherwise classified as an equity award under ASC Topic 718 to be classified as
a liability award under ASC Topic 718.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="background-color: white">(c) Notwithstanding
any provision of this Plan, each Participant is solely responsible and liable for the satisfaction of all taxes and penalties of any kind
and with respect to any tax jurisdiction that may be imposed on or for the account of such Participant in connection with the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>SECTION 13. Transfer and Leave of Absence.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">For purposes of the Plan, the following events
shall not be deemed a termination of employment:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a) a transfer to the employment of the Company
from a Subsidiary or from the Company to a Subsidiary, or from one Subsidiary to another;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b) an approved leave of absence for military service
or sickness, or for any other purpose approved by the Company, if the employee&#8217;s right to re-employment is guaranteed either by
a statute or by contract or under the policy pursuant to which the leave of absence was granted or if the Committee otherwise so provides
in writing; provided, that the vesting date or dates of any unvested Award held by such employee shall automatically be extended by a
period of time equal to the period of such approved leave of absence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>SECTION 14. Amendments and Termination.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Board may at any time amend or discontinue
the Plan and the Committee may at any time amend or cancel any outstanding Award for the purpose of satisfying changes in law or for any
other lawful purpose, but no such action shall adversely affect rights under any outstanding Award without the holder&#8217;s consent.
Notwithstanding the foregoing, neither the Board nor the Committee shall have the power or authority to decrease the exercise price of
any outstanding Stock Option or Stock Appreciation Right, whether through amendment, cancellation and regrant, exchange or any other means,
except for changes made pursuant to Section 3(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This Plan shall terminate as of the tenth anniversary
of its Effective Date. The Board may terminate this Plan at any earlier time for any reason. No Award may be granted after the Plan has
been terminated. No Award granted while this Plan is in effect shall be adversely altered or impaired by termination of this Plan, except
upon the consent of the holder of such Award. The power of the Committee to construe and interpret this Plan and the Awards granted prior
to the termination of this Plan shall continue after such termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>SECTION 15. Status of Plan.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">With respect to the portion of any Award which
has not been exercised and any payments in cash, Stock or other consideration not received by a participant, a participant shall have
no rights greater than those of a general creditor of the Company unless the Committee shall otherwise expressly determine in connection
with any Award or Awards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>SECTION 16. Change of Control Provisions.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a) Upon the occurrence of a Change of Control
as defined in this Section 16, the Committee in its discretion may, at the time an Award is made or at any time thereafter, take one or
more of the following actions: (i) provide for the acceleration of any time period relating to the exercise or payment of the Award; (ii)
provide for termination of any Awards not exercised prior to the occurrence of a Change in Control; (iii) provide for payment to the holder
of the Award of cash or other property with a Fair Market Value equal to the amount that would have been received upon the exercise or
payment of the Award had the Award been exercised or paid upon the Change in Control in exchange for cancellation of the Award; (iv) adjust
the terms of the Award in a manner determined by the Committee to reflect the Change in Control; (v) cause the Award to be assumed, or
new rights substituted therefor, by another entity; or (vi) make such other provision as the Committee may consider equitable to the holders
of Awards and in the best interests of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 46 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">A-<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b) &#8220;Change of Control&#8221; <FONT STYLE="background-color: white">shall
mean: (a) with respect to an Award that is subject to section 409A of the Code, the occurrence of any event which constitutes a change
of control under section 409A of the Code, including any regulations promulgated pursuant thereto; and (b) with respect to any other Award,
the occurrence of any of the following events</FONT>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(i) any &#8220;person&#8221; (as such term is used
in Sections 13(d) and 14(d)(2) of the Exchange Act) becomes, after the Effective Date of this Plan, a &#8220;beneficial owner&#8221; (as
such term is defined in Rule 13d-3 promulgated under the Exchange Act) (other than the Company, any trustee or other fiduciary holding
securities under an employee benefit plan of the Company, or any corporation owned, directly or indirectly, by the stockholders of the
Company in substantially the same proportions as their ownership of stock of the Company), directly or indirectly, of securities of the
Company representing more than fifty percent (50%) of the combined voting power of the Company&#8217;s then outstanding securities; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(ii) the consummation of a merger or consolidation
of the Company with any other corporation or other entity, other than a merger or consolidation which would result in the voting securities
of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into
voting securities of the surviving entity) more than fifty percent (50%) of the combined voting power of the voting securities of the
Company or such surviving entity outstanding immediately after such merger or consolidation; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(iii) the closing of a sale or other disposition
by the Company of all or substantially all of the assets of the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(iv) individuals who constitute the Board on the
Effective Date (&#8220;Incumbent Directors&#8221;) cease for any reason to constitute at least a majority of the Board; <I>provided</I>,
that any individual who becomes a member of the Board subsequent to the Effective Date, whose election or nomination for election was
approved by a vote of at least two-thirds of the Incumbent Directors shall be treated as an Incumbent Director unless he or she assumed
office as a result of an actual or threatened election contest with respect to the election or removal of directors; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(v) a complete liquidation or dissolution
of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>SECTION 17. General Provisions.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a) <U>No Distribution; Compliance with Legal Requirements</U>.
The Committee may require each person acquiring shares pursuant to an Award to represent to and agree with the Company in writing that
such person is acquiring the shares without a view to distribution thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">No shares of Stock shall be issued pursuant to
an Award until all applicable securities laws and other legal and stock exchange requirements have been satisfied. The Committee may require
the placing of such stop orders and restrictive legends on certificates for Stock and Awards as it deems appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">No Award under the Plan shall be a nonqualified
deferred compensation plan, as defined in Code Section 409A, unless such Award meets in form and in operation the requirements of Code
Section 409A(a)(2),(3), and (4).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Notwithstanding anything to the contrary contained
in this Plan, Awards may be made to an individual who is a foreign national or employed or performing services outside of the United States
on such terms and conditions different from those specified in the Plan as the Committee considers necessary or advisable to achieve the
purposes of the Plan or to comply with applicable laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b) <U>Delivery of Stock Certificates.</U> Delivery
of stock certificates to participants under this Plan shall be deemed effected for all purposes when the Company or a stock transfer agent
of the Company shall have delivered such certificates in the United States mail, addressed to the participant, at the participant&#8217;s
last known address on file with the Company. In lieu of delivery of stock certificates, the Company may, to the extent permitted by law
and the Certificate of Incorporation and by-laws of the Company, issue shares of Stock hereunder in book entry form.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(c) <U>Other Compensation Arrangements; No Employment
Rights.</U> Nothing contained in this Plan shall prevent the Board from adopting other or additional compensation arrangements, including
trusts, subject to stockholder approval if such approval is required; and such arrangements may be either generally applicable or applicable
only in specific cases. The adoption of the Plan or any Award under the Plan does not confer upon any employee any right to continued
employment with the Company or any Subsidiary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 47 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">A-<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(d) <U>Trading Policy Restrictions.</U> Option
exercises and other Awards under the Plan shall be subject to the Company&#8217;s insider trading policy, as in effect from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(e) <U>Lock-Up Agreement.</U> By accepting any
Award, the recipient shall be deemed to have agreed that, if so requested by the Company or by the underwriters managing any underwritten
offering of the Company&#8217;s securities, the recipient will not, without the prior written consent of the Company or such underwriters,
as the case may be, sell, make any short sale of, loan, grant any option for the purchase of, or otherwise dispose of any shares subject
to any such Award during the Lock-up Period, as defined below. The &#8220;Lock-Up Period&#8221; shall mean a period of time not exceeding
180 days or, if greater, such number of days as shall have been agreed to by each director and executive officer of the Company in connection
with such offering in a substantially similar lock-up agreement by which each such director and executive officer is bound. If requested
by the Company or such underwriters, the recipient shall enter into an agreement with such underwriters consistent with the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(f) <U>Section 409A Awards.</U> The Plan is intended
to comply with Section 409A of the Code to the extent subject thereto, and, accordingly, to the maximum extent permitted, the Plan shall
be interpreted and administered to be in compliance therewith. Any payments described in the Plan that are due within the &quot;short-term
deferral period&quot; as defined in Section 409A of the Code shall not be treated as deferred compensation unless Applicable Laws require
otherwise. Notwithstanding anything to the contrary in the Plan, to the extent required to avoid accelerated taxation and tax penalties
under Section 409A of the Code, amounts that would otherwise be payable and benefits that would otherwise be provided pursuant to the
Plan during the six (6) month period immediately following the Participant's termination of Continuous Service shall instead be paid on
the first payroll date after the six-month anniversary of the Participant's separation from service (or the Participant's death, if earlier).
Notwithstanding the foregoing, neither the Company nor the Committee shall have any obligation to take any action to prevent the assessment
of any additional tax or penalty on any Participant under Section 409A of the Code and neither the Company nor the Committee will have
any liability to any Participant for such tax or penalty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(g) <U>Section 16</U>. It is the intent of the
Company that the Plan satisfy, and be interpreted in a manner that satisfies, the applicable requirements of Rule 16b-3 as promulgated
under Section 16 of the Exchange Act so that Participants will be entitled to the benefit of Rule 16b-3, or any other rule promulgated
under Section 16 of the Exchange Act, and will not be subject to short-swing liability under Section 16 of the Exchange Act. Accordingly,
if the operation of any provision of the Plan would conflict with the intent expressed in this Section 17(g), such provision to the extent
possible shall be interpreted and/or deemed amended so as to avoid such conflict.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(h) <FONT STYLE="background-color: white"><U>No
Fractional Shares</U>. No fractional shares of Common Stock shall be issued or delivered pursuant to the Plan. The Committee shall determine
whether cash, additional Awards or other securities or property shall be issued or paid in lieu of fractional shares of Common Stock or
whether any fractional shares should be rounded, forfeited or otherwise eliminated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>SECTION 18. Effective Date.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Plan is effective as of March 4, 2021, subject
to approval by the holders of a majority of the shares of stock of the Company present or represented and entitled to vote at a meeting
of stockholders at which a quorum is present or by written consent of the stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>SECTION 19. Governing Law.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This Plan shall be governed by, and construed and
enforced in accordance with, the substantive laws of the State of Delaware without regard to its principles of conflicts of laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 48 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">A-<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>



<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm232136d1_def14aimg002.jpg" ALT="">&nbsp;&nbsp;</P>

<P STYLE="margin: 0pt"></P>

<!-- Field: Page; Sequence: 49 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm232136d1_def14aimg003.jpg" ALT="">&nbsp;</P>

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="margin: 0pt"></P>

<!-- Field: Page; Sequence: 50; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>tm232136d1_def14aimg001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm232136d1_def14aimg001.jpg
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MPA"-+T:TWW3#<8(<-*_^T['H/=B!Z5;_ +,OM4YU6Y,,!_Y=+5BH^CR=6_#
M^M69'TWP[IK.Y@LK2/J<!1_]<_J:Y_\ M*?Q#<17,>F7<]G$V^"!@(TD8='D
M9L=.RC/J?;8:'7+HG==6=BG811F9_P VP/TJ.[T,"WDFN;O5+YD4GRDG\O>?
M0!=HKG+32=7?7+>_719+."V):.+^T"6E)&,R$DC _N@?4UU);7I&RL>FPK_M
M.[G] *3['K<@.[5+:,]O+M,X_-J<FEWY_P!?K5RW_7.*-/\ V4TIT,/_ *S4
M=1?V\_:/T H7P_9C[SWCGU>[D.?_ !ZF?\(MI)QFTW8_O2N?ZT__ (1G2/\
MGPA_6D/AC1V!!L(>?3/^-5YO"&FNBBV^T6;JZMOMYF5N#G'4]>];M<_(FH:1
MK5]>0V!U"VO-C$PR*LT15=NW#$!E[C!R"6XJ1/$LCG T'60WHT*#]=^*E^VZ
MQ<Y$&EQVP[-=3@G_ +Y3/\Z!IFI70/V[5713_P L[.,1 ?\  CEOR(J.X\*:
M=):21Q1!+@X9;E_WDBLI!!RV2>0..]$=[KT \NXTJWN6'_+6WN0JM_P%AD?F
M:>;G79^(K"SMO]J>X+X_!1_6D_L>^NQ_Q,-7GQ_SSM%$*_3/+?K1-X5TU].N
M+:*!8WFC*&<_/)]2QY//;-5+M?%$NGM:HM@LS87[7!.R''<A&1@I(]SC-.L-
M/U>PA$5G!I5JIY=F>2=W;^\S84L?<U3U.;Q8]X]GI9@#*H+7<T(2 $C.U1EF
L<_D!ZUHZ?X;3S([W5YI-0OQA@T^"D)[A$'RCZ\GWK<I:************_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tm232136d1_def14aimg002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm232136d1_def14aimg002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 2: XP# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ME<8\_P 1ZA+MZ;T#8_,T#,K_ (:&D_Z%E/\ P-/_ ,;KUKPMK\?BCPU9:S%
MT"W*D^4S9*D,5(SWY!YKRG5_@5INFZ-?7R:U=NUM;R3!3$N&*J3C]*[GX1_\
MDOT7_=E_]'/0!VM%%% @HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* *VH?\ (-NO^N+_ ,C7"_!/_DF]M_U\2_\ H5=UJ'_(-NO^N+_R-<+\$_\
MDF]M_P!?$O\ Z%0!Z'1110!D^*/^12UK_KPG_P#1;5@?"/\ Y)?HO^[+_P"C
MGK?\4?\ (I:U_P!>$_\ Z+:L#X1_\DOT7_=E_P#1ST =K1110 4444 >0+\4
M/%GB;6[RT\%>'[2ZM[0_,]V^&89P&Y= ,X/')KM?#OB75)M%OKWQ5I0T5K(D
MR,S$HZ 9+#_ZQ->;:E\./,O;KQ'\/O$D46TN[P+.8S%R2RAQT'!^5@.G)-5K
M3Q9KOCKX2>)[*ZS/>Z>L,AF1=IEBW[F! XR C'W% S?C^*'BOQ1>S)X)\+QW
M%K"VTSWAX;Z_,JJ?;<?UKI/!_BKQ/J.N3:-XG\.C3KA+=ITN(B?*DPZJ5'+
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M"JHP !@ 4M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MHV<AO QMMDZGS]OWMF#\V.^.E %VBLD^*/#RNB'7=,#.GF(#=QY9,$[ASR,
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M4;*L5\M),YP3L4D=1@Z-Q%XA3P1I$#/J5Q>22S7-W)OECE$6V60*3'\P.3&
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MEP!0!Z%1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M&_BMHVMSLG?RX7A\P>3&<%C( 2J<H!D9.[U.B@#C+;4=>3P/=75P+N:^\[;
M88F$X0LHW,K6RGC+$XA/RC@$UF:?J/C.X2WN;@WT7DK;![<VBXG+7DD<A8F,
M-Q"$?Y0N,@X XKT:B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MD3FTM6:/AAMR83Y@(;_EIO/ (((S5ZY\":;<QO";F[CMGG2?[/%Y:1@K (,
M!.%,8P1T],5TAGA%PMN94$S*76,L-Q4$ D#K@%AS[CUI$N8)96BCFC>155V1
M6!(5L[21Z'!P>^#Z4 <;J_@FZO-=N;BRN&BMM1>-M1D:Y&Z1%*_NQ'Y1XVH
M"'4_,<Y P>NET^RGOH;V6SMY+N $0SO$IDC!X(5L9&<GI5FB@#G+KP98WEQ^
M_NKQ['SI9SIY*>3YDJ.LASMW\^:YQNQELXJ[I>@QZ;-<3R7MW?7$\20-+=%-
MPC3=M0;%48!=CDC)SR3Q6JS!5+,0% R2>@ID,\-PA>&5)%#,A9&! 9258<=P
M001V(- '-Z?X&L=.6UC2_OY+>W,+&"0Q[)7A $3/A <J%0<$ [%SD\G \4>
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MQ +'M^?!&3R.#[5GV'Q4TV\LUNFACVII4FHW"07(E>$JZKY1  Y.[.3CZ=Z
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MX/W: .CHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M8L.70)A48'(SL(;([>@1Y[<Z5XJO;1K@?VC!<)%J,UO#]O"E9FG5K97"2;6
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MS0R.+K:PBE_>%U&=P923&O=<#&!FO1** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MNK&18XBDK&UCN"1QF3RRN8CP%4_*,GU .K?Q'H<?VK?K.G+]D(6XS=(/)).
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M%/X5HT4 <!<^"-2GA@9S837<D),UQ(S V=PTAD>:#Y3DY; SMX1!G&15>_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** *M_IMAJL"P:C96UY"K!Q'<1+(H89 .&!YY/
M/O5H    8 [444 %%%% ",JNI5E#*>H(S2T44 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '">(=#M&\8+<V6E63
M:DVD7MQ#(;="QN5>#RW)Q]X$\'J,FJ^B-X?.I>'O^$;,)OBS_P!I>3_KO*\E
M]WVG^+=YOE_?YW9]Z]#HH X'7(Y(?$<_AR-'^S^))(YB5'RJJ#%T">V8TC'U
MD-9EF-(EL;%%$#^,7OXEO%P#=']Z//#C[WD^7OZ_+MVX[5ZC10!Y5JNCZ/IV
MC>+)H-*TR$1ZU9P_/$D4?DYLV9&8*=L9.2>".2<&N[\-WFFR:5;6]B=(A^1I
M%MM+N%EB5=Y!9"%7(SG)VCYLBMJH%L[=;Z2]$2BYDC6)I.Y12Q _ LWYT >7
MV4M]8R:MI5NTW_%2:I>);R*,^1(MPZ3-GM^Y =?=#ZU2BFU/4/#^@#2]/O+L
MZ%IEM<*;=T51=%4?:X9U)'E C"AN)NF<5[)10!Y59SPW7C)M:CM[9+*ZU+$>
MHC_7/OT]"D+<<1G=N!R?F & <&M3X9M$FFV*ZDI&MMIT/DO)R'M-J[!$<=!\
MN\==_)R"M>@T4 >'WI@9]>6"'3TN4_MPSRVL@>ZD7]]M6=0H*1]""6;)"8QF
MNWU/5/#VJ7VD2W]]IUWX?6&=)7>5)+870$102')7.PR8#=_?%=S10!Y9IG]C
MG4Y/[<^S_P#"*#S/[&^W8^R_>&[[_P O_7//\.=O%6-2^Q+XRD>9(W\*KIUE
MYX@P80-TWDLP P8!SG''W"?E!KTNB@#BO#CZ;;>,M1M;1]-U":;SYY+ZW"M<
M0?O1F&=AGNWR<CB/&/ES6$K0_P#"T+M$CLA<_P!IN7EC?-V8_L"X5EQQ#NYW
M$D;L# /->I44 >0>&-2T6QTKP?<%M L$BFC%U-:W:$EC93 &X^5=CDYX);DG
MFKVH7&B7%IKT\\MO)XH>61M+<,&N&!YM3;GJ4(*_<XSNSWKU&B@#QOQ?]OT]
M]1AMS*QT._&O(HSM99'C./IN:Z./0>]=?J,!3P<+QD99M0U6SO) P(8;[J':
MK ]"L813_NUVM% 'D<;W>F6UO&YEEL=5\2!HSC/V>=-1Y7V5T7(]"K?WJM>+
MYH;?Q[++Y>GM<QPZ=+$TLVV[VK/*72V7:2[,!M(R.",YS7J5% 'FT>J6#>%'
MMEO[=KFQUUKFZA64&2&%=2+,[J#E5"\DD8QSTJAK5UI]WJ)U%QI5[I<^OYC>
M_G5+24+I^PDR%6& ZD @$;EQUZ>L44 <GXB:S.DZ$UR+==":XC^V")@UN(?*
M?9N. #%O\OD@#IGC-<??6UK>:I#!X?TW3]2T8ZAFUM)"!9R3"TN#($.TKMR$
M/ QO!Y!R1ZY10!YYJTUL_P )=&=Y(+NW5M.61KUMD;A9H@PE)#;1P0V<XYSF
MJOAO5-/TR_T.>^O+*RMI+34TB+3!(.;N(JL3,1E-H^7IE0#@#@>FT4 >4#4=
M7&KW'B2UL;N--8$UI;7,CQF%E*@695=Y8$NIZJ!F8\]*NW?_  BW_" :W_9'
MV#^UO['F^T_=^V?<^;SL_O,[L9W=\5Z510!S/A%HE6\CNE*^( RG4C)R[MSM
M93@9BQG9C@#(/S;J\SD-[:^%KF_M_,DB7PE:6US"O=)4N '^JN$/^Z7KW*B@
M#S;3FBC\;:D^KJ3IG]HQ_8V;_51W?V>#F08ZD%0A/ ;=T8K5_P >I>:S<VVA
M6%I=W#11->RFU=%:-\,MN27=1CS S8SG]V.,9KNJ* /-[+5M,OO$6F:NPTR]
MU&],4,MC*%:\T^0 JQBSDA P.X8&,,=QZ5;UBQN[GQKK-Q8Z7875Y!I-N;>X
MN&Q+;R9N=IB&QLDD#/S+T'7MWM% 'D.L-H!\,#_A&C";\Z==_P!I>3_KO+^R
MR[OM/\6[S?+^_P [L^]=.WB;0?\ A+M(O/[;TW[+_9MU#YWVM-GF>9;'9NSC
M=CG'7%=O10!YA8-I1M=/,1A_X30ZC$+O&/M>?.'G;_XO*\O?U^7;MQVK$NKF
M]T/4-(NHX[F>/PQ?_P!EF)03OCE,@7 [GROLX'N:]JHH \X@L=-\/>);".2;
M2]2U*5HTFB<*UW;2L"SS19R0A9F=A@8RQR>E=_8.DNG6TD=U]K1HE9;GY?WP
M(&'^4 <]> !SQ5BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0!T=%</_ ,)/X[_Z)U_Y6X/\*Z/0+_5M1L'FUG1?[(N!*56#[4EQN3 (;<O
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M HHHH **** "N<7QWX?;5!IHN+O[9D#RO[/N,\MMS]S&,\9Z>]='7)"SNO\
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MS_P+C_QKA_\ A17A'_GKJ?\ W_7_ .)H_P"%%>$?^>NI_P#?]?\ XF@#N/\
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MZZG_ -_U_P#B:/\ A17A'_GKJ?\ W_7_ .)H [C_ (2?0/\ H.:9_P"!<?\
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M_P")H_X45X1_YZZG_P!_U_\ B: .X_X2?0/^@YIG_@7'_C1_PD^@?]!S3/\
MP+C_ ,:X?_A17A'_ )ZZG_W_ %_^)H_X45X1_P">NI_]_P!?_B: .X_X2?0/
M^@YIG_@7'_C1_P )/H'_ $'-,_\  N/_ !KA_P#A17A'_GKJ?_?]?_B:/^%%
M>$?^>NI_]_U_^)H [C_A)] _Z#FF?^!<?^-'_"3Z!_T'-,_\"X_\:X?_ (45
MX1_YZZG_ -_U_P#B:/\ A17A'_GKJ?\ W_7_ .)H [C_ (2?0/\ H.:9_P"!
M<?\ C1_PD^@?]!S3/_ N/_&N'_X45X1_YZZG_P!_U_\ B:/^%%>$?^>NI_\
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M)/H'_0<TS_P+C_QKA_\ A17A'_GKJ?\ W_7_ .)H_P"%%>$?^>NI_P#?]?\
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M_P">NI_]_P!?_B:/^%%>$?\ GKJ?_?\ 7_XF@#N/^$GT#_H.:9_X%Q_XT?\
M"3Z!_P!!S3/_  +C_P :X?\ X45X1_YZZG_W_7_XFC_A17A'_GKJ?_?]?_B:
M .X_X2?0/^@YIG_@7'_C1_PD^@?]!S3/_ N/_&N'_P"%%>$?^>NI_P#?]?\
MXFC_ (45X1_YZZG_ -_U_P#B: .X_P"$GT#_ *#FF?\ @7'_ (T?\)/H'_0<
MTS_P+C_QKA_^%%>$?^>NI_\ ?]?_ (FC_A17A'_GKJ?_ '_7_P")H [C_A)]
M _Z#FF?^!<?^-'_"3Z!_T'-,_P# N/\ QKA_^%%>$?\ GKJ?_?\ 7_XFC_A1
M7A'_ )ZZG_W_ %_^)H [C_A)] _Z#FF?^!<?^-'_  D^@?\ 0<TS_P "X_\
M&N'_ .%%>$?^>NI_]_U_^)H_X45X1_YZZG_W_7_XF@#N/^$GT#_H.:9_X%Q_
MXT?\)/H'_0<TS_P+C_QKA_\ A17A'_GKJ?\ W_7_ .)H_P"%%>$?^>NI_P#?
M]?\ XF@#N/\ A)] _P"@YIG_ (%Q_P"-'_"3Z!_T'-,_\"X_\:X?_A17A'_G
MKJ?_ '_7_P")H_X45X1_YZZG_P!_U_\ B: .X_X2?0/^@YIG_@7'_C1_PD^@
M?]!S3/\ P+C_ ,:X?_A17A'_ )ZZG_W_ %_^)H_X45X1_P">NI_]_P!?_B:
M.X_X2?0/^@YIG_@7'_C1_P )/H'_ $'-,_\  N/_ !KA_P#A17A'_GKJ?_?]
M?_B:/^%%>$?^>NI_]_U_^)H [C_A)] _Z#FF?^!<?^-'_"3Z!_T'-,_\"X_\
M:X?_ (45X1_YZZG_ -_U_P#B:/\ A17A'_GKJ?\ W_7_ .)H [C_ (2?0/\
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M6I0 4444 >._#[_DMGC+_MK_ .C5KL_B,9QX?M-OVC[ ;^$:E]GW;_LN3O\
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MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *X[XJ?\
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MV6#[9Y?D_:/+'F;,YV[NNW/..E11:5IT$]Q/#I]K'-< B>1(5#2_[Q R?QH
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M-O& 0HX7]ZK'H.>?>LRT\'RI<7.J6VA1V%\=2L7MA^Z#P6Z)"LH&UB ,"4$
M_,/7B@#T")3;VR++,\QC0!I9 -SX'+': ,GV 'M7-7FB:7XTC.H0:A?Q07-H
M+9VA0()X7 D'^LC)QA^JXST.<8%'P)H.JZ3;7PU*#R9Y((HF"1HJ32KOW3;A
M*Y=V+#+,$)PO'IBZ!X"NS)8QZ[I4,MM#;.K1RLDBAS:V48XR?XHI?H5!]#0!
MU]YX+TR^TZWLI9;H1V]W->Q,K@,LLAD.<X_A,I(^@SGG-CP]96MG-JRPZE=7
M]RUV#=R7(4,LOE1X4;45<;-G0=ZY/P[X<\0V_B73KW58CNBAA,ET$1WXM!&\
M+2>=N"^;N?:(V!;#;N>$UCPQJUSK6KRZ=I0M]2N+U)[36S)&!%&($4H<-Y@R
M59<!<'=GM0!KW'@SP[;W=O%-+<)+>:Q]OA7<#NF"M(8ON\1X5V*GOGGI6B_@
M_39(#!(]PT;0WL+ N.5NI \G0>HP/0>M<&/!GB"33;=8K 6Q2Z626T18[=&5
M;>5'(*S29,FY4+':3U(ZFKMYX.U&ZNY)]+TC^R+*[86,UD'B4QVTB@3RA48H
M"2D> #D[2>IH ZNP\%6%CKRZUY\T][@;Y)X8&9V";-V\1AU.T 85E'MR<VM<
M\,VNOONN+FYAS:3V;B$H!)%*%W [E.,%%((QR.<CBLOP+IFK:7I=LNM6A&H/
M;K;R2+(K+%'" L:$@Y);<[\ _>.2#C/74 <OKO@+2/$.K_VI=F078B2)6\N*
M5552QP$E1EYW\D@]!C'.>BL[6.QLH+2( 1P1K&N%5> ,#A0 /H !Z 5-10 4
M444 %%%% !1110 4444 %%%% !1110 4444 %>.ZU\0/B39:[J%K8^$?/LX;
MF2.";^S;AO,C#$*V0V#D '(XKV*B@#Q#_A9/Q3_Z$K_RE77_ ,51_P +)^*?
M_0E?^4JZ_P#BJ]OHH&>(?\+)^*?_ $)7_E*NO_BJ/^%D_%/_ *$K_P I5U_\
M57M]% 'B'@_XA>,M7^*5EI&MG[%!+O\ -T_[((]F(&9?O N,D!N6[^G%>WUX
MA_S=+_G_ )\J]OH *X[XJ?\ ),];_P"N2?\ HQ:[&N.^*G_),];_ .N2?^C%
MH$3_  V_Y)SH7_7L/YFNJKE?AM_R3G0O^O8?S-=50 4444 >._#[_DMGC+_M
MK_Z-6O8J\=^'W_);/&7_ &U_]&K7L5 !63XET3_A(M"FTS[1]G\R2)_,V;\;
M)%?&,CKMQU[UK57O[Q-/L9KN2.:1(EW%(8S([>RJ.2: .3O? 'VN>_A757CT
MG4;U;ZZL_(!=I 5)VR9^5247(P?8BJ8^%T+V/V2?579/L4UKE(-I#/="X5_O
M'[I &._J.E=MIE_%JNE6>HP*ZPW<"3QAP P5E##..^#5J@#A-0^'+ZKI^K?;
M=9+:MJ$D3_;8[8(L7EJ4 5-W=&<'YOXJKK\*;>*TUVVAU-E34K=+> &#(M5W
M;GP-WS;FY[8]Z]#KGE\6PE;B9M,OTM(;O[']J;RMCR^>(,*!)NQO.<E1P#[
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M_@U_^QH [BBN'_X5M_U.OC+_ ,&O_P!C1_PK;_J=?&7_ (-?_L: .XHKA_\
MA6W_ %.OC+_P:_\ V-'_  K;_J=?&7_@U_\ L: .XHKA_P#A6W_4Z^,O_!K_
M /8T?\*V_P"IU\9?^#7_ .QH [BBN'_X5M_U.OC+_P &O_V-'_"MO^IU\9?^
M#7_[&@#N**X?_A6W_4Z^,O\ P:__ &-'_"MO^IU\9?\ @U_^QH [BBN'_P"%
M;?\ 4Z^,O_!K_P#8T?\ "MO^IU\9?^#7_P"QH [BBN'_ .%;?]3KXR_\&O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M#D%R,'YL,.L:!8WDNKV%M*93)!82EK>2"*,27&'(9D"[@\I9QG.5P<$&G?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "N.^*G_),];_ZY)_Z,6NQKCOBI_P DSUO_ *Y)_P"C%H G^&W_
M "3G0O\ KV'\S755ROPV_P"2<Z%_U[#^9KJJ "BBB@#QWX??\EL\9?\ ;7_T
M:M>Q5X[\/O\ DMGC+_MK_P"C5KV*@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^)_#\N/+US3'R5 VW<9Y;[HZ]^WK5EM7TU+R2S?4;1;J-#(\)F4.J@9+%<Y
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M #;7H5% $=OY_P!FB^TB,7&P>:(R2N['.,\XSTS4E%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5SC>"=+?3;RR:2Z*W.
MHMJ0E$@$D,Y;=N0@<8/3.??-='10!S.G^!M-T_7(=:^TWMQJ*&4R7$\BLTQ=
M57YL*.@08 P!S70W4'VJTFM_-DB\V-D\R,@,F1C()SR.U2T4 <4/A;X9@@M5
ML[1H);>)HS(C -<JT91EE..0P)SC!],5D:7\,+F=;E/$&H.\36L-I D$_F%4
MC;<,LR $=MI4CUR>:],HH X>/X5Z%%9W-JEQ?K%<6\MLP5XQM2259#M 3 P5
M ';%7M7\!:=K$^IR37M_&NI.CW,4;1[6VQA !N0D<#KG.<X(KJJ* ,73/#-I
MI&L7&H6<UR@N(8XI+<N&C/EJJH_(W;@J@=<>V:->\+Z;XEEL3JBO/!:.T@MB
M1Y4C%=H+C&3C)Q@CKWK:HH XQ?AII%O.DFGWNI:<(KE[J%+61 L+L@1MH*'@
M@=#G\N*FM/AWH]E<Z7+'/>M'IC;[:!Y%*A^26)V[B26)(W8)/2NMHH X"Y^$
M6A7=I':S7NIO!"C10(TD;"%"=VU<H<8.<'KS@DC K7'@32Q=M<>?>;VDO9"-
MZXS=8\S^'M@;?3OFNHHH JZ9I\6DZ39Z= SM#:0)!&TA!8JBA03@ 9P/2N8^
M*G_),];_ .N2?^C%KL:X[XJ?\DSUO_KDG_HQ: )_AM_R3G0O^O8?S-=57*_#
M;_DG.A?]>P_F:ZJ@ HHHH \=^'W_ "6SQE_VU_\ 1JU[%7COP^_Y+9XR_P"V
MO_HU:]BH ***JW\E]%;@Z?:P7$Y8#9/.85 [G<$8_ACO0!:HK-T#5O[<T2WU
M'R/(,NX&/?O *L5)#8&Y3C(.!D$'%:5 !117*OXKO+/6[FRU.PL[>VMUB=IH
M;N2>1_-,BQJD0ARS$QG(!X!R,XH ZJBJ,6L64^DC4X9));4@G,4+N^0=I&P#
M=N!!!7&0001Q6?-XRT."&WD>XN")UE9%2SF9@(FVR;E"$IM/!W 8H WJ*YU/
M'/AR03LFH,8X/-WS?9Y?+)B4LX5]NUB%4G"DD@9'%3?\)?HF+8M<S(+A!(A>
MUE7:A8JK/E?W:D@@%\ ]LT ;E%8C^+=#CAAE-Z6$P<QHD,C.VV01L @7=NWD
M+MQD\X'!Q=BUBRGTG^TX7EEM<'_5P.SY!VE?+ W[@005QD$$8H O45SQ\;^'
MU=$-Y,&9-[9M)OW:^8T9,GR?N\.C*=V,$<XJUK'B*QT*>$:A,D,,D;R%R'9A
MAXT&%53D9E4$Y&,C@C) !KT5B_\ "6:/]G$HFN2QF,'D"SF\_>%#$>3LW_=(
M;[O0@]ZB'C30F$VV>Y<PSM;LJ6,[,9%SN50$RVW:=V,[>,XR* -^BL6?Q9HM
MML::[=89(?.CG^SR&%U\LR?+)MV$[ 6P#G Z4Z;Q3I-NMLUQ-/#]IR466UE1
ME&X+N=2N8UW$#<^!SUH V**R-6\16.B7*+?S)%"T+2EL.S#$D<8PJJ<C=*HS
MG(R.",D1W/BG3X?#=_K<0N)H+)',L0@=)0RC)4HRAE/3J  #D\<T ;=%<Y'X
MRL&UH:?-%<PB2"WEBE>WE&3,[H%<%/W9W*H&XC); K0L/$&F:E>R6=I<,\R!
MFYB=5<*VUBC$ . V 2I(!(]: -.BL!O&N@(UP'O)46 3%Y'M950^5GS K%=K
ME<'(4D\&I]3\4Z1I%T;6\N)1<?)^ZBMI)6.X.5X13GB*0^VWGM0!L45S-UXY
MTF/37OK1I;F..6W5QY,B'RYI!&)$!7,B_>(*@AMI -6'\9Z"D22/>2*#OW@V
MTNZ$*0&,J[<Q $C)<*.: -ZBLZQUS3]12[DMIG,5I(T<TLD+QH&4D-AF #8*
MG)!(&*Q=2\>Z=;:2UW817%Y-YT,2P-;3QG]ZP",?W98(><,%.XC"Y/% '5T5
M2NM6M+*]M;.9I3<W6?+CBA>3@%06;:#M4%ERS8'/6L?0O&^F:YI$5ZJW$<IM
MEN'MQ;2NP!."$^3][AN"4!YH Z6BL*+QCH4UP($O)!)Y#W#[[:51%&C.K&0E
M0(\-&X(;!R,=Q3[;Q7H]W+;Q037#S3N46(6<V]2-N2Z[,QC]XAW, ,,#G!H
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M9=RE+>1F89P"J!=QSVP.1@CBJ5KXLT2\5S#>'*2QPLCPR(ZO(YC52K*#G<K
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MSN\GKQC=TXYT;W0I+SQ)::H+B&)+>-D98X")I058;&DWX* MN"[>&&<UM44
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MCVKL:* .5\-137'BGQ%K(M[B&SO/LT<!N('A=S&C!CL<!@,L!D@9P:ZJBB@
MHHHH Y._=])\??VM<6MW)8SZ8MLLEK:R7!61968AEC5B,AA@XQP:CMB^L?$*
MVU:VMKR.RM=-D@>2ZM9+?,CR*0JB15)X4G(&*["B@ HHHH *Y?Q.DUOX@\.Z
ML+:XGM+.6=;C[/"TKH)(RJML4%B,]< XS7444 <7JUQ_PD>N^'%T^TU +9WQ
MNIY+FPFMT1!&XZR(N22P  S7:444 %<=\5/^29ZW_P!<D_\ 1BUV-<=\5/\
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M]S(+@M:QK&9(O(?9*6RX4X8@?*Q)SQF@#I**XNS^(=I_8EM>WUK<;C9+//+
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MC$HP0 "<YP<* =?15>UN9)[);B:SGM7(),$Q0NN">I1F7GKP>]<W9^/]-O\
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M.&6*(1&.5$9F ;>C$??8?*1P:J67A&&STFWTM]4U"YM+62W>W2;RAY7DN'4
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MYCN+>6VLIKA77RE4@F-6VD%3P<>U=C10!ROAJ*:X\4^(M9%O<0V=Y]FC@-Q
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MP6X!FECND98@>A8@X'XT?\))H6ZW7^VM.W7(4P#[4G[W<2!MY^;)! QW!]*
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MJ]A%#A&\Q[E%7#@E#DG^( D>N#B@#1HK/N-=TBTN1;W.JV,,[1F4127"*Q0
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MR$9X;@\=>* -2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5QWQ4_Y)GK?_7)/_1BUV-<
M=\5/^29ZW_UR3_T8M $_PV_Y)SH7_7L/YFNJKE?AM_R3G0O^O8?S-=50 444
M4 >._#[_ )+9XR_[:_\ HU:]BKQWX??\EL\9?]M?_1JU[%0 5G:YHUOK^DR:
M;=/*D,CQN6B(#91U<=01U4=NE:-% '(O\.=$-[JEY&]W#/J%U%>%HI%'D31[
ML/'\O!)=B<Y!S4T7@73H!9O#=WT=U:WDE[]K$BF2620;9-^5P0R\< 8'3%=1
M10!R&G?#C1]'-V=+GN[%[@!1);F-9(EWARJOLW$$J =Q;CBMO6]%_MRV-K+J
M%Y;VLB/%/#;^6!.C#!5BR$CC(RI4\GFM2B@#E[KP-87DDBSWM^UB\TTQL-Z"
M$/*CI(<A=_/F.?O<$Y%7[/P^+>\BN[C4[Z^GB@EMT>Y\O(1S&2/D1<X,8P3S
MR<YXQLT4 8K^&K?^QM+TZ"[N[<Z6(Q:W,3)YJ;(S'D[E*G*E@<KCGH.*I_\
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M]E7<(DAFC1$5(U!SY[9)(/ ZYJ^?!EM)%BXU34;B9%B2WGE:/?;B.19%V80
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M[F"2PG2W?_1I6$DC*I CPF7.6X &2!NQM(-65\4:3(MH8IY9C= F-(+:61P
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M0Z;'%!9!;7:RQI-#)B0[SO8B!%R H&2<&MW7M-O-6L&L[>XLHX959)UN[,W
M=3TP-Z@$>^?I6K10!R8\'7$$KO::MAA-!<PM<6YE998X5A)<[QO5D7D<')SG
MM4MAX7O=+N(KJRU2'[2XD%XT]H72;?,TQ**'4IAI' Y;@C.<9KIZ* .,T/P$
M=#@TBTAU0RV6G3BY$+P<M+Y4B.5;=\JL9-VT@X(.#@\.N/ TSQWT=OJPB345
MN8KS=;;RT4LSR83YAM8>:Z[CN!SG;Q78T4 <7=>!;EK?48K#6([<ZC'<PW#2
MVAE_=RRR2 +\ZX9?-<9.<^@JO=_#?[2]^HU1OL]T;B1$D$SF"25&4LH\X1\;
MV_Y9YP2,]Z[RB@#$;0IG\6)K(NH(HTC,9BAMRLDPVX E?>0Z@DD#:"#WZYY[
M5?APVJZC=W3ZE K3&X*RFRW7"B6)X]IEW\HN_A0 ..<GFN\HH YS4O#$]WKW
M]M6FH);W:>281+;F1%*+.IW ,I8%;ANA&"H.3TJM_P (;-_PB=OHKZE%-)'=
M/<RR36NZ*XW2.Y1X@XRN7Z;NJCZ5UE% &5X;T5?#VA0Z8LJ2"-Y7W1Q")?GD
M9\!02 !NQ@>E:M%% !1110 4444 %%%% !1110 4444 %%%% !1110 5QWQ4
M_P"29ZW_ -<D_P#1BUV-<=\5/^29ZW_UR3_T8M $_P -O^2<Z%_U[#^9KJJY
M7X;?\DYT+_KV'\S754 %%%% 'COP^_Y+9XR_[:_^C5KV*O'?A]_R6SQE_P!M
M?_1JU[%0 4444 %%%% $-K9VMC$T=I;0V\;,7*Q($!8G).!W)[U-110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!2LM'TS399I;#3K2U
MDG.97@@5#(>3\Q YZGKZU=HHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MN.^*G_),];_ZY)_Z,6NQKCOBI_R3/6_^N2?^C%H G^&W_).="_Z]A_,UU5<K
M\-O^2<Z%_P!>P_F:ZJ@ HHHH \=^'W_);/&7_;7_ -&K7L5>._#[_DMGC+_M
MK_Z-6O8J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *X[XJ?\
M),];_P"N2?\ HQ:[&N.^*G_),];_ .N2?^C%H G^&W_).="_Z]A_,UU5<K\-
MO^2<Z%_U[#^9KJJ "BBB@#QWX??\EL\9?]M?_1JU[%7COP^_Y+9XR_[:_P#H
MU:]BH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KCOBI_R3/6_
M^N2?^C%KL:X[XJ?\DSUO_KDG_HQ: )_AM_R3G0O^O8?S-=57*_#;_DG.A?\
M7L/YFNJH **** /'?A]_R6SQE_VU_P#1JU[%7COP^_Y+9XR_[:_^C5KV*@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N.^*G_ "3/6_\ KDG_
M *,6NQKCOBI_R3/6_P#KDG_HQ: )_AM_R3G0O^O8?S-=57*_#;_DG.A?]>P_
MF:ZJ@ HHHH \=^'W_);/&7_;7_T:M>Q5X[\/O^2V>,O^VO\ Z-6O8J "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH *X[XJ?\DSUO_KDG_HQ:[&N
M.^*G_),];_ZY)_Z,6@"?X;?\DYT+_KV'\S755ROPV_Y)SH7_ %[#^9KJJ "B
MBB@#QWX??\EL\9?]M?\ T:M>Q5X[\/O^2V>,O^VO_HU:]BH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ KCOBI_P DSUO_ *Y)_P"C%KL:X[XJ
M?\DSUO\ ZY)_Z,6@"?X;?\DYT+_KV'\S755ROPV_Y)SH7_7L/YFNJH ****
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M/=RVJRJ9XD61XP>55BP4GZ[6_*@":BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N.^*G_)
M,];_ .N2?^C%KL:X[XJ?\DSUO_KDG_HQ: )_AM_R3G0O^O8?S-=57*_#;_DG
M.A?]>P_F:ZJ@ HHHH \=^'W_ "6SQE_VU_\ 1JU[%7COP^_Y+9XR_P"VO_HU
M:]BH *Q/%6G76JZ1#;6;.DHO;67S$*AHU2=&9AN!!( )P0<XZ'I6W61XCU.;
M3-.1K0C[9/,L-NA@\[S'.3M"[T'0'DL ,9]J ..U?P?JEO+=II4 N[5S:/*E
MUME-WB6YDE#*70-\\J/@E5/0>E4XO"NO)?Z3(VGREK*:W,5Q'':QE(!)F2-V
M+O(-JEE"H^W;W))%+JGC+7=2\'ZK/;R6>GRVFFM+.S*V]W,TT/[IEDPA'DY!
MR_+ 9[G8A\0^)KV_B@MYM(1+EK\QE[20F);:81@-^]&XMN'(VXYZT#,*3PEK
M*Z=:VL.A1-80O.BV]Q;V\DS;DB"32*L\<9E!61?,#[L$'&22.J\3:->7OA;3
MK9;275+^U*.JRI"T<DHC*YG61L%"2<[26!P1G%8VD^+M;UJ[2/35LK<W:27+
M&Z668(%MK20 #S!CF<CC [XSG+[3QCJ=Q;R:I%%#;:<TT#W4TB27'V='M8)!
M\GF+@9=@2O P"5.6- &!XIL%T^TU*+5[&WO9[R.^&G6S7$)DBDDN)761$9@2
M65X\; 6RH&.:ZG2O"4]A>V%^MA%'??VU=SW4X*[S;.)]HW9R5):([?7G&0:C
MT/6O$<NK6EA+>Z?/'->:B9Y&M7#)'!.J;5_>8&=_!.=HQG=C)I2>+=>U.)H[
M2>"W#3Z=-;W#617S8)YRGW/.)Q\H.25)!8;5R&H T?%&A:I?^+[6]CM/M-DD
M<&UDBC>2%DE9Y%4O,FP2+M5B ^X<$#'.3;^%=9MM$EL;G1DN1-<PR2%#!.R6
MXB8+"@G.S,3!5RPP58L 6)QH7GC36+/1!JY&G217=K=36UN(W#P-$C,/,;?\
MX^7:V N&(%=5?WUYHWA6]U"\,%S=V=K)._DH8HW*J6P 2Q XQU/K[4".4T/P
MS<PI:P:_H*ZE*UA;P)=2&&5;3;%LD0AVR 6R24#;MW/2N??0-3T73=/GM[6/
M3-6CL[&PLXVDC#2S$SQSX",<C]\)2?;)P0<=6WB'7EUBVT03Z4]W)<QHUVEM
M(8O+:"67 3S,[AY77=@A@<"K?B/Q%J.FW6I_8_L2PZ5IRZA,EPC,UP"9!L0A
MAL_U1^8AN6'''(,7Q)HDC>&].TBPT_[79P/'')$(X))%B2-@I03?N]VX)R0<
M G SBLOPQH&I:9K&E37&EL95TZ*"]N[GR7V,D0 $+AC(.>&!&TX)'/WHI+[Q
M'-XE:WBU6W0?V\T$"O;/L6/["9"K*)!O'(.,CYE+=PH2R\?ZEJ4EHUK8[AY=
MF9X$L9Y-QF56=A,OR1J@?.&SG:W(H$-O=&NM2\3^(+/2KI/(BM9;F/9+CR;^
M:(P@$C[I"JS'N/-SWYDM=$U"QU"VU.Q\.RV=C;WB2+I,4L(?_CWEC>10'\L9
M:1/X@2$)//%6[W5=<N?A)=:TUY:PW\^FF[1[:!U$:M'NVC+D[ADX;/!P<<<U
M8]:U>UO;[1;6XLTEM1,S75WYTJNL-O:D@!I25),Q.=QP%R0Q))!D_@SPU=VF
ML76J:QI<4-TT;>0[,DC1%[FY=PI!./EDCYXSG'8@/N?"TSZK?ZK'IT/]HG6K
M6>WNLJ)/LRK LF&SD# F!7OZ'(JIH'B^^7PM9-.8Y;A9]+M%:7<SRK/%;L[$
MYY;]Y(0?]GG.#4I\47Z:1HFNWUS9+:7V^X5((I1]G06LTI#D28E(VJ,;0,@X
M&<$ C&TOP7J=SJ]M)JNBQI9M<6\UY Z6RQ-(L5R'94C/S)NDC&7R[=^!@2?\
M(3JUGH%A%I^GPI=OI:IJ2EE/VF99H'*/\R[\H)UY8#!(W '-:6F^*?$VI:XF
MCB*PMKA'G\Y[BU8'8D=NZX19F"D^?C[YX . <K6YX2\177B.*YFEMXX([<10
M2*,Y%R%S,O7[JEE4>X;D] #.0MO#]U!]JL]2L;KRM1M72UM+6&&'R&64.T:*
M97C ;(?:7P0K#&!BNA\,6]VNM0":S@LWL],\BYBMT5(P[2;HUPI*A@@+$ D#
MS.,@BL;6?%NM_P!B:Q-Y]DD+3:E80+;(Z3PM#%,ZR%]Y&?W0X"C[P.>U:5UX
MSO+36KV P_Z!8@I<2_8IG\L"U\_SFE'R8R53R_O'.<\@4 <QXIT#5?M6HW\^
MD_NIYA#((_L\:7(:^M_) *GS&)13N:3H2<8'6Q/H?E^)[!)_"7GV$IOI[?1\
MP?N$\NU3.TOY8RX=L!N-^>O%;,7B[7Q!-)>06]M#97ODWMP]F6,49BC=6,2S
MG;G>02';&!E>3MO>%/%=_P"(+Y&>U86-Q!),CBQGA\@JZA4:1_DE+!B<KC!0
M]>M '.0>%O%5M>V[R6\$]W##;F*^,:R,"ENJ/$TK3*ZHSA\@1MG>3U. NB^"
M;UM8MOM^BA=*%S%/+;W$=JJ!Q!<*S".'Y<;FA SD\ DG'%R\\7ZRVC37<IL#
M;W6CWE]#!$LL<T!B*!5:029/W^2H4@@XJQ/XYU*&.^C-M;_:-/86]TRQ2.$E
MDN1%"P13N(\L-(5&6.5 (SR 5-/TZ6&71KPZ=YL^EE[>_N+I83#"%D8R2#<W
MF)(1\X91A@ZY]1J1Z'<:C\/]-L)+3>)+R"=[:7 V6_VD2%6!Q]V/C'MBDUC4
MM:O_  #'<)(=.O);Z*VD=K>6)FC:Y$0=5+*\>X%6Y.0"1G)#"GKWBC4+;P1<
MF.2*.Z\_4+$R1LP=%ABN"CJ2Q8/^Z0Y)/WL^AH$4=;\&ZNT\]MIUA&FE"XN/
MLL,44;_9O,B@VS1(98PC*ZSX.<J6.%(;(=?>#=2C7[1!I%G=&?4KV>\@F@CG
M,X>1O(<JTL:G:A; +?+OX&<UKW.HZE%X9\<7-O>LEQ9N[6[R9?R@MI"Y"C(Q
MR6([ G.#R#6_M773K-K;)J-JA_MF.VG?R9&2938B7A3*=@SG@'K@^NX&01>%
MM4C:&.33Y;J_$ED\.L2R1AX(8XXA+&WSEP6*2Y5=RGS>6ZFM#PWX<N/#DFBS
M6^D)$?[)6#4EMVC4O<;H<,WS#>5'G'=D\9 R2 <OPWXSU6>UTBTCBENS%!8I
M<[K.>:28S*A>0S#Y$"AMWS9SM;D5N:UXIOK#Q)!:6D4=Q9BYM[6Z!@P8WF("
M_O#*.<,K86-N.I&> "UXSTB^U.RM)-+C5[R&8IRP7]U*C12'D]@X?'J@KDX/
M 6I+I^L:9/;(]@-30Z=&LH'^C/<Q2RYYXP(^.AX;CD9ZW2=7UF]\.:C+)! ^
MNVN]#9"(Q+'-Y:NL9)=@P.X'>" 0PX'-9+^-KR'2-7N6:UDEL=+^TJ6MWAS.
M)9XVC9"[$;6B52 QY).<$4",W6_"&JK<W$&FZ5:OHOVQY([%8(W0!K>)0ZQF
M6)1AUEZL""VX ]:T-,\*7MGK5MJ,EJKWBZDC37S;!+);"Q$9W').#+_#D\\\
M]:=J>KZW?:7+>6E[9VT0UB.RAB6)_,5DO%B)D<.,JP#90*.& SZ]'H&HW=Y_
M:%M?M UU8W9MVD@0HD@V)(&"EF(XD /)Y% '.^,M OM2U.YFT[3&N)I]+GM&
MGF\G8F8I0GE,6\Q'+NH/&TJ>3D5C106Y\<V=F+.WN-8CU*>>:^BGB>18#!(%
MC<!C(H7<B_, N0,'D5T&HZQJ5MXVFT^RN(E-TMG#&UR&DBA8K=R,0@9<L1$H
MQD=0>V*S;?Q?K%]JEM!9I91SW;6\#/)YDD0_X_-SJN\#'^C@C&"0<$G@@&0V
M7@W4;#3+2VM=-BMP;;2&N$B9%#3Q3EIV.#RP7&6_BP "<57NO"S:%X>TV7[#
M9V<":9 NL*9HXDN)%GMV*.Q8*Q91.H).#NP3@UO:/K.M:EXJL(I[FV6V6#4(
M[B&.!@)'@N%B#@ESMSD$ YP-PYR"K-4\3:]#!>7>G)ITBI?/I\%E)$YE:4 A
M6+!P.6PVW;]SG- #?!$;?\(]X@N-*TZ&UBNKZ:6PMRR&(CRD4<QDKM+*?NDC
MK@US=KX/U>WO&N$\/S,089(+>>*Q%LLOS"4O'&P"C&S#+N<;>IY%;FD_$*ZU
MO7)K&SM[<13K#<6#L&)>WRPG9N>H,;*N,#++G/>O)X[UNQM]"^V?89)-=M4G
MMWMK&=Q;GY"P:-79I.'&,;>1S0!J?$31=3UNRBMK"P^U#R)]KHL!DBF(41G,
MI^5?O99/G&!C'6J&J>#S+<ZRY\-V]V9]1L[Y'5(,S(GE"6/YR/F.V4G.%.\\
MY)%3V_B7Q9?S316=C:+);60G>*>TE229C/-&K*KNI0%8@X5N>=NX9W#7N=;U
M*3PE;:IIAANI2W^D2?9& 1 2'(A,@8E2,%=^>#C. "".6NO">JS:3<6UOHOD
MZB;.[BN[\RQ#^T6=6"C(;<<L5;YPNW&!6B_@>.UN]3NM/TBVAF&IV4MB\:HI
MC@3R/-*?W<[901P6]\BHH/%>H65Y?7XN8=0TN:^,<<2QN).-/6<%"6(524^[
MM/WR<]JNMXHUBRFLH;IM-NFO!:2H]M$ZK&DMQ'$P.7;=Q)E6XSM/RT <K)HN
MN:%;/J=T(8-7AE06S+&B+J-RTA&2PF9I'*-*HRB$!SV&*]&\,1PVNBC2[83
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M.TE3D8)=_P" #GD$>E44 >3V;^*)95?4EU6&W\U?[5C@DNWD;YVP8<1J%4'
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZO/_ ([1_P (GIW_ #\ZS_X.KS_X[0!N45A_\(GIW_/SK/\ X.KS_P".T?\
M")Z=_P _.L_^#J\_^.T ;E%8?_")Z=_S\ZS_ .#J\_\ CM'_  B>G?\ /SK/
M_@ZO/_CM &Y16'_PB>G?\_.L_P#@ZO/_ ([1_P (GIW_ #\ZS_X.KS_X[0!N
M45A_\(GIW_/SK/\ X.KS_P".T?\ ")Z=_P _.L_^#J\_^.T ;E%8?_")Z=_S
M\ZS_ .#J\_\ CM'_  B>G?\ /SK/_@ZO/_CM &Y16'_PB>G?\_.L_P#@ZO/_
M ([1_P (GIW_ #\ZS_X.KS_X[0!N45A_\(GIW_/SK/\ X.KS_P".T?\ ")Z=
M_P _.L_^#J\_^.T ;E%8?_")Z=_S\ZS_ .#J\_\ CM'_  B>G?\ /SK/_@ZO
M/_CM &Y16'_PB>G?\_.L_P#@ZO/_ ([1_P (GIW_ #\ZS_X.KS_X[0!N45A_
M\(GIW_/SK/\ X.KS_P".T?\ ")Z=_P _.L_^#J\_^.T ;E%8?_")Z=_S\ZS_
M .#J\_\ CM'_  B>G?\ /SK/_@ZO/_CM &Y16'_PB>G?\_.L_P#@ZO/_ ([6
M5I/A^UN=2UV&:\UEDM;Y881_;%V-J&WA?'$G/S.QY]: .QHK#_X1/3O^?G6?
M_!U>?_':/^$3T[_GYUG_ ,'5Y_\ ': -RBL/_A$]._Y^=9_\'5Y_\=H_X1/3
MO^?G6?\ P=7G_P =H W**P_^$3T[_GYUG_P=7G_QVC_A$]._Y^=9_P#!U>?_
M !V@#<HK#\)%_P"PW1YII?*OKR%7GE:1]B7,JJ"S$DX4 <GM6Y0 4444 %%%
M% !1110 4444 %%%% !1110 4444 %<=\5/^29ZW_P!<D_\ 1BUV-<=\5/\
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MPQ_V$W_])+BMRN7\<V=K>Z98I/<:M!.MZIM3I4RQ3M*4==H9L #:SYR1]>Q
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MY<;@% 9"'!)&5(]<5;B\+O-JRZ:NN?$(3+#%-.3JT&VW60N%W?-R?W;?<W4
M>I45YI-X06/6UTJ'Q/X[N9A&DLSQ:K&$@1V959MVTGE&^Z&/'3D9HQ:+;W<%
M@VG^)/B#?37EHEX((=3C#11-]UG+E5&3D ;B3@XZ&@#UFBO)'TO2XKK6[63Q
MEXZ2XT>U^U7$3:DN73RQ(=G') 90>F"P]<UJS^#+>WU"QLY/&?C56O$D>-_[
M4&P; "03MZD$D?[I_$ ]&HKQQ8-'?P[;:VOC#QZ;>X$[+'_:*^8JQ([,6&,
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MNFH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K#T+_ )#'B?\
M[":?^DEO6Y7GFJ^'H-4\8:C]DU3Q;;.[1O>'3;^*"VA?RE )5B&)*HN2 W]
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MMT]#6I#\/([F".>'QQXP>*10Z.NJ\,I&01\M '=T5P__  K;_J=?&7_@U_\
ML:/^%;?]3KXR_P#!K_\ 8T =Q17#_P#"MO\ J=?&7_@U_P#L:/\ A6W_ %.O
MC+_P:_\ V- '<45P_P#PK;_J=?&7_@U_^QH_X5M_U.OC+_P:_P#V- '<45P_
M_"MO^IU\9?\ @U_^QH_X5M_U.OC+_P &O_V- '<45P__  K;_J=?&7_@U_\
ML:/^%;?]3KXR_P#!K_\ 8T =Q17#_P#"MO\ J=?&7_@U_P#L:/\ A6W_ %.O
MC+_P:_\ V- '<5AZ%_R&/$__ &$T_P#22WK#_P"%;?\ 4Z^,O_!K_P#8U@WO
MA.'3-7N;.VUKQ_=S^2EY=26>HQ=&W(I(;:SMB+' )PH'H* /5J*\TC\-:'+Y
M87XF>)-TEN+E4;7%5O**[M^TKD+MYSZ5%8:#H.HVEC<0?$KQ-MON+='UM5>1
MN/E"E<[AD CJ#0!ZA17#_P#"MO\ J=?&7_@U_P#L:/\ A6W_ %.OC+_P:_\
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M$JLN!@'(S@XXZ$$8!Q64+?XT@ ?;--/OB+_XF@9ZW6;KEI+?:8UM'I]E?AV
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M\CXT_P#/WIGY1?\ Q- 'K=%>2>1\:?\ G[TS\HO_ (FCR/C3_P _>F?E%_\
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MY'QI_P"?O3/RB_\ B: /6Z*\D\CXT_\ /WIGY1?_ !-'D?&G_G[TS\HO_B:
M/6Z*\D\CXT_\_>F?E%_\31Y'QI_Y^],_*+_XF@#UNN,^+$L<7PSUG>ZKN1%7
M)ZDR+P*Y?R/C3_S]Z9^47_Q-5I/A]XY\97]N/&FL0IIL#;O(MR,L?8* ,]1N
M.2,\"@9W?PW!'PYT($$?Z*#S]374U%;6\-G:PVUO&L<$*+'&B]%4#  _ 5+0
M(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
&HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>tm232136d1_def14aimg003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm232136d1_def14aimg003.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 1, U$# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'KT->_5PGQI;6['X?:WK&A>(;K0+S2;"YOE-O;P3+.R1,RJXEC?"Y7^'!]Z
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M#GW-9*?&^ZT+QA\0II=(UG7_  YI7V*\:ZLA#Y5A:O9QR,P#R*S_ ,;E4#$
M'N0#=TWXP-IGB+Q3 R7GB*:ZUV*RT33K-HPS(=/@G8AI&150 NY9F[\9) H
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M \J\8?!O5=<U+Q0-(\30Z/HOBN../6;.73C/,<1B)WMY1*@B9X@J'<D@&T$
M'.=7Q7\$_#6N^%_$6G:;I6F:'JFL:;)ILFLP:?&;@(R;<LPVLX&!P6YP*] H
MH XCP]\-CX0\6SZGHNI?8])OT+:EHQ@W0S7. !<Q'</)<X^< ,'X. V6/&?%
M?]GB?XE:[KUZNK:7!'K&FIIQDU+1?MUSIX4."UI(95$6_?EAM/*@YZ8]JHH
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M:S=-=PW6G330:JFHV=KK.E+?6BH+*.T:&6(N-X*QA@X*E3CK@Y]LHH X_3?
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MKZ!HH Y;P+X^C\=^#8_$2:#K^A(_F?\ $MUW3GM+Y=A(YA;GYL97U!%>3_\
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MB'XD:.-)#?>'/#4U[:'<,[1*I +#N.U>M44 ?/W_  V':_\ 1'OC#_X1<_\
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MO&"S+L>13@/\N=O7!4]Z]/HH ^?O^&P[7_HCWQA_\(N?_&O6$\?1O\.3XO\
M[!UX1_83??V*VG.-4X7=Y/V;[WF]MGK74T4 ?/W_  V':_\ 1'OC#_X1<_\
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M8L>9>:A<)!"GU=R /SH TJ*\T_X:;^#W_15_ _\ X4=G_P#'*/\ AIOX/?\
M15_ _P#X4=G_ /'* /2Z*\T_X:;^#W_15_ __A1V?_QRC_AIOX/?]%7\#_\
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M%'9__'*/^&F_@]_T5?P/_P"%'9__ !R@#TNBO-/^&F_@]_T5?P/_ .%'9_\
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M<H_X:;^#W_15_ __ (4=G_\ '* /2Z*\T_X:;^#W_15_ _\ X4=G_P#'*/\
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M_P"%'9__ !R@#TNBO-/^&F_@]_T5?P/_ .%'9_\ QRC_ (:;^#W_ $5?P/\
M^%'9_P#QR@#TNBO-/^&F_@]_T5?P/_X4=G_\<H_X:;^#W_15_ __ (4=G_\
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MMW_\=KZ%HH"Y\]?\._OV?O\ HG%G_P"!MW_\=H_X=_?L_?\ 1.+/_P #;O\
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M6?\ X&W?_P =H_X=_?L_?]$XL_\ P-N__CM?0M% 7/GK_AW]^S]_T3BS_P#
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M ,=H_P"'?W[/W_1.+/\ \#;O_P".U]"T4!<^>O\ AW]^S]_T3BS_ / V[_\
MCM'_  [^_9^_Z)Q9_P#@;=__ !VOH6B@+GSU_P ._OV?O^B<6?\ X&W?_P =
MH_X=_?L_?]$XL_\ P-N__CM?0M% 7/GK_AW]^S]_T3BS_P# V[_^.T?\._OV
M?O\ HG%G_P"!MW_\=KZ%HH"Y\]?\._OV?O\ HG%G_P"!MW_\=H_X=_?L_?\
M1.+/_P #;O\ ^.U]"T4!<^>O^'?W[/W_ $3BS_\  V[_ /CM'_#O[]G[_HG%
MG_X&W?\ \=KZ%HH"Y\]?\._OV?O^B<6?_@;=_P#QVC_AW]^S]_T3BS_\#;O_
M ..U]"T4!<^>O^'?W[/W_1.+/_P-N_\ X[1_P[^_9^_Z)Q9_^!MW_P#':^A:
M* N?/7_#O[]G[_HG%G_X&W?_ ,=H_P"'?W[/W_1.+/\ \#;O_P".U]"T4!<^
M>O\ AW]^S]_T3BS_ / V[_\ CM'_  [^_9^_Z)Q9_P#@;=__ !VOH6B@+GSU
M_P ._OV?O^B<6?\ X&W?_P =H_X=_?L_?]$XL_\ P-N__CM?0M% 7/GK_AW]
M^S]_T3BS_P# V[_^.T?\._OV?O\ HG%G_P"!MW_\=KZ%HH"Y\]?\._OV?O\
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MMW_\=KZ%HH"Y\]?\._OV?O\ HG%G_P"!MW_\=H_X=_?L_?\ 1.+/_P #;O\
M^.U]"T4!<^>O^'?W[/W_ $3BS_\  V[_ /CM'_#O[]G[_HG%G_X&W?\ \=KZ
M%HH"Y\]?\._OV?O^B<6?_@;=_P#QVC_AW]^S]_T3BS_\#;O_ ..U]"T4!<_.
M[]IOX,:/^PKKWA'XT?"8W6@6*:K%IFN>'UNGEM[RW<,Y \PL0"(V!!) )1EV
ME:_1 '(!'0U\9_\ !5__ )->M?\ L8;3_P!%3U]E1?ZI/H* 'T444""BBB@
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MK\7?A;KNA:=XNN=.33M<T?74F.G:@B@8(>,%U(P ./X0<CD'J-=\%?%3XJ?
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MQSP!\)_BA^RS\./#_AGPK%9:UXG\6^+_ +7K%SI^GR2:7H]HZCS=@.W:JA5
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M@SZ38^'+RWUZ=P&^T07LQ8JX(#99P%Z8QTK]4*C$$2S-,(T$K#:9 HW$>F:
MN?D:/#PNYO&/A[QSXI\)>"_B _BB2Z^UZSX>O)_$+2^<&@DMKF-N8VP H5<8
MSGL:^AO%_A_P'\-_V_?#U]XUT?1[2RUCPW&;6^GTM3#=ZS]H'[Y2$/[\G^,_
M,,CFONQX(I)4D:-&D3.URH)7Z'M1)!',4,D:N4.Y2R@[3ZCTH"Y^4=_ID&M?
MLP#3KD,;:[^,[V\H5L$HS%3@CIP37JGQ$^'C?#_]H_XK>&/A3I,>@37_ ,+I
M)8--T:/R5DG$@4,J+_RT*@@$<DGU-?H95?4+5KVPN;=)Y+5YHFC6>$@/&2"
MRY[CJ/I0%S\G[.\^%EWI'[-%MX-\/2:?XUL/$EA;>([K^S);=Q/O7>EQ,R@2
MN7#,HRQ"@]!Q7W-^WCIGBC6/V8?%=MX4BNY[UO):Z@L 3/):"13.J@<GY,Y
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MOU2IB1)%NV(J;B6.T8R?6@+GY+>*=!CN/$WQ7T'XA^)?"/@_Q9>^(I;F&_\
M$7A^\NM::+S ;:2QN8V^Y@ *J#USD$5]!:/\*-&^(W[>.I:?XV@3Q&-*\%:;
M=D2[UBENTV*)RF1DC<Y .<;O6ON:2"*5T=XT=T.49E!*_3TJ2@+GYP?L^W_A
MWX;_ +4VF>&_!UQX;^+=EKNIWU[/K?\ 8SQZ]H#$$.9;EEY3DK@GGGA<\_H_
M4:011R/(L:+(^-SA0"WID]ZDH ****!!1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'QE_P5?\
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M-,\;Z3<Q:?IZZI>3>:4CM[9CA9'9@ N21P3GD<<BI/AQ^T?\-/BY<7UOX/\
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M?7O FI^#_@O\'-<T_1?B3X?^,&@>&FM]-GT/PZ]Y;AV=_P#1+N-U_=L22?F
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M-WV"9ONPLY5=[D8("@YSQ78>#?CY\//B!X6U3Q'H'B_3+_1-+!:_N_-\L6@
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MU=2".*) ,EF8\ #U->>> _VG/A9\3KR_M/"_C?2]7N[&)YYX(G99!&HRSJK
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M37 >#_@IXCU7P=^R-I6N^"-7FM-)U*^DUJTO=*EVV:&3<GVE63]VI(&-^ :
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ML<XI:!!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P"37K7_ +&&T_\ 14]?947^J3Z"@?0?1110(**** "BBB@ KXP_8(_Y+/\
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M=:_=ZU\ -8UGPK>75]<W6@/<V%VB;;B4-#N5PH PY!R  .>@%;/P^L_"FG^
MM&G\,Q6*^'TM5GM9K15*%=O+Y'5CSD]2<YYS0!UU%?+\_P 8?$:ZHU_IM]KB
M:+K?AK5M6TY]<-@2Q@C1X)H8H%WHHW])>H*[AN!KO/ &N:_I?B[P[INM^)KC
M6(M1\,3:S</=Q0QK]H\RWSY>Q%VHBNP"DGAN23S0![)17S?I7C_Q5<>$/ WC
M?6-=U(^#Y[*,WUWHJVH=+AYRHEN(Y(B7@92B_NL,N2=I^\MFU\=^*#X8T[QR
MWB:X>ZNO$PTE_"QAM_LRQ&^-L8!^[\WS50>86W]5.1MX !]#U@^(?'WACPC=
M6]MKOB/2=%N+G_40ZC?10/+SCY0[ MSZ5MQRI*"4=7 )4E3G!'45Y-\"+33;
MZV\77%]#;S^+7UR]AUEIE#7  F?[.C9Y$?D>44'3:<CJ: /3K/6K'4+^^LK:
MZCFNK%D6YB0Y,1=0Z@_52#5ZOG'Q<==T;Q)\:_$FD>([K2#HD-G>0V=M#"T=
MQ)'9*Y$WF(Q*$ +A2N,L<YP1/XY^+.KQ>)K34=!N=;&FV>O:?HM]Y[6*:89)
M9(5EA1&7[2[;90=P( 8<$@$4#/>M4UFQT2*"2_N8[6.>>.VC:0X#2R,%1![D
MD 5-=WUM8"(W-Q%;B6188S*X7>['"J,]23T'4U\R:YK&M>)M&\+>)-3\5SJU
MWX^@L/\ A'GB@6WB2'4&C2),()/-41!RQ<YRW&,8[[]J4:T? ^@#PX;9=>_X
M233OL)O,^3YWF_)NQVS0!ZW%J5I/?3V45U#)>6ZJTUND@,D8;.TLN<@'!QGK
M@U'JFLV6BI;O?7,=JMQ<1VL1D.-\KMM1![DG KPBR\56?AOX5PCPQ<W.D:_?
M:]::9XAU#54234+&ZFE1)IK@,"A?! 0D&/#1E04P*I>,-6U;3?&D?A*[UFY\
M2V.G:YX>OH;R\2(7$#S73AH':)$5N(E=<KN ?DD8H$?2-%?-?PZ^)WCG5;&P
M\;ZI'K*>&'6^N-:^U'3OL5G;QK*5%LD3&Y\R-HU4B0$ME]P!  RM7^*_C31X
M/%B6VH:S9&3PJ=<TYO$/]GS7$,GGI&DH2V7:J,LG*/G[O&.: /JFBO,_!<^M
MZ!\4-3\,ZAXAO?$5DVC6^II+J$<*R13--)'(%,4:#80JD @X.<'!KC_V@?B;
MJOA]/$3^&;O7(K[PSIR7]ZULUC'I\);<T8F\]3+(6"$;8^,8Y#8H ]\JEK&L
MV7A_3Y+[4;F.SLXRH>:4X52S!5_,D#\:\"\3>*_&"P?$KQ-!XKN[2#PQ>VWV
M#28;>W^SNAMK:65)2T9=@QD8## KG(-8WQ4UG6O$O@SQQJ]YXLGTZ#3?$]OH
M\.@^5 +8PK=6ZJ'RGFF23=Y@8..J@#&<@SZCJK8:I9ZK'))97<%Y''(T+O;R
M*X213AD)!X8'@CJ*YCXN>,YO 7P^U;5;.![O5=@MM.M8UW//=RD1PH!WR[+^
M ->$_#]M9\&7^O>#/"MCJGAV\UW1EO=+NO$%H(%DU2%%CNF!.\%I$\N3)4_,
M')4\B@1]-7FLV.GW]A97-S'#=W[NEK$Q^:5E0NP7Z*"?PJ[7S6U_>^,O$'P[
MTV'7=>TW6+#7=0LM2DU1+22^M'%@[M$CQQ^2P*LI5]K</V/"P2?$GQI=ZUHW
M@^&\US4)!?:U!)J6D#3HK^[6TF1(E)N=D(.V3<VQ=QV#  +4 ?3=9'B'Q?H7
MA&&&77=:T[18IVV1/J-W' LC=<*7(R?85Y+X+O\ Q_KWQ T'2?$NL7.BM8Z#
M'J-_I]K':EKN?[5+&ID=5<*K1JI98V SC! !S+\>;;6[OQ_\.(O#UMI-WJA.
MI^5#K:NUJW^BCA@G- SV>VN8;RWCGMY4G@E4.DL;!E=3T((X(JO+K-C#J]OI
M3W,:ZC<0O<16Y/S/&A4.P]@70?\  A7A?P:UU]&T[X5Z/I]XT6GZC%JYU&S>
M%(PEXCAW@"\^6(I#,JHI^ZO?&:Y[1-=U+XD_$_P>6\7S:9)/%XGMX[S3T@\Z
M:&'4(4CCC+HR8"HN3M)(3KR30(^F#JEFNJ)IINHAJ#PFX6UWCS#$&"E]O7:"
MP&?4BK5?*UU\9/&I\&ZE-#K:F]M/#VJ20:A]EB*W$UOJ26T5T5VX^:/)*C"G
M<< <8];\'W>L^&_B;JGAS5/$EWK^G_V+;ZHL^I) CPRF:6.0*8HT&PA5."#@
M@X.#0!Z=16!X[\46?@WP;J^MW\]Q;VEG;-(TMHBO,O8;%8%2V2,;AC.,\5\^
M77Q%\=Z?+XKT(:KJFDWT,^@O;2ZS]@NKRU6\O##*"+=?*P47(4Y().#C% 'U
M%5*TUFROM0OK&WN8Y;RQ*"YA4_-$77<N?J.:\'U_Q9XI\+:]JG@]/%5]/#+J
M^CVL>O7D-NUU90W8E\P B(1DEH0J%D.#-WP!71?!2">Q^)?Q6LKC7)/$$EK?
M6$7VNX6,3 ?9%;9)Y:JI9=V,A1QC/.20#V.BOGF7QK\0_$OQ!\3C0+;5Y(]"
MUZ'3DLXGTU-.-L%A:5I_,<7)=TD=E9  ,( #\V<KQ-\;=?TOQ%8:]H/]N:CH
M.H3:G;V]MJC60MKQK>VN) MO%$OV@ 208#.<D$Y!RIH ^CM6UFQT*U6YU"YC
MM(&EC@620X!DD<(B_4LR@>YJ[7SMXTTW6=1^">DZRWC>\UR]UF]T2=)Y(;;[
M+!(][;MOA1(U.!G #,W &<G)/HOPZOM6LO''C'PUJ&M7>O6VFI975M=7Z1+.
MHG23>A,2(I :+(^7(W$9P!0!Z)62?%>D_P#"3?\ "/"\1]9\@736B*S,D1)
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M#C:O.2<[/BF3QKH&I>/+:+X@ZO+!X=\.Q:[;-):V?F27+"?<DA$ !A_T<80
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MT_6X[;5WTJ;6;RTU&WN'TU=.MK6.2:-1$%?[2)59(R=X^;+Y &W !]#4444
M?&7_  5?_P"37K7_ +&&T_\ 14]?947^J3Z"OC7_ (*O_P#)KUK_ -C#:?\
MHJ>OLJ+_ %2?04#Z#Z***!!1110 4444 %?&'[!'_)9_VI/^QVF_]*;ROL^O
MC#]@C_DL_P"U)_V.TW_I3>4#Z'V?1110(JW.EV=Y=VEW/:03W5HS-;3R1JSP
MEEVL48C*DJ2#CJ#BJ\GAO2)K>[MY-*LG@NYQ<W,36Z%9I05(D<8PS#8GS'GY
M5]!7C'C/Q#X@OO'OQ)M;;QW/X<M/#.B6FI6=I;P6S 2/',S23&6-BT>8E&T$
M=3STQCQ?$/Q7XM\*^-?%$OB:?PA=>&M.MKF#1XX(# SM8QW+-<"2-G97=VC
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M.FWC)+9_V="R07!12V5*XW%"F3W& >*\ZA\7^*)[W3_!\GB>\@5_%MWHLGB
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M"!D#V+X,>)=2\2^&-0&J7G]J3:;JUYID>I^6J?;8X92BRD( N[C:VT!=RM@
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M&"1\J':N5Z':/05YK^SMINJ6MMXUN=4O;"^GG\2Z@IEM+ V[LR3,I+,97+#
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MV+*%^[&&4# &3UH ^F4T/38]8EU9=/M5U6:%;:2^$*B=XE)98R^-Q4$DA2<
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M>64('EYW,%_VJ -VQ^!?@ZRN9+EK&]O;N06RO=:AJMW=2LMO,)H%WR2L<)(
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M0=V  >@Z3\'O#.C6EO:0QZE/9VUQ;W5M;7NKW=S%;/"VZ+RUDE8(%/\ "."
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M3R".*\_U7]J:TBLO#_V2#1;"_P!1T?\ MF:#Q#K2V*1KN*"&-_+;S)"ZN,X
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MVNL(E*A&;Y6D(R><@ #C9_@-J.F>(O MOH_B/6H-*T&/4O)U%6M/.LA*(A'
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M)8P0;N]V>;)R3EMBJO?'"CI5VB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /C+_@J_P#\
MFO6O_8PVG_HJ>OLJ+_5)]!7QK_P5?_Y->M?^QAM/_14]?947^J3Z"@?0?111
M0(**** "BBB@ KXP_8(_Y+/^U)_V.TW_ *4WE?9]?&'[!'_)9_VI/^QVF_\
M2F\H'T/L^BBB@045\U?'3XQ?&'X:_$KPKH>BZ=X'N])\6:I_9FDRW\EX)XF$
M>\M<;!M R#]S/;BL2V_:]N?AM\7O&_AKXK7EI:VNBZ;IMPJ^'M-N;J.*26,M
M<2%E1G$*DK\S@8R!U- ['UA17B'B']HO0?"GQ%O#JOB[2K?P=;^%(_$#0BRG
M>XV/,$6<3*"C(P*J(P-Y)%>B_#CXDZ5\4=";5M'M]4MK99/**:MIL]C*3M#
MA)E4E2&!##(/K0(ZJBO$M9_;*^%&@>(M1T6^UZZANM-U'^R[^4:7=-;V<^0H
M$TPC*(I8X#$X.#Z&M*\_:K^&6G^,M6\+W/B+R-5TCSFU /:RB&U2.$3,\DNW
M8%V$8.?F/ R>* /6Z*\D\&_M3_#SQZ=4CTC4-0:[L+!M4:RNM)NK>XN+0?\
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M*6C;'##(K#^(_P"U7\./A3XDU#0/$6K7D&JZ?;17MU!:Z9<W/DV[DXE8QQL
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M?'/[97A/PIXQ^'ND:?9:AXCT[Q<C3Q:MIMI<311P["RM&$B;SF)&&12"@Y;
MH#4;^TSH=QX?_8F\8:/<,DMU8^%UM9&A)96=(T4E<@$C(.,@5YUX/_9[^(_Q
M$&A^(O$]YX9LK?3? =QX>T.+2GGW7+75L$$MSNC'E@ CY4WX.<5[E!^T]\.K
MGQV/"<>LSG4#?'2ENC87 L7O0,FV%UL\HR_[.[KQUXKRKXP_MK:#9WFAZ/X
MU;[;JTGBRST2[GFTR<VDD9DV7"13LHC=UROW6)&<\B@!R_LQ>-?"GA?X):CX
M9O- G\9_#NQDL9K'4)9ETZ]26()+MD6,NC9&0Q3G/(%>3?%OX*>+OAOHG@J[
MO+[1[KQUXJ^*D&N2QP)*VF6T[HX2(9 <H-HRV >>G%?7/Q6^(%QX,\4_#O3X
M=8L-,37M:%A+!>6<T[W:^6S>7$R<1OQG<_RX&*YO2_VR/A5K/B6ST.UUZZ:Z
MNM2?1TF?2[E+9;Q6*^0TQC"*Y*G )Y&#T(H \6\2_L7>.OB$WBCQ;X@U+0;7
MQOJGB&QUJ#2M-O;R+3A%;0M$(7N8U2=6=78^8@!! QUXV+/]D'6Y]*\-2)H_
MAWPYJ%MXULO$FIP1Z]J6J"XMX(RG,UTK,TW/ PJX R<BOI+XB_$O1_A?I$&H
M:Q'J5PEQ-Y$-OI.FSWT\C[2V!'"C-C"DY( XZUQE]^U?\,['P3HOB@:Y-=6.
MLW+V>GVMI87$U[<7"$B2(6RH9 RD?,"HQQZC(%SSWXK?"+3=%U[XY^,O'NM:
M5IG@7Q=H-EI:32/(9;:2-#'OD79@?.R%=K,21T%._8$\#:WI7PFF\8^+&DF\
M3>*7BD::9"C_ &.")8+4$'D91"_/]^O2-4_:;\!Z7KVAZ%)=:G<ZUJ]M%>1:
M;:Z/=33V\$A 22X18R8 20/WFTCN*K0_M8_#&?QJOAA-?D-VU\=+6^^P7 L&
MO/\ GW%UL\HR=L;NO'6@#R'XM?L?:WXF^+'C#Q%I]AHWBC1/%J6_VJQUGQ%J
MNE?9)(X_+;*69V7$;* =KX(/ .,TOQ'_ &2/''C#XH6/Q!TW4_#NFZQX2:PM
MO".FR/++;-:0Y\X7DC1%][;CM*[]N!R22:]5U7]L#X5:)KWB#1[[Q&]O>>'V
MG75"UC.8[0PXW;G"8Y+ *!DN<A<UQW@7]K.U^('Q^U71]-N9D\$:=X1.M7"7
MFE3V]Y%.LV"2CJ'*F(JP 4YR,9H#4XS6_P!B_6[KXB^);V;2M"\3>'/$NL)K
M$XU'Q-J]D]B[%&E3[/;%8KC#+E&;:>F[@"N\^'_P/^('PU\3^.="L)O#FH_#
MSQ;JEYJDM]<3SQZI9M<1D/&(Q&8Y,-MP2XXS["NMTW]K/X<:AI?B6]EU#4M+
M_P"$=LAJ5_:ZKH]U:7"VI.!.D4D89T)XRH-2^$/VKOAEXWO-5M]/\0/ =-TX
MZO++J-E/:1R60ZW$;2HHDC!XW+F@#QCX8_LO?%;P_K?P9M]?U#PD?#GPWGNT
MB.GSW+75[%+&RK(0T056&5&S..IW=!6=>?L:^/;[P)>^%9;W0'M=(\72>*-"
MN%U"\MVO1+([207)B57@PKX#Q,Q!KW33_P!K'X<ZCX,N_%:W^IP:)#/#;0SW
M.C7<37TDN?*%JC1AI]V#CRP??%=E\.OBMX;^*FAW>J>';N:XCLYWM;NVN;66
MVN;690"T4L,BJZ, 1P1SGB@#YG/[(?BJQTG1/$/A_2O#/AWQQI'B:/7UL)]=
MU+5+2^18?**SW-R&D$F,X*I@ #ZUK^$? GQD^"UQXUU^'3?#FO>*/'GBNQG,
M6FBXFL].MBNV>27<(FPBC@@\G!(&<5ZA<?M9_"^U\-^&M>F\1&'3?$6HOI.G
MN]I,&:Y1]CHZ;-T>UN"6  R.>:S_ (B_M$Z1IGB"PTC1/$=I9WEEXHM-"U9+
MS3+FX$CRQ-)]GA:,8$I4 [N57H>2* U.I_:&^%3_ !H^$/B#PK;30VFIW,:R
MZ?=3DA(+J-Q)"Y(!( 91D@$X)XKYGU']A3QIJFF^#S-XAT4:K>37 \>S+)-M
MU*"6^CNRL'[K+$%-HW[>#70>*OVYFU[X3?%S6/">CWNBZSX.G$5K/JMA.89X
MQ-"A=]\:+&Y\P_N22X R>*]N^$7[1'@WXOW]QHVBZE/+KEE9PWEQ;75A/:F2
M)P )HO-1?,C+<!ER.G8@D \;^)G[(_BSQAXA^)E[IVH:';VWB76=!U"QCGGF
M4Q16.WS5D B(#''RA=P/<K7KGP@^$VK_  _^)/Q9\0ZC<V4UEXLU>"_L8[5W
M:2.-(!&1*&0 -D<;2PQWKEO$W[6VG:;\9/$'PUMM$U1=0L-&EOH]5:QN&B-P
M-VU"OE8$7&?.+;"?E!S6=^S1^V%X<^*7A?P7IGB#5O*\<ZQI[W$@_LZ:WLYI
M8\F5(IF7RV9% )56..>_% :G%^._V7OBQJFJ_&>QT.^\'#PW\2KZ)II[^6Y^
MV6,"HJLP58MKN0& 7=@'!W<G%;QG^Q%JX\9ZU=:5::1XNT#7+&RM+BUUSQ%J
MNE&W:"!82S)9G9<(RJ#M?!!X!QFO?? W[37P]^(WBF+0-#U>XFOKD2M8RW&G
MW%O;Z@(CB4VTTB!)@IZ["?7D<UPO[2_[17B7X2_$3P9X7T!_"%BFNV=Y=2ZE
MXQNY;6UA, 4A?,0\;LD#(/.* U/6O&WPRTWQM\)M4\"7,2QZ;>Z4=-5=S.(A
MY>U""Q).TA2"23Q7S1H?[$_B^\^!GB/1O%'B;2[KXCZEJ5C?Q:K!YDMGML51
M+2&3<BN5VHV["]7)&<5Z-X&_;"T&Z^$'A3Q9XULKCP_K&OR30VFBZ=;3W\]X
M8F(:2WCC0NT9 #!B, $<],]?/^TUX"_X0;3/%MA>ZCKNDZC,\%NNC:1=7EQY
MB F17ACC+QE,'=O"XH \MN/V:_'OQ,UGX@^)O'=_X>TC7M>\*/X5T^RT"2:>
MVA0DL9IGD1&8ER,*%X7N37*:O^R7\0];B\":YJ-MX<OM=\/Z'_PC=UH]OXCU
M/3K:XMD*F*=+JV1) ^0=T;*4((YR*]QUO]K7X7>'_"/AOQ+=>(V.D>(A.--E
MALIY'G>(?O(]@3<K@_+M8 D\5YC^T!^W)X;\,>"-:3P+JKW'BNSGLX UQI-P
M]I')))&7@>4H(Q*(V8["V1@]P10&I5L?V6O'7PX\0^'M=^'D'A"QD_X1>3PW
MJ6CZC>7LMK:;YGF\VVE=7ED 9VRLA7/J,\>N_LV?"/6/@Y\ M#\#ZU=6-WJU
MC%<1RSV#NT#&261P5+*K='&?E]>M=AX\^)_AWX6>$/\ A(O%6I+ING QQ[Q&
MTCRROPL<<: L[$]%4$UY'\1OVQ?#&F_!#QGXP\)R75_K.B(UNVF7NE74<UI=
M,A:/[3"4#QQ\9WMA>/O4!N<S\(OV3_%?@+4?@A<:E?Z)<)X'AU=-0%M-*QE:
MZ9C$8=T0SC/S;MN.V:]4_9J^$NK_  ;\%ZUH^LW%C<W%[K^H:K$U@[NBQ3RE
MT4[D4A@.H (]":R/ WQ6U^/]EBZ\?ZE?#Q!KMMI%SJ9>YTB32T=T1G$9A8[M
MH(V[P?G W#K7G_A?]JSXA:#IWPX\0?$3PEH(\&^.9+:WM=7\.7DQDT^:X7,2
MW$,J\@],HQ P>O0@&;XP_91^(6LZ)\7O"MC=>&GT#Q?K\7B*QO;JYG2XCD\^
M!WAEC6%E"A(WPP)R=O !..D^+'[)FK_%'QG\2KU]6L-.TGQ/X5LM%M&C:1IX
M;FWF\T-(@4#RR0HX;.,\"NBTC]J3PUX5T'Q#J_CCQ98O8V_BNZ\/VT]AIES&
M('0%E@D!4EG 5LNORDXQ6I)^V%\+X+RSMYM8OH?.CMY)YWTFZ\BP\_'DK=2B
M/9 SY&!(01GG% :F%^S=\ ]6^&GBK4=>\0>']$T[5'TU-,2_T[Q+JNK37"!P
M[;A>';$F5!"J"0<\XZUOB1^S?XC\8^/?B]KEG>:3';>+_!T?AZP6>60213KO
MRTN(R%C^8<J6/'2N\U3]I;P+IGCF^\(QW>I:KK>GH6O8])TFZO([4["X222*
M-E5RH.%SDGCJ0*XGX:_MN>"O&?P_UWQ;KEO?>$K'2]1>PVW=I<2?:#YC)$(C
MY0\R5]IS$@9DZ-0&ISNI?LN>/DU+2K_0?$FF:#?V'PX'A**^MY9?-AO@RD2I
M^[&(_E(W9##.0O%<)'^Q1\0]0M?&,MS<>&]/NM=\&OX>6+^VM0OV^U&9'\^6
M:>-F*MM8G:/E) "GDU]"1?M;?#!O!VI>)9]>FT_3]+O8=/U"&_L+BWN;*:4@
M1B6!T#H#G.XC;C//!IFG?M;_  ZUG5-&TW3;K6-2OM4B6XCM[/0[R5X(6E,2
M2SA8SY*,RG!?'&#T(- 'G_Q$_97\4>*]5M[FPOM%@AC^&\_@[;--*I^UOC:X
M B/[H8Z_>_V:LW?[*FM:MJWPX%WJ&FV^EZ%X'O/"NI&VDD\XRSP)$'A!C 9
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MXO:CX]\0GP_:W&H^"'\/2VFGW,THBNVF9\J7B7,6T@;OO9S\N*Z'X4_!&_\
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ME-Y7V?7QA^P1_P EG_:D_P"QVF_]*;R@?0^SZ***!'Q9X[T7Q]K/[9/Q+MO
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M9B ",Y)KE?CI\=H_@MKWP]M[N.QCTKQ%JSV%]J%_<>2EE$L+2&7<>.-O<XH
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M,^*&J>*O$?C.\\+:9KL_@VX\*:39:)/<26Q,N2T\\CQ!@,]%56P#W(Y^LZ*
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MQQ1^4W$0;Y]TI'+?4UT.@?LV^(_#7@?]FVST[PG;6>H^%]6AO_$RP36R-&1
MZN[N'_?'>V/E+'GTK["HH"Y\1^#?A)\2_&'Q-\::_P"-_AC/H6KZU97FD:'J
M]KJFG-8^'K5XG576*.8RO*Y(W2!<\]AFN<^'O[)OC:ZT2+1=8TKQ7HVN:3X7
MU'1+35;K6-)?1PT\)B"Q1V\(N61R0_[P@J1DDG.?O^B@+GQ'\)/@W\0T^+7P
M1U/4OA5;^#--\$Z1=:3J>HQZC9RM<N8-BR!8G+%"V2,@G+MD <GUC]I'X?\
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M@_5+Z*QTW5[#6XI-5TR&"8SV[HL=G';[#'"Q(4%B6!.2  2?ONB@#YI_8]\
M^/\ X>2^)=*UO3=1T;P%;I!#X=T[Q!<V=SJ4 4-YBM+:Y5H@2 NXD_KGS3XH
M?LM^,/%>C_'LP>$;>]U+Q/XHTZ]TB22XM@]Q:1&/S&#,_P @&'^5BI/. <U]
MPT4!<^-O&WP7^*/AWQ=\8]5\ ^'K6VMM<BT..P$36>;B. 8NA#'*2B2J/NF5
M0,\C.!7":I\ ?$VG_#GX[:IXNM[CPNFI+I^M>'[[Q!JUE-<_;+2-W'F/ 0BR
M97:<#&&P"V":_02L?Q3X-T#QQIJZ?XCT/3M?L%E69;75+2.YB$B_=<*X(W#)
MP>O- 7/%/V*M"U2X^&-Y\0/$<(B\3^/;UM=NUQS'$0$MXQGL(U!'^]7R[<?#
M[Q9\3[C]HCPCX8^'UKK<VO>.&A_X2B6\MX?[+,;QN2ZN1(0%R5\O/+-QZ_I%
M%$EO$D42+'&BA51!@*!T '851TGPYI.@RWTNF:79:=+?SFZNWM+=(C<3'@R2
M%0-[G ^8Y/% 7/DW4_V4O$7B;Q)\?Y[FQMK6^\2:38Z?X=\0W+Q.[,EIY<Q&
MTF2(,P"L2 2#W%<?K/PE\<ZG8Z=KFI_#VW^&FF^!O FJZ7>317UM,VK2/9F,
M)&L#$^4""^9,')Z9K[SJ"]LK?4[.>TO+>*ZM)T:*:"= \<B,,,K*>"""00:
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M:4QD15$<,=K")FCW#>ID(*XYR2:^VJ* N?$WPM^"OQ&MK7]GNRU/P+)H?_"
MWM]!JURU_:.LL;6^Q+A DA9E9CMQC<,<@#FJG@_]EKQGH7PP^%%H/"<%GXET
MCX@/KFK21W-KYL5F993YID#X?Y#'\JDMT&.*^Y** N?F!K?A_5? ^G^!?AW?
MZ'X?O]2@^)L=W#XDT_5[:ZN]0#7+,W[A,RHR@X<R;0-H')K]&O"&O>(=9OM?
MBUWPN?#MO97S6^G7!U"*Z_M&W &+C:@S%DY&QN1BHM.^%/@K1_$\_B2P\'Z#
M9>(IV9Y=6M],ACNY&;[Q:4+N).3DYYKJJ "BBB@04444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110!\9?\%7_^37K7_L8;3_T5/7V5%_JD^@KX
MU_X*O_\ )KUK_P!C#:?^BIZ^RHO]4GT% ^@^BBB@04444 %%%% !7QA^P1_R
M6?\ :D_[':;_ -*;ROL^OC#]@C_DL_[4G_8[3?\ I3>4#Z'V?1110(**** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH ^,O^"K_P#R:]:_]C#:?^BIZ^RHO]4GT%?&O_!5_P#Y->M?^QAM
M/_14]?947^J3Z"@?0?1110(**** "BBB@ KXP_8(_P"2S_M2?]CM-_Z4WE?9
M]?&'[!'_ "6?]J3_ +':;_TIO*!]#[/HHHH$%%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^,O^"K_ /R:]:_]C#:?
M^BIZ^RHO]4GT%?&O_!5__DUZU_[&&T_]%3U]E1?ZI/H*!]!]%%% @HHHH **
M** "OC#]@C_DL_[4G_8[3?\ I3>5]GU\8?L$?\EG_:D_[':;_P!*;R@?0^SZ
M***!!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% 'QE_P5?_ .37K7_L8;3_ -%3U]E1?ZI/H*^-?^"K
M_P#R:]:_]C#:?^BIZ^RHO]4GT% ^@^BBB@04444 %%%% !7QA^P1_P EG_:D
M_P"QVF_]*;ROL^OC#]@C_DL_[4G_ &.TW_I3>4#Z'V?1110(**** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH ^,O^"K__ ":]:_\ 8PVG_HJ>OLJ+_5)]!7QK_P %7_\ DUZU_P"QAM/_
M $5/7V5%_JD^@H'T'T444""BBB@ HHHH *^,/V"/^2S_ +4G_8[3?^E-Y7V?
M7QA^P1_R6?\ :D_[':;_ -*;R@?0^SZ***!!1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'QE_P5?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110!\9?\%7_^37K7_L8;3_T5/7V5%_JD^@KXU_X*O_\
M)KUK_P!C#:?^BIZ^RHO]4GT% ^@^BBB@04444 %%%% !7QA^P1_R6?\ :D_[
M':;_ -*;ROL^OC#]@C_DL_[4G_8[3?\ I3>4#Z'V?1110(**** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH ^,O^"K_P#R:]:_]C#:?^BIZ^RHO]4GT%?&O_!5_P#Y->M?^QAM/_14]?94
M7^J3Z"@?0?1110(**** "BBB@ KXP_8(_P"2S_M2?]CM-_Z4WE?9]?&'[!'_
M "6?]J3_ +':;_TIO*!]#[/HHHH$%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?&7_  5?_P"37K7_
M +&&T_\ 14]?947^J3Z"OC7_ (*O_P#)KUK_ -C#:?\ HJ>OLJ+_ %2?04#Z
M#Z***!!1110 4444 %?&'[!'_)9_VI/^QVF_]*;ROL^OC#]@C_DL_P"U)_V.
MTW_I3>4#Z'V?1110(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH ^,O^"K_ /R:]:_]C#:?^BIZ^RHO
M]4GT%?&O_!5__DUZU_[&&T_]%3U]E1?ZI/H*!]!]%%% @HHHH **** "OC#]
M@C_DL_[4G_8[3?\ I3>5]GU\8?L$?\EG_:D_[':;_P!*;R@?0^SZ***!!111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:V_^1:^SZ* NSXP_X=5_#/\ Z'?XB?\ @VMO_D6C_AU7\,_^AW^(G_@VMO\
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M:V_^1:^SZ* NSXP_X=5_#/\ Z'?XB?\ @VMO_D6C_AU7\,_^AW^(G_@VMO\
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M:V_^1:^SZ* NSXP_X=5_#/\ Z'?XB?\ @VMO_D6C_AU7\,_^AW^(G_@VMO\
MY%K[/HH"[/C#_AU7\,_^AW^(G_@VMO\ Y%H_X=5_#/\ Z'?XB?\ @VMO_D6O
ML^B@+L\"^ _[$7PP_9\UQM>T.RO]8\2%65-9UVY%Q<1*W#! JJBDCC<%W8)&
M<$BO?:**!!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
)10 4444 ?__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
